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Zusammenfassung 
 
Retinitis pigmentosa (RP) ist eine genetisch und klinisch heterogene Krankheit, die 
zur Degeneration von Photorezeptoren führt und vollständige Blindheit verursachen 
kann. Zirka eine von 3000 bis 4000 Personen erkrankt an RP und weltweit sind mind. 
1.5 Millionen Menschen betroffen. RP kann auch Teil einer syndromalen Krankheit, 
wie zum Beispiel dem Bardet-Biedl Syndrom (BBS) sein. 
Wir haben Mutationen in den  Genen RPGR und BBS1 gefunden, welche für das 
Funktionieren des Verbindenden Ziliums (connecting cilium) im Photorezeptor 
wichtig sind. Die Mutationen führen zu Defekten im Spleissen der pre-mRNA. 
Mutationen in BBS1 sind normalerweise mit BBS assoziiert, wohingegen die meisten 
RPGR Mutationen nicht syndromale RP verursachen. Unsere Patienten zeigen aber 
Symptome, die dem zu erwartenden Krankheitsbild widersprechen. In der Familie des 
einen Patienten mit Spleissdefekten in RPGR, sind heterozygote Trägerinnen der 
Mutation ebenfalls betroffen. Im anderen Fall leidet der Patient zusätzlich zu RP an 
einer milden Höhrschwäche. Die zwei Patienten mit der Splice Donor Mutation in 
BBS1 zeigen RP, aber keine weiteren Symptome von BBS. Unsere Beobachtungen 
deuten an, dass Spleissdefekte das Krankheitsbild und den Krankheitsverlauf 
modifizieren können. 
Die zwei RPGR Mutationen verändern die exprimierte Menge von neu entdeckten, 
alternativen RPGR Transkriptisoformen. Wir haben gefunden, dass deren Menge in 
gesunden Menschen gewebespezifisch reguliert ist. Dies impliziert, dass eine 
Misregulation dieser Isoformen Schäden in den entsprechenden Geweben verursachen 
oder den Schweregrad der Krankheit erhöhen könnte. Im Gegensatz dazu, führt die 
BBS1 Mutation zu RP, höchstwahrscheinlich durch eine Reduktion der Menge an 
funktionellem BBS1 Protein. Die reduzierte Menge an BBS1 scheint auf die anderen 
Gewebe aber keinen Einfluss zu haben. 
In unserer Gruppe wurde ein gentherapeutischer Ansatz entwickelt, um die 
pathogenen Effekte von Spleissendefekten zu mildern. Der Ansatz basiert auf der 
Expression einer modifizierten Form des U1 small nuclear Ribonukleoproteins (U1). 
U1 ist ein Spleissfaktor der direkt am Pozess des Transkriptspleissens beteiligt ist. 
Höchstwahrscheinlich stört die Mutation in BBS1 die Interaktion von U1 mit dem 
Transkript, was dadurch den Spleissdefekt verursacht. Um die Interaktion von U1 mit 
Zusammenfassung 
2 
dem Transkript und damit die Erkennung des von der Mutation betroffenen Exons zu 
verbessern, wurde U1 an die Mutation angepasst. Die Behandlung von Patientenzellen 
mit dem angepassten U1 verhindert das Überspringen von Exon 5 und erhöht die 
Menge an korrekt gespleisstem BBS1 Transkript. Diese Resultate, werden 
möglicherweise dazu beitragen, eine Behandlungsmethode für solche Mutationen in 
betroffenen Patienten zu etablieren. 
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Summary 
 
Retinitis pigmentosa (RP) is a genetically and clinically heterogeneous disease 
leading to the degeneration of photoreceptors and can cause complete blindness. The 
prevalence of the disease is about 1 in 3000 to 4000 people with more than 1.5 million 
affected worldwide. RP can be a part of several syndromic disorders, as for example 
the Bardet-Biedl syndrome (BBS). 
We have identified mutations in the genes RPGR and BBS1 which are important for 
the functioning of the photoreceptor‟s connecting cilium. The mutations lead to 
defects in pre-mRNA splicing. Mutations in BBS1 are generally associated with BBS, 
whereas most of the mutations in RPGR cause non-syndromic RP. However, our 
patients show different phenotypes. In the family of one of the two male RP patients 
who show RPGR splice defects, heterozygous female carriers are affected. The other 
patient suffers from mild hearing impairments in addition to RP. Furthermore, the two 
patients with a splice site mutation in BBS1 show RP without any further signs of 
BBS. Our findings implicate that defects in mRNA splicing might modify progression 
and expression of the disease. The two mutations found in RPGR change the amount 
of novel, alternative transcript isoforms. We have found that the novel RPGR 
isoforms were expressed in a tissue-dependent manner in healthy individuals which 
suggests that misregulation of these variants could affect other tissues or increase 
disease severity. In contrast, the splice site mutation in BBS1 causes RP, most 
probably by reducing the amount of functional protein, whereas other tissues remain 
unaffected. 
To correct spliced defects a gene therapeutic approach using a modified form of the 
U1 small nuclear ribonucleoprotein has been developed in our group. U1 is a splicing 
factor directly involved in the general splicing process. The mutation in BBS1 causes 
the splice defect most probably by interfering with U1 binding to the transcript. To 
increase its binding affinity to the transcript and thereby improve recognition of the 
affected exon, U1 was adapted to the mutation. Treatment of patient-derived 
fibroblasts with the adapted form of U1 increased the amount of correctly spliced 
BBS1 transcripts and completely abolished skipping of exon 5. These results could 
help to establish a gene therapeutic treatment to correct splice defects in patients. 
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1. General Introduction 
 
1.1. General structure and function of the eye 
The eye is a sensory organ for visual perception converting light impulses into 
neuronal signals. In general, these signals are hierarchically transferred to different 
areas of the brain ending in the visual cortex. This area is part of the occipital lobe 
which is responsible for image processing making us capable to see images of the 
external environment. 
The eye is situated in the orbital bone cavity of the skull. A light beam has to cross 
different parts of the eye before it hits photoreceptor neurons of the retina where 
phototransduction takes place. At first, the light passes through the cornea, a 
translucent membrane built up by evenly arranged collagen fibers that covers the 
pupil and iris. Together with the cornea, the crystalline lens refracts light to ensure 
sharp images at the level of photoreceptor outer segments (Figure 1A). The cornea is 
connected with the sclera that surrounds the rest of the eye ball including optical 
nerve fibers. The next layer which is directly attached to the sclera is the choroid, a 
vascularized and pigmented tissue that supplies adjacent cells with nutritions. This 
energy supply is mainly relevant for photoreceptors and cells of the retinal pigment 
epithelium (RPE) (Blanks, 2001). Cells of the RPE carry microvilli which 
interdigitate part of photoreceptor outer segments and perform phagocytosis of shed 
outer segments (Thumann and Hinton, 2001). Furthermore components in RPE cells 
are involved in restoration of the visual pigment chromophore (Lamb and Pugh, Jr., 
2004) as described in chapter 1.1.3. on page 8. 
 
1.1.1. Structure and function of the retina 
Before light enters the retina it has to cross the vitreus body, a transparent mass of 
collagen and water which fills the space between the lens and the retina. During its 
way through the retina light encounters different, histologic layers composed of either 
cell body nuclei (nuclear layers) or synaptic interconnections (plexiform layers) 
(Figure 1B). The first layer penetrated by light is the ganglion cell layer (GCL) which 
consists of bodies of retinal ganglion cell neurons (G), whose axons center to form the 
optic nerve. Fibers of the optic nerve project to neurons of the laterate geniculate 
nuclei, the primary processing center of vision in the brain. The dendrites of ganglion 
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cells connect with synapses from bipolar (B) and amacrine (A) cells which form the 
inner plexiform layer (IPL). Bipolar cells are selectively connected to rod (R) or cone 
(C) photoreceptors and transmit neuronal signals from photoreceptors to ganglion 
cells. The inner nuclear layer (INL) is built up by cell bodies of bipolar, amacrine, 
horizontal (H) and Müller cells (M). Amacrine and horizontal cells are considered to 
be local-circuit neurons which modulate and transform visual information (Blanks, 
2001). Müller cells are a specialized type of glia cells, whose processes build synaptic 
junctions to neurons of the INL and the outer nuclear layer (ONL). Müller cells 
contribute to many essential retinal functions (Newman, 2001). The ONL is composed 
exclusively of cell bodies from cone and rod photoreceptors. Dendrites of 
photoreceptor neurons build synapses with horizontal and bipolar cells in the outer 
plexiform layer (OPL) (Blanks, 2001). 
 
Figure 1 Cell types and histologic layers of the healthy human retina. A Schematic display of 
the human eye showing different functional components. A beam of light falls directly to the 
fovea, the region of highest visual acuity located close to the optical nerve head margin. A 
histological section through the retina comprising the ganglion cell layer (GCL), inner 
plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), photoreceptors 
inner (IS) and outer segments (OS). Apical microvilli of retinal pigment epithelium (RPE) cells 
encircle the distal half of photoreceptor OS. The retina is surrounded by the choroid 
vasculature which is itself enclosed by the sclera, the eye’s most external layer. B Graphical 
illustration of cell types and synaptic processes building the different retinal layers: G, 
ganglion cell; M, Müller cell; A, amacrine cell; B, bipolar cell; H, horizontal cell; R, rods; C, 
cones. Modified from Sung and Chuang (2010) and http://biology.clc.uc.edu/fankhauser/Labs/ 
Anatomy_&_Physiology/A&P202/Special_Senses/Eye/eye_jpegs/retina_PC271517.JPG 
 
1.1.2. Rod and Cone photoreceptors 
The human retina is composed of two different types of sensory neurons termed rod 
and cone photoreceptors. Originally, photoreceptor classification was based on the 
morphologic appearance of outer segments in microscopic images. Rod outer 
segments have a more cylindrical shape, whereas the shape of cones taper in width 
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from inner to outer segments (Figure 2). Nevertheless, it seems that functional 
properties such as photosensitivity are much more useful for classification of 
photoreceptors. In average 4.6 million cones and 92 million rods are present on the 
human retina. Both cones and rods are unevenly distributed. Cones are highly 
concentrated in the macular region. Within the macula, cones center to the highest 
density in the fovea centralis, a region which lays on the optical axis of the eye ball 
and features best visional acuity (Figure 1A). The density of cones decreases 
drastically from the fovea to the periphery. Except for the rod-free fovea, rods show a 
nearly equal distribution across the retina with a slight decrease to the periphery 
(Blanks, 2001). 
A photoreceptor cell can be subdivided into an outer segment (OS) that contains the 
visual pigment and an inner segment (IS) that contains the metabolic machinery of the 
cell and the nucleus (Figure 2B). Inner and outer segments are connected through a 
modified primary cilium, referred to as the connecting cilium, which represents the 
only link between the two compartments (Blanks, 2001). Active transport of new 
membrane lipids and proteins to the OS is performed along the microtubule-based 
cytoskeleton of the cilium, called the axoneme (Kennedy and Malicki, 2009). 
Structure and function of the connecting cilium will be further described in chapter 
1.1.4. on page 11. 
Rod photoreceptors are the most predominant cell type in the human retina and are 
responsible for night vision (scotopic) by absorbing mainly blue-green light. A rod OS 
(ROS) is composed of about 1000 flattened, lamellar-shaped membrane discs which 
are stacked perpendicular to the axis of the OS (Figure 3A). These discs are enclosed 
by the plasma membrane. Although membrane discs of rods are not directly fused 
with the plasma membrane, it appears that different proteins bridge them to the 
membrane. The mechanism underlying disc morphogenesis in the ROS remains 
poorly understood. At least two models have been postulated. In one model, formation 
of new discs is explained by evaginations of the ciliary plasma membrane at the base 
of the ROS and development of a disc rim by fusing the lower membrane of an 
already existing with the upper membrane of the adjacent, nascent evagination. In the 
other model, discs of rods form by regulated fusion of membrane vesicles directly in 
the ROS (Kennedy and Malicki, 2009). The disc membranes mainly contain 
rhodopsin (RHO) which accounts for 95% of their total protein load (Sung and 
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Chuang, 2010). RHO together with its chromophore is the visual pigment of rods and 
is most sensitive to light at a wavelength of about 500 nm. 
 
Figure 2 Cone and rod photoreceptors are the light sensing neurons of the retina. A 
Scanning electron micrograph of cone (C) and rod (R) photoreceptors in the human retina. 
Image adapted from http://www.faqs.org/health/Sick-V1/Color-Blindness-Causes.html. 
B Schematic drawing of the cellular components of rods and cones. Picture taken from  
http://thebrain.mcgill.ca/flash/d/d_02/d_02_m/d_02_m_vis/d_02_m_vis.html. 
 
There are three different types of cones in the human retina that are activated 
depending on the wavelength of the light stimulus. Each cone type contains a 
wavelength-specific visual pigment that is encoded by a certain variant of the opsin 
gene. The different opsin variants have evolved through gene duplication and genetic 
divergence from a common ancestral gene. L-cones are most sensitive to red light at 
wavelengths near 560 nm, M-cones to green light at around 530 nm and S-cones to 
blue light at 420 nm. L-cones are twice as abundant as M-cones in human. Both cone 
types are most concentrated in the fovea whereas S-cones are located more towards 
the periphery. The later accounts for only 5% of the total cone population. Cone outer 
segments (COS) are shorter than ROS. Disc membranes of cones develop by the 
evagination of the ciliary membrane and remain continuously connected to the 
axoneme of the connecting cilium that extends the entire length of the COS (Figure 
3B) (Mustafi et al., 2009). Likewise in rods, the visual pigment of cones is located in 
the disc membranes of the COS. 
In summary, the high density of opsins together with the orderly arrangement of disc 
membranes in photoreceptor OS provide most efficient visual sensitivity and spatial 
control over phototransduction (Kennedy and Malicki, 2009; Sung and Chuang, 
2010). 
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Figure 3 Structure of photoreceptor outer segments. A Electron microscopic image and 
schematic drawing of stacked membrane discs in rod outer segments which are not 
connected to the connecting cilium (red line) and plasma membrane. B Electron micrograph 
of evaginated membrane discs in the cone outer segment which retain associated to the 
connecting cilium. In contrast to rods, the ciliary axoneme of cones (red line) extends the 
entire length of the outer segment. Pictures are adapted from Kennedy and Malicki  (2009) 
and Mustafi (2009). 
 
1.1.3. The phototransduction cascade 
The photopigment responsible for light sensing and signal transduction in rods and 
cones consists of a protein part and a retinal-derived chromophore. In humans, the 
protein part is encoded by the rhodopsin (RHO) gene or by three different cone opsin 
genes. In all visual pigments the chromophore 11-cis-retinal is covalently bound to a 
Lysine in the protein binding pocket and confers light sensitivity to the pigment 
(Nickle and Robinson, 2007). For simplicity, the term opsin is used in the following to 
refer to all types of chromophore-bound, light-sensitive visual pigments. Opsins are 
members of the G-protein-coupled receptor (GPCR) protein family. GPCRs are 
defined by their seven-transmembrane spanning domain and the ability to activate 
GTP-binding proteins (G-proteins). Opsins are activated throught light-induced 
isomerization of 11-cis retinal to all-trans retinal leading to a conformational change 
in the protein. It is assumed that substitutions of amino acids that are in close contact 
to the chromophore interfere with its double bound system. This can result in higher 
need of energy for chromophore isomerization and explains the differences in light 
sensitivity between opsins (Nickle and Robinson, 2007). 
The phototransduction cascade in vertebrate rods is well understood (Figure 4). In 
darkness, there is a high concentration of cyclic GMP (cGMP) in the cytoplasm of 
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ROS which is produced by a constitutively active guanylate cyclase (GC) integrated 
into the disc membrane. The thereby synthesized cGMP can bind to cyclic-nucleotide-
gated (CNG) cation channels on the plasma membrane of ROS. On the condition that 
cGMP is bound, these channels are permeable to monovalent and divalent cations, 
such as for instance Ca
2+
. Influx of Ca
2+
 is balanced by an equal Ca
2+
 efflux via a 
Na
+
/Ca
2+
, K
+
 exchanger (NCKX) keeping the photoreceptor in a depolarized state. 
Likewise, the level of cytoplasmic cGMP is held in a steady state in the dark by the 
activity of a membrane-attached phosphodiesterase (PDE), which hydrolyses cGMP 
(Yau and Hardie, 2009). 
The activity of PDE is further increased upon a light stimulus as described in the 
following. Light-induced activation of rhodopsin leads to its association with the G-
protein transducin (Gt) which causes an exchange of bound GDP with GTP in the  
subunit of Gt (Gt). After this step, Gt dissociates from transducin  subunits (Gt) 
and associates with the  subunit of PDE (PDE), which blocks hydrolytic activity of 
PDE and subunits. When bound to Gtthe inhibitory effect of PDEon PDE 
subunits is removed and cGMP can be hydrolyzed leading to lower cytosolic cGMP 
concentrations. This decrease lead to a rapid dissociation of cGMP bound to CNG 
channels and closes the cannels. The closure of CNG channels stop cation influx (e.g. 
Ca
2+
) but not efflux by NCKX. Consequently, photoreceptors are hyperpolarized what 
reduces or stops their release of glutamate neurotransmitter at the synapse (Yau and 
Hardie, 2009). The reduced glutamate-release from photoreceptors activates bipolar 
cells that further process and transmit the signal to other retinal neurons. Finally, 
neuronal signals are sent to the brain for higher-order processing. 
The processes that deactivate the phosphotransduction cascade are complex and not 
completely understood (Figure 4). Active rhodopsin can be deactivated through 
phosphorylation by a rhodopsin kinase (GRK1) and subsequent binding of arrestin 
(Arr). Gt is deactivated by itself because of its intrinsic GTPase activity, which can 
be facilitated by the GTPase activating-protein (GAP) complex. Inactivation of 
phototransduction can also be achieved through multiple negative-feedback 
mechanisms mediated by Ca
2+
 levels. A decrease in Ca
2+
 has three effects. First, 
activity of GC is increased. 
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Figure 4 Phototransduction cascade in a rod photoreceptor outer segment. Different 
components involved in the process are shown: activated rhodopsin (Rh*), G-protein (Gt), 
phosphodiesterase (PDE), guanylat cyclase (GC), cyclic-nucleotide-gated (CNG) cation 
channels Na
+
/Ca
2+
, K
+
 exchanger (NCKX). Mechanisms for deactivation of phototransduction 
are indicated in red and includes activities of G protein-coupled-receptor-kinase 1 (GRK1), 
arrestin (Arr) and guanylate cyclase-activating proteins (GCAP). Figure is taken from Yau and 
Hardie (2009). 
 
Elevation of GC activity requires two guanylate cyclase-activating proteins, termed 
GCAP1 and GCAP2, which are negatively modulated by Ca
2+
. Second, the activity of 
GRK1 is negatively influence by the Ca
2+
 binding protein recoverin leading to higher 
amounts of inactive rhodopsin when Ca
2+
 is low. Third, low amounts of Ca
2+
 result in 
higher affinity of CNG channels to cGMP what increases the frequency of these 
channels to be in the open state (Yau and Hardie, 2009). Together, all these 
mechanisms ensure deactivation of phototransduction and a fast response to the next 
light stimulus. Furthermore, it has been found that transducin, arrestin and recoverin 
change their localization in photoreceptor segments upon stimulation to bright light: 
Transducin translocates to the IS and recoverin towards the synapse whereas arrestin 
moves to the OS of photoreceptors. These light-driven translocations may contribute 
to the process by which photoreceptors adjust their sensitivity to ambient light 
intensities (Calvert et al., 2006). 
In order to prepare rhodopsin to activate another phototransduction event, light-
induced isomerization of all-trans retinal has to be restored into 11-cis retinal. 
Thereby, the isomerized retinoid undergoes a long series of reactions referred to as the 
retinoid cycle. In rods, the enzymatic steps of the retinoid cycle are accomplished in 
ROS and the adjacent RPE (Figure 5) (Yau and Hardie, 2009). The covalent bond 
between rhodopsin and all-trans retinal (RAL) is hydrolyzed and reduced to all-trans 
retinol (ROL; vitamin A) in the ROS. Vitamin A then exits the photoreceptor and 
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enters the RPE cell. Within the RPE, vitamin A is converted into 11-cis retinal after 
several subsequent reactions preformed by different enzymes including RPE65. 
Finally, the restored chromophore is transported back to the ROS where it associates 
with rhodopsin (Lamb and Pugh, Jr., 2004). 
 
Figure 5 Restoration of isomerized retinoid from rods or 
cones which is accomplished by enzymes in 
photoreceptor OS and RPE cells. A photon (h ) 
produces the isomerized chromophore intermediate 
(Meta-II) which is enzymatically recycled from all-trans 
retinal (RAL) via all-trans retinol (ROL, vitamin A) to 11-
cis retinal (RAL). These steps are performed mainly by 
the activities of all-trans retinol dehydrogenase (RDH), 
the extracellular carrier interphotoreceptor retinoid-
binding protein (IRBP), RPE intracellular carriers 
(cellular retinol binding (CRBP) and retinaldehyde 
binding protein (CRALBP)), retinyl isomerohydrolase 
RPE65, and all-cis RDH. Figure is adapted from Yau 
and Hardie (2009). 
 
 
 
 
 
 
1.1.4. The photoreceptor connecting cilium 
The eukaryotic cilium is a cell organelle whose structure is based on centriole-derived 
microtubule projections. It is wrapped by the plasma membrane, called ciliary 
membrane. The microtubule cytoskeleton of the cilium is termed the ciliary axoneme. 
Mammalian ciliary axonemes can appear in two different configurations. Motile cilia 
usually have nine doublet microtubules surrounding a single central doublet (9+2 
configuration) with axonemal dynein arms, whereas nonmotile cilia miss the doublet 
microtubules in the center (9+0 configuration) and are devoid of dynein (Figure 6A). 
In general, nonmotile cilia are found singly on almost every cell of the human body 
(Satir and Christensen, 2007). Because of their widespread distribution they are now 
defined as primary cilia. It has been demonstrated for many cases that primary cilia 
carry out different sensory functions. 
The photoreceptor OS is a highly elaborated structure, which has been derived from a 
primary cilium. During differentiation of rod photoreceptors, the ROS is formed from 
a primary cilium located on post-mitotic retinal progenitor cells. After huge structural 
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modifications of the distal part of the ROS, there is only a segment of the cilium left 
that bridges the IS with the OS. This structure is called the connecting cilium (CC) 
(Pazour and Rosenbaum, 2002). The CC represents the only link between the two 
compartments of photoreceptor cells (Figure 6B) and is assumed to act as a ciliary 
necklace having similar properties as the passage formed by the nuclear pore complex 
(Satir and Christensen, 2007). Consequently, all lipids and proteins which are 
synthesized in the IS, but needed in photoreceptor OS, must be actively transported 
through the CC. The need for opsin in the OS is immense. It has been estimated that 
2000 opsin molecules have to be transported through the CC within a minute (Pazour 
and Rosenbaum, 2002). 
The transport of lipids and proteins along the CC is mediated by a process called 
intraflagellar transport (IFT). Initially, IFT was found to play a crucial role in 
assembly and disassembly of cilia and flagella. The main components of the IFT 
protein machinery that actively transports cargo along the ciliary axoneme are 
members of the kinesin and dynein superfamily. These microtuble-based motors move 
either to the plus (anterograde) or to the minus end (retrograde) of the axoneme 
(Figure 6C). The kinesin II complex moves anterogradely from the basal body to the 
cilia tip and is composed at least of KIF3A, KIF3B and the non-motor subunit 
kinesin-associated protein (KAP) (Rosenbaum and Witman, 2002). Recent findings 
identified homodimeric kinesin OSM-3/KIF17 as an additional anterograde molecular 
motor. The retrograde transport is mediated by a cytoplasmic dynein heavy chain 
subunit, known as dynein 2 (Dhc2) in mammals. Other components of the retrograde 
IFT motor are dynein light intermediate and the dynein light chain (Silverman and 
Leroux, 2009). These molecular motors transport large protein complexes, called IFT 
particles, which are suggested to assist transport of target proteins (Pazour and 
Rosenbaum, 2002). Studies in a conditional KIF3A knock out and mice affected by a 
hypomorphic mutation in the IFT particle gene Tg737 (IFT88) showed accumulation 
of rhodopsin in IS and retinal degeneration at later stages (Marszalek et al., 2000; 
Pazour et al., 2002). These results provided first evidence that IFT is important for 
development, maintenance and function of photoreceptors and for precise localization 
of rhodopsin to the OS. Further support for a rhodopsin transport by IFT was aquired 
recently by pull down assays demonstrating the interaction of rhodopsin with 
components of IFT particle. In the same study, the existence of a IFT cargo complex 
containing GC was also suggested (Bhowmick et al., 2009). 
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Figure 6 Structure and transport along the connecting cilium in the vertebrate rod 
photoreceptor. A Electron microscopic image of a cross section through the axoneme of a 
primary cilium featuring the 9+0 configuration. B Electron micrograph showing inner segment 
(IS), outer segment (OS) and the connecting cilium (CC). C Interflagellar transport (IFT) 
among the connecting cilium. Images are adapted from Rosenbaum and Witman (2002) and 
Insinna and Besharse (2008). 
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1.2. Inherited diseases affecting photoreceptors 
Photoreceptors are highly organized structures, especially in the OS and are 
specialized to react upon a light stimulus. The correct development and maintenance 
of these dynamic structures is a prerequisite to perform their tasks. It is plausible, that 
photoreceptors are highly susceptible to mutations in genes involved in e.g. 
phototransduction or structure formation. Indeed, a significant fraction of human 
inherited disorders results in retinal degeneration. 
In many cases, the cause for the disease is directly found in the photoreceptors. These 
ocular diseases can be classified into three major groups depending whether mainly 
rods, cones or both cell types are affected (Berger et al., 2010). For some of the 
disorders, the ocular manifestation is part of a syndromic phenotype showing also 
dysfunctions of other tissues. This makes it necessary to further subdivide the 
disorders into non-syndromic or syndromic types. A prominent example for a non-
syndromic, non-progressive disease which mainly causes defects in the rod visual 
system is congenital stationary night blindness (CNGB). In contrast, retinitis 
pigmentosa (RP) shows a progressive loss of rod photoreceptors. Disruption of the 
cone visual system includes stationary and progressive forms. Stationary forms of 
cone dystrophies are represented by complete and incomplete achromatopsia which 
are usually congenital. Progressive loss of cones is described for cone dystrophies 
(CODs) , cone rod dystrophies (CORDs) and monogenic or age-related macular 
degenerations (Berger et al., 2010). 
 
1.2.1. Retinitis pigmentosa 
Retinitis pigmentosa (RP; OMIM 268000) is a group of inherited retinal dystrophies 
that show progressive loss of primarily rod photoreceptors and subsequent retinal 
pigment deposits. The disease is clinically and genetically heterogeneous. In the early 
stage of non-syndromic RP, night blindness is the main symptom which is present 
within the first decade or during the second decade of life. At this stage of the disease 
visual acuity and fundus examinations appear to be normal. At the mid stage, rod 
photoreceptors start to degenerate at the periphery resulting in the presence of bone 
spicule-shaped pigment deposits in the mid periphery of the retina (Figure 7A). At 
this stage patients may notice the beginning of vision loss in the peripheral visual field 
leading to tunnel-vision. At later stages, complete loss of peripheral vision disables 
patients to move autonomously. In the fundus of patients, pigment deposits can be 
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detected in many retinal areas, as well as clear reduction of retinal vessels thickness 
(Figure 7B). At late stages, cone photoreceptors may die, which lead to loss of central 
vision and can cause complete blindness (Hamel, 2006). 
 
Figure 7 Funduscopic images of an RP patient. A Image at mid stage of the disease showing 
mid-peripheral pigment deposits. B At the final stage of the disease, pigment deposits are 
abundantly distributed over the whole retina and the retinal vessel system is largely 
attenuated. Pictures are taken from Hamel (2006). 
 
The prevalence of RP is approximately 1 in 4000 individuals. More than 40 RP-
associated genes have been identified. These genes may be involved in 
phototransduction, retinal metabolism, development and maintenance of cellular 
structures, and mRNA splicing (Berger et al., 2010). It has been described that in non-
syndromic RP 30-40% of all cases are autosomal dominant (adRP), 50-60% are 
autosomal recessive (arRP) and 5-15% are X-linked (XlRP) (Hartong et al., 2006). 
Furthermore, a digenic inheritance mode has been reported in which a heterozygous 
mutation in the retinal outer segment membrane protein 1 (ROM1) together with a 
heterozygous mutation in peripherin 2 (PRPH2) cause the RP phenotype (Kajiwara et 
al., 1994). Mutations in RHO were the first to be associated with the disease and 
account for more than 25% of all adRP cases. Among the different inheritance modes, 
XlRP is the most severe form. Here, most of the mutations were found in the retinitis 
pigmentosa GTPase regulator gene (RPGR) which account for more than 70% of all 
XlRP cases (Hartong et al., 2006). 
RP can also be part of a syndromic phenotype affecting other tissues. A prominent 
example is Usher syndrome, in which RP is associated with neurosensory deafness. 
Another example is Bardet-Biedl syndrome (BBS) which will be described in detail 
further below in this chapter. In addition, many other syndromes include RP as an 
ocular manifestation (Hamel, 2006). Descriptions of inherited retinal diseases are 
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summarized in RetNet (http://www.sph.uth.tmc.edu/Retnet/) or http://www.ncbi. 
nlm.nih.gov/sites/ GeneTests. 
 
1.2.2. The retinitis pigmentosa GTPase regulator 
The retinitis pigmentosa GTPase regulator (RPGR) gene contains 19 constitutive 
exons and was initially found to be disrupted in XlRP (Meindl et al., 1996; Roepman 
et al., 1996a; Roepman et al., 1996b). To date, a minor fraction of mutations could be 
identified in exons 1-14, whereas the majority of mutations were detected in an 
alternatively spliced exon designated ORF15 (Vervoort et al., 2000). 
A minor portion of RPGR mutations cause a broader phenotypic spectrum than typical 
XlRP. For some XlRP families it has been reported that females are also affected 
(Mears et al., 2000; Rozet et al., 2002; Banin et al., 2007; Pelletier et al., 2007; 
Neidhardt et al., 2008). In other cases mutations in RPGR can lead to ocular 
phenotypes which are clearly distinct from RP. For instance mutations in RPGR exon 
ORF15 can cause CORD (Mears et al., 2000; Demirci et al., 2002; Walia et al., 2008), 
COD (Pelletier et al., 2007), atrophic macular degeneration (Ayyagari et al., 2002) or 
RP and Coats‟-like exudative vasculopathy (Demirci et al., 2006). Furthermore, non-
ocular manifestations in syndromic phenotypes with RP have also been described. 
This includes primary ciliary dyskinesia (Moore et al., 2006) or hearing loss and 
infections of respiratory tract (Iannaccone et al., 2003; Zito et al., 2003). In summary, 
these findings implicate that the function of RPGR might not only be important for the 
retina, but is also needed in other tissues. It further raises the possibility that other 
factors may modify the phenotypic expression of the disease in patients with RPGR 
mutations. 
The RPGR transcript is widely expressed in human tissues including retina, brain, 
lung, kidney and testis. Interestingly, many alternative transcript isoforms have been 
identified (Figure 8) demonstrating skipping of constitutive exons 14 and 15 together 
or usage of alternative exons 9a, 15a or 15b or parts of ORF15 (Kirschner et al., 1999; 
Vervoort et al., 2000; Neidhardt et al., 2007). However, the physiological functions of 
these alternative transcript isoforms are not completely understood. 
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Figure 8 Schematic drawings of known RPGR transcript isoforms. Constitutive exons are 
labeled in black and alternatively used exons in gray. All alternative exons contain a stop 
codon (*) which truncates the protein. Thus, only the translated open reading frame of these 
transcripts is displayed. a) constitutive isoform (exons 1 to 19); b) transcript variant skipping 
exons 14 and 15; c) isoform containing exon ORF15; inclusion of either d) 15b or 15a or e) 
exon 9a. 
 
Part of the RPGR protein encoded by exons 2 to 11 shows homology to a common 
domain found in the regulator of chromosome condensation (RCC1) and was 
designated RCC1-like domain (Meindl et al., 1996; Roepman et al., 1996b). RCC1 is 
a guanine nucleotide exchange factor (GEF) for Ran GTPases whose form has the 
structure of a seven-bladed propeller (Renault et al., 2001). Although, the RCC1-like 
domain in RPGR exhibits homology to GEFs, no such activity has been identified so 
far. However, a ciliary function has been proposed because of its colocalization to this 
cell organelle. It has been demonstrated that RPGR protein isoforms mainly locate in 
the connecting cilium and basal body of photoreceptors and to the tip and axoneme of 
sperm flagella (Shu et al., 2005; Khanna et al., 2005). Furthermore, male infertility 
was found in RPGR overexpressing mice (Brunner et al., 2008). Together these 
results might implicate that RPGR has an essential function in the cilium. Further 
evidence that RPGR is involved in cilia-specific processes has been acquired through 
binding studies which revealed interaction to other cilia-associated proteins e.g. 
RPGRIP, NPHP5, IFT88, CEP290, RPGRIPL and RAB8A (Boylan and Wright, 
2000; Roepman et al., 2000; Otto et al., 2005; Chang et al., 2006; Khanna et al., 2009; 
Murga-Zamalloa et al., 2010). 
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1.2.3. Bardet-Biedl syndrome 
Bardet-Biedl syndrome (BBS; OMIM 209900) is a multisystemic disorder, primarily 
caused by dysfunctions of cilia. The prevalence of BBS is about 1 in 120‟000 
individuals for all live births in North America and Europe (Blacque and Leroux, 
2006). The main symptoms found in BBS patients are retinal degeneration, 
polydactyly, mental retardation, truncal obesity, genital and renal anomalies. 
Secondary features are also associated with the disease including speech disorders, 
developmental delay, hearing loss and situs inversus (Tobin and Beales, 2007). BBS 
is clinically diagnosed on the condition that either 4 primary or three primary and two 
secondary features are present in the patient (Beales et al., 1999). To date, mutations 
in 15 genes have been identified to be disease-causing (Zaghloul and Katsanis, 2009; 
Kim et al., 2010). These mutations account for 80% of all BBS cases and most of 
them are recessively inherited. Nevertheless, complex multiallelic inheritance has also 
been described for BBS (Katsanis et al., 2001; Beales et al., 2003; Fauser et al., 2003). 
Additionally, the disease phenotype in patients with BBS can be highly variable. For 
instance, it has been demonstrated that the gain of a third mutant allele at a second 
locus in BBS patients from the same family, increased severity of the disease 
compared to those having only two mutations at the same locus (Badano et al., 2003; 
Fan et al., 2004). Furthermore, mutations in BBS genes have been reported to lead to 
a non-syndromic RP phenotype (Aldahmesh et al., 2009; Riazuddin et al., 2010). In 
summary, these findings indicate that the total mutational load in these genes is 
mainly responsible for the variable phenotypic expression diagnosed in BBS. 
Initially, Bardet-Biedl syndrome proteins 4 (BBS4) and 8 (BBS8) were found to 
localize to centriolar satellites and to the basal body of ciliated cells (Ansley et al., 
2003; Kim et al., 2004). Interestingly, BBS4 can interact with the pericentriolar 
material 1 protein (PCM1) (Kim et al., 2004), which is important for centrosome 
integrity, microtubule organization (Dammermann and Merdes, 2002) and 
ciliogenesis (Mikule et al., 2007). Specific staining of BBS8 in mice revealed 
association to ciliary structures in spermatids, bronchial epithelial cells and to the 
photoreceptor connecting cilium (Ansley et al., 2003). In summary, these findings 
suggested that BBS4 and BBS8 function at the primary cilium. Moreover, BBS4 and 
BBS8 were found in a protein complex named the BBSome together with BBS1, 
BBS2, BBS5, BBS7, and BBS9 (Nachury et al., 2007). The complex might be 
transported through centriolar satellites to the basal body where it associates with the 
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ciliary membrane and interacts via BBS1 with the GEF Rabin8. Rabin8 activates the 
Rab8 GTPase which associates with post-Golgi vesicles and enters the primary cilium 
upon GTP loading (Nachury et al., 2007). It has been found that docking and fusion of 
rhodopsin containing membrane vesicles with the ciliary membrane depend on the 
function of Rab8 (Moritz et al., 2001). Supportively, loss of BBS proteins leads to 
rhodopsin mislocalization in mice (Nishimura et al., 2004; Mykytyn et al., 2004). It 
seems very likely that the BBSome is involved in rhodopsin transport to the 
connecting cilium. Furthermore, two different studies demonstrated that the BBSome 
is required for correct ciliary localization of leptin and G-coupled receptors (Berbari 
et al., 2008; Seo et al., 2009). Together, all these data suggest that the BBSome plays 
an important role in the vesicular trafficking of membrane proteins to the primary 
cilium. Consequently, disruptions in this vesicular transport process could affect the 
function of several tissues causing the different phenotypes associated with BBS. 
 
1.3. Splicing of pre-mRNA transcripts 
A typical eukaryotic gene contains protein coding sequences, called exons and non-
coding sequences, called introns, which are arrayed alternately along the gene. Introns 
account for more than 90% of the primary transcript in humans (Wang and Burge, 
2008). After transcription of the gene, introns have to be removed and exons joined 
together to produce a functional mRNA. Consensus sequences at 5‟end, near to and at 
the 3‟ end of introns are required for the precise defininition of exon-intron 
boundaries (Figure 9A). These classical splice sites encompass the splice donor site 
(SD), the branch point sequence (BPS), the polypyrimidine tract and the splice 
acceptor site (SA). The chemical reactions essential for intron removal are two 
phosphoryl-transfer steps (Figure 9B). In the first step the 2‟ hydroxyl group of an 
Adenosine in the BPS attacks the phosphodiester bond between the nucleotides at the 
exon-intron boundary in the SD. This first transesterification reaction generates a free 
hydroxyl group at the 5‟ exon. This free 3‟ hydroxyl group at the 5‟ exon then attacks 
the phosphodiester at the exon intron boundary of the SA, which results in exon 
ligation and excision of the intron (Collins and Guthrie, 2000). These chemical 
reactions can occur spontaneously without additional need for energy and protein 
components. This has become evident when a type of intron was identified that could 
self-splice in vitro by absolutely identical transesterification reactions (Michel and 
Ferat, 1995). 
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Correct recognition of splice sites within a multitude of similar sequences and the 
establishment of the active splice complex which is a prerequisite to perform the two 
transesterification reactions, poses a challenge for the splicing machinery. Interactions 
of many RNA and protein components within a complex, designated the spliceosome, 
are needed to control the process of splicing. The spliceosomal components act 
through a multitude of RNA-RNA, RNA-protein and protein-protein interactions. 
Most important interactions between the degenerated sequences in classical splice 
sites and components of the spliceosome are weak. This implicates the necessity of 
trans-acting splicing factors to increase exon definition by binding to other sequences 
in the pre-mRNA (Wahl et al., 2009). In addition to these factors, many proteins have 
been identified that regulate the usage of specific splice sites. The mechanisms by 
which these regulatory proteins act on the pre-mRNA to influence splicing will be 
summarized in the next chapter about alternative splicing. In this chapter, the focus 
will be on the basic splicing process. 
A 
 
 
B 
 
Figure 9. Classical splicing signals and chemical transesterification reactions involved in pre-
mRNA splicing. A Degenerated sequence motifs found at the splice donor (5’ splice site), 
branch site and splice acceptor (3’ splice site) of human gene transcripts evaluated by the 
alignment of conserved sequences from 1’683 human introns. The size of a nucleotide at a 
given position is proportional to its conservation. Nucleotides which are part of the classical 
consensus are shown in blue, except for the branch point A nucleotide, which is coloured in 
orange. B Two step transesterification reactions resulting in excision of the intron form the 
pre-mRNA. Illustrations are taken from Collins and Guthrie (2000) and Cartegni (2002). 
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The splicing machinery features a highly dynamic structure, where different factors 
enter or exit during the splicing process. Furthermore, conformational changes in 
several spliceosomal subunits can be observed, which require chemical energy in the 
form of ATP and GTP. Together, this all ensures the time-controlled and accurate 
process of pre-mRNA splicing (Wahl et al., 2009). In general, the spliceosome 
comprises five main building blocks of uridine-rich small nuclear ribonucleoproteins 
(UsnRNP) termed U1, U2, U4/U6 and U5 snRNP which assemble stepwise on the 
pre-mRNA. An UsnRNP contains a snRNA (or two in case of U4/U6) and complex-
specific proteins. All snRNPs, except U6, contain seven Sm proteins which bind to 
the highly conserved Sm sequence in the snRNA (Will and Luhrmann, 2001). 
Spliceosome assembly starts with binding of the U1 snRNP to the SD which is 
mediated through base-pairing interactions of the 5‟end of the U1 snRNA to the 9 
nucleotides spanning SD (Lund and Kjems, 2002). At the same time, the branch point 
binding protein (BBP) and the U2 auxiliary factor (U2AF) bind to the BPS, the 
polypyrimidine tract and the SA. These processes lead to the formation of the 
spliceosomal E complex. ATP-dependent base-pairing of the U2 snRNP with the BPS 
then causes dissociation of BBP building the A complex. Subsequently, the 
heterotrimeric complex preassembled from U4/U6 and U5 snRNPs, termed U4/U6.U5 
tri-snRNP is recruited to form the B complex. After dissociation of U1 and U4 this 
complex becomes activated and the spliceosome undergoes the first catalytic step of 
splicing which generates the C complex. After spliceosomal rearrangements and 
performance of the second catalytic step, spliceosomal components dissociate from 
the mRNA (Wahl et al., 2009). The mRNA is then transported through the nuclear 
pore into the cytoplasm where it serves as template for protein synthesis. 
 
1.3.1. Alternative splicing 
Human proteins can exist in many different isoforms which mainly arise from 
alternative splicing of the same pre-mRNA transcript (Black, 2000). Alternative 
splicing is regulated often in a tissue- or developmental stage-dependent fashion and 
thus contributes to the complexity of multi-cellular organisms. 
It is now clear that more than 90% of all human genes are alternatively spliced (Wang 
et al., 2008). Alternative transcript isoforms may arise through five major mechanisms 
in most eukaryotes, but their utilization are species dependent (Figure 10). In human 
and mice, skipping of constitutive exons accounts for 38% of all alternative splicing 
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events. Another mechanism involves the usage of alternative SDs or SAs and is 
responsible for 18% and 8%, respectively. Furthermore, retention of the intron can be 
detected in 3% of alternatively spliced transcripts. The remaining 33% may include 
mutually exclusive events, the usage of alternative transcription start sites and 
multiple polyadenylation sites (Ast, 2004). 
Figure 10 Alternative splicing of the pre-mRNA 
results in 5 major classes of spliced products. 
Constitutively used exons are labeled in red. 
Regions in the pre-mRNA transcript which are 
alternatively spliced are shown in green. Dashed 
lines represent different splice events whereas 
solid lines represent introns. The frequency of 
each splicing event in accordance to all 
alternative splicing events is given in 
percentages. Figure taken from Ast (2004). 
 
 
 
 
 
 
 
 
 
Recognition of exons and introns is performed by the interaction of spliceosomal 
subunits with classical splice sites, as described above in detail. In mammals, the SD 
and SA are predominantly recognized in pairs across exons by a process called exon 
definition. However, the core splicing signals at the SD, SA and BPS are degenerated 
making interactions between the spliceosome and these core splice signals weak. It is 
assumed that these sequences account for only half of the information needed to 
define the boarders of the exon (Wang and Burge, 2008). As a consequence, there 
must be other splicing factors that guide the spliceosome to its target. These factors 
act in trans by binding to cis-regulatory elements and mainly control spliceosome 
assembly. The splicing regulatory elements (SRE) in exons are classified into either 
negative or positive regulators called, exonic splicing enhancer (ESE) or silencer 
(ESS). If they are found in introns they are named intronic splicing enhancer (ISE) or 
silencer (ISS). ESEs are predominantly found in constitutive exons and bound by 
serine/arginine (SR) proteins through their RNA recognition motiv. SR proteins 
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enhance splicing of its exon by facilitating spliceosome assembly. On the other hand, 
ESSs often recruit proteins from the class of heterogenous nuclear ribonucleoproteins 
(hnRNPs). Proteins in this group contain one or more RNA-binding domains and or 
glycine-rich motifs that can block the splicing process. The hnRNPs inhibit splicing 
either by blocking essential interactions of spliceosomal subunits or by occupying 
classical splice sites. In a few cases intronic SREs have also been identified, but many 
of them remain to be discovered (Wang and Burge, 2008). Because intronic regions 
that flank alternatively spliced exons are more conserved compared to constitutive 
exons, it is presumed that intronic cis-regulatory elements are more important for the 
regulation of alternative exon usage (Ast, 2004). Splicing enhancers and silencers 
often act additively by increasing their effect with the amount of additional copies 
(Wang and Burge, 2008). All together, the integration of all signals from classical 
splice sites and SREs will finally determine whether the exon is skipped or included 
into the transcript. 
 
1.3.2. Splicing and disease 
Mutations in classical splice sites reduce interactions of spliceosomal components 
with the pre-mRNA. As a consequence, the lower binding affinity of general splicing 
factors leads to impaired exon definition and finally to aberrant splicing of the 
transcript. Initially, it has been estimated that about 15% of all disease causing point 
mutations lay in classical splice sites. Many other mutations have been identified so 
far that are not within classical splice sites, but also disrupt the splicing process. 
Together, it has been proposed to date that 60% of all point mutations have their 
major pathogenic effect through impaired pre-mRNA splicing (Wang and Cooper, 
2007). Interestingly, mutations identified in the Versican (VCAN) gene cause Wagner 
disease, by inducing missplicing of the transcript (Miyamoto et al., 2005; Kloeckener-
Gruissem et al., 2006; Mukhopadhyay et al., 2006; Ronan et al., 2009). 
Mutations affecting splicing of gene transcripts can be classified into different groups 
depending on their localization and effect on splicing. Mutations that affect the gene 
in which they are localized are termed cis-acting mutations. These mutations can 
either affect the usage of constitutive or alternative exons. Impaired exon recognition 
through cis-acting mutations in classical splice sites can cause exon skipping, intron 
retention or activation of a pre-existing cryptic splice site, which is distal to the 
mutation. Many of these aberrantly spliced products contain a premature termination 
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codon (PTC) as a consequence of a shift in the open reading frame (Faustino and 
Cooper, 2003). Transcripts possessing a PTC are usually degraded through an RNA 
quality control mechanism termed nonsense-mediated mRNA decay (NMD). In 
mammals, this control mechanism is tightly bound to the splicing events in the pre-
mRNA and is most efficient when the PTC resides more than 50-55 nucleotides 
upstream of the next exon-intron junction (Lejeune and Maquat, 2005). Because 
classical splice site mutations usually lead to transcript degradation by NMD, it is 
assumed that these mutations gain their pathogenic effect mainly through loss of the 
gene product. In contrast, it seems that cis-acting mutations affecting the usage of 
alternative splice sites are pathogenic because they shift the ratio of expressed 
transcript isoforms (Faustino and Cooper, 2003). Changes in splice patterns can have 
deleterious effects on the function of a gene which often leads to diseases. Especially, 
neurons seem to be highly susceptible to alterations in the expression of alternative 
isoforms (Dredge et al., 2001). 
In contrast to defects in cis-acting splice sites, mutations in trans have also been 
identified and are considered to affect expression of a large number of different genes, 
rather than only one (Cooper et al., 2009). Trans-acting splicing factors that can be 
affected by mutations include components of the basal splicing machinery or genes 
that promote correct maturation of these components. A prominent example for 
mutations leading to a dysfunction of the basal splicing machinery is found in spinal 
muscular atrophy (SMA). Patients with SMA show degeneration of motor neurons. 
Deletions in the survival motor neuron 1 gene (SMN1) lead to a reduction of 
functional SMN proteins and are considered to be the primary cause for SMA. The 
SMN protein is part of a multimeric complex essential for spliceosomal snRNP 
assembly (Yong et al., 2004). In mice, SMN deficiency reveals global defects in pre-
mRNA splicing which are most probably due to the impaired functions of immature 
snRNPs. These findings might help to further elucidate the pathogenic mechanisms in 
patients with SMA (Zhang et al., 2008). A second class of trans-acting splicing 
factors is involved in regulation of alternative splicing only (Faustino and Cooper, 
2003). For instance, It has been found that the small nucleolar RNA HBII-52 regulates 
alternative splicing of the serotonin receptor 5-HT2CR and its expression is lost in 
patients with Prader-Willi Syndrome (PWS). Alterations in splicing of the serotonin 
receptor have been detected as a consequence of the lack of HBII-52 which may lead 
to the disease (Kishore and Stamm, 2006). Recently, novel transcript targets of HBII-
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52 have been identified that, when aberrantly spliced, may contribute to the 
pathogenesis in PWS patients (Kishore et al., 2010). 
In addition, defects in the basal splicing machinery are also involved in the 
pathogenesis of autosomal dominant RP. Mutations in the common splicing factors 
PRPF31, PRPF8, PRPF3 and PAP1 have been identified in RP patients. The proteins 
are all components of the basal splicing machinery and are crucial for the formation of 
the U4/U6.U5 tri-snRNP and for general assembly of several spliceosomal subunits. 
PRPF31 is part of the U4/U6 snRNP and is directly involved in the formation of the 
tri-snRNP by binding to the U4 snRNA. Furthermore, it is assumed to mediate the 
recruitment of the tri-snRNP into the spliceosome. Like PRPF31, PRPF3 is also a 
component of the U4/U6 snRNP and may recruit other factors necessary for correct 
assembly. A subunit of the tri-snRNP is PAP1, which interacts with other splicing 
factors that perform the early steps of spliceosome assembly (Mordes et al., 2006). 
PRPF8 is a core protein of the U5 snRNP and presumed to control spliceosome 
activity during the splice process (Wahl et al., 2009). 
It still remains an open question why mutations in these widely expressed splicing 
factors lead to a tissue-specific disease, such as RP. In lymphoblasts from patients 
with PRPF31 null alleles, no specific effect on splicing was observed. In contrast, 
splice defects in different photoreceptor-specific transcripts were observed due to 
mutations in PRPF31 (Yuan et al., 2005; Mordes et al., 2007). These findings support 
a model where the impaired functioning of spliceosomal components cannot sustain 
the high demand of photoreceptors for correctly spliced transcripts. As a consequence, 
lower amounts of these transcripts, derived for instance from the RHO gene, may 
subsequently promote cell death (Mordes et al., 2006). 
 
1.3.3. Therapeutic approaches to treat splice defects 
Defects in pre-mRNA splicing not only decrease the amount of functional transcripts, 
but can also lead to aberrant splicing products or a shift in the ratio of alternative 
transcript isoforms. All these defects may cause the disease by acting through distinct 
pathogenic mechanisms. In order to fully restore the splicing pattern, these findings 
implicate the necessity to increase normal transcript levels and to remove the presence 
of potentially toxic splicing products. Many different approaches have been 
established where the mutant pre-mRNA is the direct target of the therapeutic 
intervention (Figure 11). 
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Figure 11 Overview of different therapeutic interventions to treat defects in pre-mRNA 
splicing. A-E Five approaches have been established using either: RNAs, antibodies or small 
molecules as the therapeutic agent. In spliceosome-mediated RNA trans-splicing (SMaRT) a 
mutated exon can be replaced by splicing with an artifical RNA template containing the wild-
type cDNA sequence. Figure is adapted from Wang and Cooper (2007). 
 
The amount of inclusion of a specific exon into the transcript can be modulated for 
instance by small pharmacological reagents that influence the activity state of certain 
splicing regulatory factors (Figure 11A). Another strategy for the treatment of splice 
defects is the usage of specific antisense oligonucleotides (AOs). These chemically 
modified nucleotides are designed with the aim to hybridize with a specific splice site 
on the transcript, where they can block binding of splicing factors. In most of the 
cases this will lead to skipping of the targeted exon, which is most favorable for loss 
of function approaches (Figure 11B). In gain of function approaches (Figure 11C) the 
AOs can be linked to an ESE which recruits SR proteins that enhance exon inclusion 
(Wang and Cooper, 2007). Although the AO approach appears to be successful in 
many model systems, the transcript accessibility may be difficult in some cases. The 
application of AO linked to a specific snRNA as U7 or U1 is an alternative approach. 
These snRNA-fused AOs assemble into mature snRNPs which often increase their 
nuclear localization, stability and hybridization to the mutant mRNA. Another 
approach that aims to reduce aberrantly spliced transcript variants or thereby derived 
aberrant proteins, uses RNA interference (RNAi) or specific antibodies, respectively 
(Figure 11E). The approach with RNAi appeared to be highly accurate in terms of 
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targeting specific splice isoforms. Several strategies have been established that either 
use synthetic double stranded small interfering RNAs, short hairpin RNAs or artificial 
micro RNAs (Cooper et al., 2009). Restoration of correctly spliced transcripts can also 
be achieved through combined splicing of two RNA molecules in trans, termed trans-
splicing (Figure 11D) (Rodriguez-Martin et al., 2009; Fiskaa and Birgisdottir, 2010). 
The group of Dr. John Neidhardt at the University of Zurich and other groups have 
established a therapeutic approach that uses a modified U1 snRNA. It has been 
previously shown that mutations in the splice donor site reduce interaction of the U1 
snRNA at this position and thus lead to impaired recognition of the affected exon 
(Zhuang and Weiner, 1986). The strategy involves the adaptation of the U1 snRNA to 
the mutated splice site in order to restore normal binding affinities. Thereby, highly 
reduced levels of normal RHO transcripts which were induced by a splice donor site 
mutation, could be restored to more than 90% in minigene assays (Tanner et al., 
2009). Recently, the adaptation of the U1 snRNA was used to restore normal splicing 
of endogenously expressed transcripts in patient fibroblasts (Hartmann et al., 2010; 
Glaus et al., 2011). 
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2. Aims of the thesis 
 
1. Based on the findings that RPGR frequently undergoes alternative splicing and 
that mutations can cause variable phenotypes, we aimed to understand the 
contribution of RPGR splicing to the pathogenesis of several, clinically 
distinct phenotypes. 
 
2. To analyze whether a therapeutic approach using an adapted U1 snRNA can 
correct endogenously expressed transcripts, we designed experiments to 
restore a splice defect induced by a BBS1 splice donor site mutation in patient-
derived fibroblasts. 
 
3. Because the usage of an adapted U1 snRNA could interfere with mRNA 
splicing of other genes than the target, we investigated possible side effects 
caused by this treatment. 
 
4. Given that an increase in the amount of correctly spliced BBS1 transcripts 
could improve properties of cilia in fibroblasts from the patients, we aimed to 
identify genes which expression is regulated by the ciliary function of BBS1.
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3. Results 
 
3.1. Mutation- and tissue-specific alterations of RPGR transcripts  
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3.1.1. Abstract 
The majority of patients with X chromosome-linked Retinitis pigmentosa (XlRP) 
carry mutations in the RPGR gene. We studied whether patients with RPGR mutations 
show additional splice defects that may interfere with RPGR properties. 
Patient-derived cell lines with RPGR mutations were raised in suspension. To verify 
mutations, direct sequencing of PCR products was performed. Patient-specific 
alterations in RPGR splicing were analyzed by RT-PCR and confirmed by 
sequencing. Tissue-specific expression levels of RPGR splice variants were quantified 
by real-time PCR using pools of different human donor tissues. 
We have analyzed splicing of RPGR in seven RP patient-derived lymphoblastoid cell 
lines carrying hemizygous RPGR mutations. In three patient cell lines, we identified 
and characterized splice defects that were present in addition to a mutation. These 
splice defects were likely to interfere with normal RPGR properties. Furthermore, we 
identified four novel RPGR transcripts, either containing a new exon termed 11a or 
skipping the constitutive exons 12, 14 or 15. Novel and known RPGR isoforms were 
found to be differentially regulated in several human tissues. In human retina, 
approximately 10% of RPGR transcripts are alternatively spliced between exons 9 and 
15. 
Our findings show that splicing of RPGR is precisely regulated in a tissue-dependent 
fashion and suggest that mutations in RPGR frequently interfere with the expression 
of alternative transcript isoforms. These results implicate the importance of RPGR 
transcript analysis in patients with RP. We further discuss RPGR splicing as a 
modifier of different disease phenotypes described in patients with XlRP. 
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3.1.2. Introduction 
Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous eye disorder 
leading to the degeneration of photoreceptors in the human retina. Most patients with 
RP exhibit difficulties in dark adaptation and night blindness in adolescence and loss 
of midperipheral vision in young adulthood. In general, the rod photoreceptors 
degenerate first, causing a loss of peripheral vision. During progression of the disease, 
cone photoreceptors may also die, which ultimately leads to loss of central vision and 
complete blindness (Hartong et al., 2006). The disease prevalence is about 1 in 3000 
to 4000 people affecting more than 1.5 million worldwide. More than 35 RP-
associated genes have been identified so far. Most of them have been reported to be 
involved in phototransduction, basic metabolic pathways, maintenance of 
photoreceptor morphology, transcripional regulation, or pre-mRNA splicing as 
reviewed by Kennan (2005). 
The inheritance pattern of RP can either be autosomal recessive (arRP), autosomal 
dominant (adRP) or X-linked (XlRP). The latter is considered to cause the clinically 
severest form of RP. Approximately 60 to 70% of all X-linked families show 
mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene (Breuer et al., 
2002; Iannaccone et al., 2003). Here, the majority of mutations were found in the 
alternatively spliced exon ORF15, whereas exons 1 to 15 carry a minor portion of all 
RPGR mutations (Vervoort and Wright, 2002; Sharon et al., 2003; Pelletier et al., 
2007; Neidhardt et al., 2008; Shu et al., 2008). A few mutations in exon 1 to 15 of 
RPGR have been associated with additional nonocular manifestations. In a family 
with XlRP described previously, two members displayed a complex phenotype 
combining primary ciliary dyskinesia (PCD) and retinitis pigmentosa. In this case, 
aberrant splicing of RPGR was found in nasal epithelial cells due to a 57 bp deletion 
in exon 6 (Moore et al., 2006). Additionally, a syndromic phenotype including RP, 
hearing defects and severe sinorespiratory infections has been associated with 
mutations either in RPGR exon 6 (Iannaccone et al., 2003) or exon 8 (Zito et al., 
2003). These reports indicate that the function of the widely expressed RPGR is 
important not only for the retina but also for other tissues. 
RPGR transcripts have been identified in several human tissues (e.g. retina, brain, 
lung, kidney, and testis) (Meindl et al., 1996; Roepman et al., 1996a; Kirschner et al., 
1999). Moreover, transcript isoforms of RPGR have been described and occasionally 
found to be expressed in a tissue- or cell-type-specific manner. One of these 
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transcripts includes the alternative exon 15a (Kirschner et al., 1999) and another 
contains exon 15b (Vervoort et al., 2000). RPGR isoforms may also show skipping of 
constitutive exons (e.g. exon 14 and 15) (Kirschner et al., 1999). Transcripts 
containing the alternative exon 9a produce a truncated protein that is predominantly 
expressed in human cone photoreceptors (Neidhardt et al., 2007). 
The effect of many RPGR mutations on protein structure has been predicted (Meindl 
et al., 1996; Roepman et al., 1996a; Roepman et al., 1996b; Kirschner et al., 1999; 
Vervoort et al., 2000; Vervoort and Wright, 2002; Neidhardt et al., 2008). However, 
as has been described for other genes, a large fraction of exonic mutations also leads 
to splice defects by disruption of constitutive and regulatory splice-relevant sequences 
(Wang and Cooper, 2007). Because mutation-induced alterations of splice patterns in 
RPGR may contribute to the pathogenic mechanism for RP (Fujita et al., 1997; Bauer 
et al., 1998; Dry et al., 1999; Demirci et al., 2004; Neidhardt et al., 2007), we 
analyzed the effect of different RPGR mutations on splicing. Four novel RPGR 
isoforms were identified that showed differential expression in several tissues. Our 
results suggest that RPGR splicing is part of the pathogenic mechanism underlying the 
complex disease of RP. This further raises the possibility that alterations in RPGR 
splicing act as modifiers of the disease expression. 
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3.1.3. Materials and Methods 
Cell culture 
Splicing of RPGR was analyzed in seven EBV-transformed lymphoblastoid cell lines 
(LCLs) which have been derived from blood of male patients with RP (Table 1) and 
an unaffected male control. Informed consent was obtained from each patient and 
unaffected control in this study. Additional family members were not available for 
further tests. LCLs were grown in RPMI 1640 medium (LabForce, Nunningen, 
Switzerland), 10 % FBS (LabForce), 1.1 % Penicillin-Streptomycin (LabForce), 1.3 
% L-Gutamine (LabForce) at 37°C, 5% CO2 by using 75 cm
2
 cell culture flasks 
(Techno Plastic Products [TPP], Trasadingen, Switzerland). Between 8x10
6
 and 4x10
7
 
cells were pelleted by centrifugation at 4°C with 2000 x g for 10 minutes. The pellets 
were washed with 1x DPBS (LabForce), snap frozen and stored at -80°C before 
extraction of DNA or RNA. To inhibit nonsense-mediated mRNA decay (NMD), 
1x10
6
 cells/ml were incubated in 30g/ml cycloheximide (Sigma-Aldrich, 
Schnelldorf, Germany) at 37°C, 5% CO2 in 25cm
2
 cell culture flasks (TPP) for 4h as 
previously described (Chatr-Aryamontri et al., 2004). 
 
RNA extraction, cDNA synthesis and RT-PCRs 
To extract total RNA from LCLs, the cells were disrupted using either QIAshredder 
columns (Qiagen, Hombrechtikon, Switzerland) or a rotor-stator homogenizer (Ultra-
Turrax T8, IKA Analysetechnik GmbH, Germany). Subsequently, RNA was isolated 
with RNeasy Mini or Midi kits (Qiagen) according to the manufacturer‟s instructions. 
RNA quality was verified by the Agilent 2100 Bioanalyzer and the amount was 
determined by the NanoDrop photometer (ND-1000, Litau, Switzerland). One 
thousand ng of total RNA were randomly primed before reverse transcription by 
reverse transcriptase (Superscript III; Invitrogen, Basel, Switzerland) according to the 
manufacturer‟s protocol. To verify correct splicing of the RPGR transcripts, RT-PCR 
reactions were performed with 50 ng cDNA, as described previously (Neidhardt et al., 
2007). Primers used in the RT-PCR assays are shown in Supplementary Table S1. 
RT-PCR products were confirmed by sequencing. Each RT-PCR experiment was 
replicated three times using RNA from independently grown LCL cells.  
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Quantitative real-time PCR of alternative RPGR transcript variants 
Quantifications of RPGR transcript levels were performed by quantitative real-time 
PCR on HT 7900 TaqMan using Assay by Design MGB FAM-TAMRA labeled 
probes (Applied Biosystems, Rotkreuz, Switzerland). To study the expression of 
RPGR transcript isoforms in several tissues, total RNA from pools of different human 
donor tissues (brain: n=5, kidney: n=5, lung: n=3, retina: n=25 and testis: n=39) was 
purchased from Becton Dickinson (BD, Allschwil, Switzerland) or BioCat 
(Heidelberg, Germany). Three to four cDNA batches were independently generated 
and analyzed from each tissue. 
We designed TaqMan probes to quantify exon/exon boundaries for each alternative 
RPGR transcript isoforms as well as a corresponding probe for the constitutive 
transcript. Probes specific to the constitutive transcript of RPGR were used as 
endogenous controls. Their comparability was tested following the manufacturer‟s 
instructions. Each quantification reaction was technically replicated at least 4 times 
and gave results with amplification curves starting between 25 and 30 cycles. Using 
equal amounts of cDNA per sample, Ct values of the constitutive transcript did not 
differ significantly between tissues (errors represent confidence intervals of 95%): 
retina 26.3 (+/- 0.86), brain 25.75 (+/- 1.45), lung 25.9 (+/- 0.37), kidney 26.53 (+/- 
1.23), and testis 25.6 (+/- 1.49). The outcome was anayzed using the SDS 2.2 
software (ABI). The expression levels of the tested tissues or LCLs were normalized 
to human retina or an unaffected male control, respectively. Confidence intervals 
(CIs) of 95% were calculated from 3 to 4 independently generated samples. 
 
DNA purification and sequencing 
RT-PCR products were gel-extracted using the QIAquick Gel Extraction Kit 
(Qiagen). Gel-purified DNA was either cloned into the pCRII-TOPO vector (Topo 
TA Cloning Kit Dual Promoter, Invitrogen) according to the manufacturer‟s 
instructions or sequenced directly. DNA from LCLs was extracted as previously 
described (Neidhardt et al., 2006). To identify or verify mutations in patient cell lines, 
exons of RPGR were amplified by PCR using HotFirePol and sequenced directly 
(Sequencing analyzer, model 3100, ABI). Mutations were designated according to the 
nomenclature provided by the human genome variation society (www.hgvs.org). The 
numbering of mutations refers to the human RPGR reference sequence 
NM_001034853 for cDNA or reference assembly NC_000023.9 (range: 38013367 to 
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38071732) for genomic DNA from the NCBI database. The potential effect of exonic 
mutations on exonic splicing enhancer (ESE) binding sites was analyzed using 
ESEfinder 3.0 (http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home). 
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3.1.4 Results 
We followed the hypothesis that splice defects frequently occur in addition to 
mutations found in RPGR. To detect splice defects, we established RT-PCR assays 
that allow analysis of RPGR transcripts and screened lymphoblastoid cell lines 
(LCLs) derived from seven male patients with RP affected by known hemizygous 
RPGR mutations (Table 1). The LCLs used were not preselected for possible splice 
defects. 
 
Splice site mutation in RPGR intron 1 
In patient cell line LCL 2616, RT-PCR amplification of exons 1 through 5 yielded no 
product (Fig. 1). In contrast, using primers that bind to exons 2 and 5 resulted in a 
fragment, although weaker compared to that of the unaffected control and other cell 
lines. Furthermore, RT-PCRs with primer combinations specific to downstream 
located exons confirmed that LCL 2616 shows reduced RPGR transcript amounts 
(Fig.1). These analyses suggested the presence of a mutation affecting normal 
transcript processing in this patient cell line. Indeed, a mutation at the first base of 
intron 1 (c.28+1G>A; Table 1) was present in LCL 2616. This mutation is expected to 
result in a splice defect. Although extensively assayed, we were not able to amplify 
splice products between exon 1 and 2. These results suggest defective splicing of 
RPGR because of the mutation c.28+1G>A leading to a reduced amount of 
transcripts. It further raises the possibility that translation of RPGR may start from 
exon 3, where the next in-frame start codon is located.  
 
The novel RPGR exon 11a  
We performed RT-PCR analyses of RPGR transcripts containing exons 11 through 15 
in all patient cell lines listed in table 1. In LCL 4767 we detected an additional 
amplicon of approximately 700 bp in length by conventional RT-PCR (Fig. 2A). 
Sequencing revealed that this fragment includes a novel exon spliced between exons 
11 and 12. It was thus termed exon 11a. It contains 160 nucleotides and starts 1‟139 
bp downstream of the splice donor site of exon 11 (Fig. 2B). The resultant new coding 
sequence contains a stop codon. 
These results suggested elevated expression levels of RPGR transcripts containing 
exon 11a (RPGR
+Ex11a
) in LCL 4767. We confirmed this observation by quantitative 
RT-PCR and detected a four-fold increased expression of RPGR
+Ex11a
 only in this 
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patient cell line (Fig. 2C). These results document a splice alteration specific to LCL 
4767.  
The previously identified missense mutation in exon 5 (c.289T>G, p.Phe130Cys, 
Table 1) in this patient (Roepman et al., 1996a) is most likely not causing the 
overexpression of exon 11a because of the distance between the two affected exons. 
Therefore we searched for additional sequence alterations in exon 11a and identified a 
G>A transition at position 36 (g.31259G>A), 15 bp upstream of the stop codon of 
exon 11a (fig. 2D, table 1). The sequence alteration was not annotated as a single 
nucleotide polymorphism (SNP) in databases (UCSC, ENSEMBL, NCBI) and was 
not found in 300 ethnically matched control alleles (Caucasians), suggesting a 
pathogenic nature of this variant. 
Application of the ESEfinder program to this sequence alteration predicted a novel 
binding site for the splice factor SC35 only in the mutated exon 11a (Fig. 2D). 
Enhanced binding of SC35 to exon 11a may thus explain the significantly elevated 
levels of RPGR
+Ex11a
 transcripts specifically found in patient 4767. 
 
RPGR exon 12, 14 or 15 skipping 
RT-PCR analysis of RPGR transcripts including exons 11 through 19, revealed two 
major isoforms either containing all known exons or simultaneously skipping exons 
14 and 15 (Fig. 3A). The control samples showed an additional band at 1000 bp (Fig. 
3A). Cloning and sequencing of this band documented that this amplicon is a mixture 
of two so far unknown RPGR isoforms that either skip only exon 14 (RPGR
skipEx14
) or 
15 (RPGR
skipEx15
). 
Comparing all patient-derived cell lines, LCL 2550 showed an alteration from the 
control splice pattern in conventional RT-PCR analyses. We detected two additional 
fragments, both migrating 92 bp below the two major products. As confirmed by 
sequencing, these novel transcripts lack exon 12 of RPGR (RPGR
skipEx12
, Fig. 3A). 
Patient 2550 carries a deletion of 4 bp in exon 11 (c.1402_1405delCCAG, 
p.Arg468fs, Table 1) (Roepman et al., 1996a). This deletion affects positions -12 to -9 
upstream of the last nucleotide of exon 11, an exonic region spatially unrelated to the 
splice donor site. Importantly, the deletion causes a frame-shift that leads to a 
premature termination codon (PTC) in exon 12 (Fig. 3C). Because transcripts 
containing a PTC are susceptible to nonsense-mediated mRNA decay (NMD) 
(Maquat, 1995), we searched for such potential effects. To inhibit NMD, we treated 
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cells with cycloheximide (CHX) and compared them with untreated cells. We found 
only in LCL 2550 that inhibition of NMD affects splicing and restores the 
amplification pattern identified in the control cell line (Fig. 3B). These findings show 
that the 4 bp deletion in exon 11 causes a PTC in exon 12 which activates partial 
degradation by NMD. Interestingly, LCL 2550 showed a transcript combining exon 
12 skipping (deletion of 92 bp) and deleting 4 bp in exon 11. This combination 
restores the open reading frame in the RPGR transcript (Fig. 3C). Thus, a protein 
migh be translated which lacks amino acids coded by exon 12. 
 
Tissue-specific expression analysis of RPGR isoforms 
Our studies identified the four novel RPGR transcripts RPGR
+Ex11a
, RPGR
skipEx12
, 
RPGR
skipEx14
 and RPGR
skipEx15
. To verify whether they are also generated in human 
tissues other than lymphoblastoid cell lines, transcript analysis was performed by 
quantitative RT-PCR using cDNA from pools of different human tissues, including 
retina, brain, lung, kidney and testis. In addition, we tested whether the expression of 
previously reported RPGR isoforms also shows tissue-specific variation. This 
included RPGR
+Ex9a
, which has recently been found to be expressed predominantely 
in cone photoreceptors of the human retina (Neidhardt et al., 2007) and transcripts 
simultaneously skipping exons 14 and 15 (RPGR
skipEx14/15
) (Kirschner et al., 
1999).The assessment of isoform quantities was performed in comparison to the 
constitutive transcript of RPGR. 
Our data show that the abundance of each of the alternative RPGR isoforms varied 
between 0.8% (RPGR
skipEx12
) and 2.7% (RPGR
skipEx14/15
) within retina (Fig. 4). In 
summary, we document that in human retina approximately 10% of RPGR transcripts 
are alternatively spliced between exons 9 and 15 (Fig. 4). 
The amount of each alternative isoform also varied among different tissues (Fig. 5). 
Highest levels of RPGR
+Ex11a
 were observed in the retina, while other tissues 
contained significantly lower amounts (Fig. 5A). Furthermore, we detected highest 
expression of RPGR
skipEx12
 in lung and kidney and found 10 to 12 fold lower amounts 
of this isoform in retina, brain and testis (Fig. 5B). Similarly, RPGR
+Ex9a
 transcripts 
were expressed higher in lung and kidney than in retina (Fig. 5E). Highest expression 
of the novel RPGR variant RPGR
skipEx14
 was found in brain (Fig. 5C), whereas 
RPGR
skipEx15
 expression was lowest in retina (Fig. 5D). Isoform RPGR
skipEx14/15
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exhibited the largest variation: it was 20 times higher expressed in brain than in retina 
(Fig. 5F).  
Taken together, these findings show that the expression of alternative RPGR 
transcripts varies significantly among and within tissues. This indicates distinct tissue-
specific RPGR splicing which may confer specialized function of the different 
isoforms. 
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3.1.5. Discussion 
Alternative splicing of pre-mRNA transcripts is considered to be an important 
mechanism to increase protein variability from a single gene (Black, 2000). This 
process also acts on human RPGR and generates alternative transcript isoforms, the 
expression of which is spatially and temporally regulated (Kirschner et al., 1999; 
Vervoort et al., 2000; Neidhardt et al., 2007). 
In this article, we describe four novel transcript isoforms of RPGR termed 
RPGR
+Ex11a
, RPGR
skipEx12
, RPGR
skipEx14
 and RPGR
skipEx15
. We showed that all are 
expressed in a tissue-dependent fashion, which suggests functional consequences. The 
highest expression levels of both RPGR
skipEx14
 and RPGR
skipEx14/15
 were detected in 
brain. Consequently, misregulation of transcripts lacking exon 14 or exons 14/15 
might disturb their function in brain. To date, no mutation in RPGR has been 
described that shows a phenotypic manifestation in this tissue. However, only a few 
patients are known to contain mutations in exon 14 or 15 (compare to 
http://rpgr.hgu.mrc.ac.uk). A detailed clinical characterization of the brain functions 
in these patients might add valuable information on the phenotypic spectrum caused 
by mutations in RPGR. 
Our data suggest that RPGR transcripts are differentially spliced among tissues. They 
further show that the novel isoforms described herein are expressed at lower levels 
compared to the constitutive transcript of RPGR. Nevertheless, a significant portion of 
RPGR transcripts are alternatively spliced between exon 9 and 15 in the retina. Since 
tissues are heterogenous with respect to cell type, one possible explanation for our 
observation is that either only a fraction of cells within a given tissue expresses a 
distinct isoform or that expression is cell type specific. Similar observations have been 
published for RPGR containing exon 9a (Neidhardt et al., 2007). The corresponding 
protein of the exon 9a-containing transcript was predominantly present in cones of the 
retina suggesting a specialized function of this isoforms in a subfraction of 
photorecptors. It is a matter of future studies to evaluate whether the novel RPGR 
isoforms described herein are also expressed by a specific cell type within distinct 
tissues. 
Regulation of alternative and tissue-specific splicing is thought to be controlled by 
proteins that stimulate or repress exon recognition. In general, such factors are called 
exonic or intronic splicing enhancers (ESEs or ISEs) and silencers (ESSs or ISSs). 
Some of these factors are expressed only in certain tissues and regulate splicing of 
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specific sets of pre-mRNAs (Maniatis and Tasic, 2002). A well known example is the 
mammalian splicing factor NOVA-1, which is involved in the control of alternative 
pre-mRNA splicing in neurons. This protein binds specific intronic sequences of pre-
mRNA targets through its K-homology (KH) domains. NOVA-1 is reported to 
enhance the inclusion of specific alternative exons into target transcripts and is 
expressed in distinct populations of neurons in the brain (Dredge et al., 2001). Taking 
this into account, we envision that factors with similar functions might regulate the 
expression of alternative RPGR transcript isoforms within tissues. 
 
A different mechanism of gene regulation acts through NMD which constitutes a 
posttranscriptional regulatory process. We found that NMD reduces the amount of a 
mutated RPGR transcript which contains a PTC. Of note, NMD may also act on non-
mutated transcripts (Mendell et al., 2004; Rehwinkel et al., 2005; Wittmann et al., 
2006). In addition, it has been documented that it can be active in a tissue specific-
manner (Bateman et al., 2003; Linde et al., 2007; Weischenfeldt et al., 2008). These 
observations provide a possible explanation why RPGR isoforms were found to be 
expressed at elevated levels among tissues. 
Interestingly, most RPGR isoforms truncate the deduced protein downstream of the 
Regulator of Chromosome Condensation 1-like domain (RCC1). The RCC1-like 
domain of RPGR includes exons 2 through 11 (Kirschner et al., 1999; Vervoort and 
Wright, 2002; Neidhardt et al., 2007). This domain has been shown to bind four 
different interaction partners: RPGR interacting protein 1 (RPGRIP1), prenyl-binding 
protein delta as well as structural maintenance of chromosomes 1 and 3 proteins 
(Linari et al., 1999; Boylan and Wright, 2000; Roepman et al., 2000; Khanna et al., 
2005). Different RPGR protein isoforms have been shown to be associated with a 
multiprotein complex, which is thought to be involved in intraphotoreceptor protein 
transport through the connecting cilium (He et al., 2008). We have previously shown 
that exon 9a containing RPGR transcripts give rise to a truncated protein which binds 
distinct isoforms of RPGRIP1 (Neidhardt et al., 2007). On the assumption that the 
other transcript variants described herein are also translated, our data support a model 
that predicts binding of distinct RPGR isoforms to different sets of interaction 
partners to form various functionally unique protein complexes. Mutations that 
modify distinct RPGR isoforms would influence the formation of these complexes. 
Supportively, cases have been reported where RPGR mutations in the RCC1-like 
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domain (affecting exons 6 and 8) are associated with non-ocular manifestations 
(Iannaccone et al., 2003; Zito et al., 2003; Moore et al., 2006). These reports further 
support our hypothesis that RPGR isoform-specific protein complexes fulfill tissue-
specific functions. 
The disease phenotype in patients affected by RPGR mutations can be highly variable 
even within one family. These observations imply the existence of modifiers that 
influence the severity of the disease. Here, we showed that not only does a mutation in 
RPGR affect the predicted amino acid sequence of the protein, but may also results in 
missplicing or altered regulation of specific transcripts. Since alternative splicing is 
precisely regulated in a tissue-specific and developmental stage-dependent manner, 
changes in this process may cause or modify disease symptoms (Nissim-Rafinia and 
Kerem, 2002). Taking this into account, our results suggest that defects in RPGR 
splicing could modify the disease phenotype of RP. Several examples for splicing-
induced modifications of a disease have been reported (Garcia-Blanco et al., 2004). 
We have identified alterations in splicing of RPGR in three out of seven RP patient 
cell lines. Our findings implicate the importance of including the analyis of RPGR 
splicing in patients with retinal degenerations and associated phenotypes. 
Furthermore, patient-derived cell lines showed splice alterations in RPGR isoforms 
which are differentially regulated among distinct human tissues. Thus, a change in the 
expression of these isoforms could not only affect the retina, but also disrupt their 
function in other tissues.  
In patient cell line 2550, we detected elevated levels of RPGR
skipEx12
 transcripts. The 
deletion of 4 bp in combination with exon 12 skipping abolishes the deleterious 
effects of the frame-shift. Therefore, these trancripts can now escape degradation by 
NMD and may be expressed as a truncated RPGR protein in the patient. The splice 
defect is likely to take place in most tissues indicating that not only the retina is 
affected. Interestingly, there is evidence that patient 2550 suffers from a mild hearing 
impairment. The audiogram showed a dip with high frequency pure tones (personal 
communication: Thomas Rosenberg). Although speculatory, the nonocular 
manifestation of auditory problems might be the result of the expression of this 
aberrant protein isoform. Supportively, it has been observed in a different patient 
(patient ID 2557) that an 6.4 kb deletion within RPGR (Roepman et al., 1996b), in 
addition to a single bp deletion at the 3‟ end of exon ORF15 (c.3395delA) (Neidhardt 
et al., 2008) may affect the audiogram (Rosenberg et al., 1997). Nevertheless, an age-
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related effect on hearing in these patients cannot be excluded. It would further be of 
interest to clarify whether the respiratory function of patient 2550 impaired, because 
our expression data suggest that RPGR
skipEx12
 transcripts might be relevant in lung. 
We showed that patient 4767 expresses increased levels of RPGR
+Ex11a
, likely because 
of a sequence alteration in exon 11a. This novel mutation is predicted to change the 
activity of a splice enhancer site of SC35, which might control the frequency of exon 
11a inclusion into the transcript. SC35, a ubiquitously expressed splice factor, has 
been shown to increase the integration of a target exon by mediating specific 
interactions with components of the spliceosome (Fu and Maniatis, 1992). Mutations 
that increase the binding affinity for an exonic splicing enhancer have already been 
associated with other human diseases, e.g. frontotemporal dementia with 
Parkinsonism-chromosome 17 type (FTDP-17) (D'Souza and Schellenberg, 2000) and 
a cardiac phenotype of Fabry disease (Ishii et al., 2002). We demonstrated that the 
expression of exon 11a was significantly increased only in cell line 4767. Toxic 
effects leading to premature death of photoreceptors might be caused by 
overexpression of a distinct RPGR isoform, a mechanism similar as proposed by us 
for RPGR
+Ex9a
 (Neidhardt et al., 2007). Furthermore, the overexpression of RPGR in 
mice also leads to a severe phenotype in sperm flagella resulting in male infertility 
(Brunner et al., 2008). 
Interestingly, the family pedigree of patient 4767 shows over a period of six 
generations an inheritance pattern by which female carriers are also affected (data not 
shown). We cannot exclude that this mode of inheritance is caused by skewed X-
inactivation in affected females. However, this mechanism has never been found to 
influence the phenotype of female carriers of RPGR mutations (Banin et al., 2007; 
Neidhardt et al., 2008; Walia et al., 2008) and thus, is unlikely to be a common 
mechanism explaining symptomatic female carriers. In the patient described herein, 
either a cumulative or a separate effect of the two identified sequence alternation in 
exons 5 and 11a might be the cause of the disease. 
Taken together, the results reported here provide new insights into alternative splicing 
of RPGR and will help to elucidate its role in distinct tissues. Moreover, RPGR splice 
defects provide a pathogenic mechanism newly associated with RPGR, which implies 
that classical and syndromic RP patients should be analyzed for alterations in RPGR 
splicing. 
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3.1.8. Figure and Tables 
 
Table 1. RPGR mutations of analyzed lymphoblastoid cell lines derived from male patients with XlRP 
    
Patient ID Mutation in Exon/Intron Sequence alteration Conseq. of Seq. alteration 
2616 intron 1 c.28+1G>A potential splice defect 
4767 
†
 exon 5 c.389T>G p.Phe130Cys 
 exon 11a g.31259G>A *
, 
** Splice defect/ p.Asp484Asn 
2884 exon 7 c.706C>T p.Glu236X 
2555 exon 8 c.823G>A p.Gly275Ser 
2603 exon 8 c.823G>A p.Gly275Ser 
2549 exon 11 c.1399C>T p.Gln467X 
2550
††
 exon 11 c.1402_1405delCCAG p.Arg468fs 
    
cDNA reference sequence: NM_001034853 
*genomic DNA reference sequence: NC_000023.9 (range: 38013367 to 38071732) 
** Mutation is first described in this report.   
†
 Female carriers are affected in this family.   
††
 Patient has a mild hearing impairment (personal communication: Thomas Rosenberg). 
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Figure 1 Characterization of a splice site mutation in LCL 2616. RPGR transcript analysis in 
the patient cell line 2616 and the unaffected control using different primer combinations that 
span the whole RPGR transcript. DNA marker sizes are given in base pairs. 
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Figure 2 Overexpression of the RPGR
+Ex11a
 transcript isoform in patient cell line 4767. 
A RT-PCR amplification of RPGR transcripts containing exons 11 through 15. Schematic 
drawings illustrate the exon composition of amplified RT-PCR products. Primer binding sites 
are indicated as horizontal gray bars. DNA marker sizes are given in base pairs. B Sequence 
of the novel RPGR exon 11a and flanking intronic regions. Nucleotides in gray represent exon 
11a sequences, whereas deduced amino acids are indicated as single letter code above of 
each nucleotide triplet. The stop codon is presented in italics and coding sequences are 
shown in uppercase letters. The position mutated in patient 4767 (g.31259G>A) is marked by 
a box. NC_000023.9 was used as reference sequence for genomic DNA (numbers at the right 
indicate the nucleotide position). C Real-time quantitative RT-PCR of exon 11a expression 
levels detected in the unaffected control (I), in a pool of 6 LCLs carrying hemizygous RPGR 
mutations (n=6) different from the sequence alteration in exon 11a (II) and in the patient cell 
line 4767(III). Error bars represent confidence intervals of 95% calculated from cDNA batches 
which were generated from RNA of three independently grown LCL cells. Asterisk illustrates 
statistical significance between measurements. D Electropherograms from parts of the exon 
11a sequence of patient cell line 4767 and a control. Arrows indicate the postition of the 
mutation g.31259G>A in patient 4767. The stop codon is shown in italics. Positions of putative 
binding sites for exonic splicing enhancers (ESEs) SF2/ASF and SC35 are depicted as 
horizontal bars. The results suggest the existence of an additional SC35 binding site uniquely 
in the patient. 
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Figure 3 Upregulation of the novel RPGR
skipEx12
 transcript. A RT-PCR amplification of exons 
11 to 19 of the RPGR transcript. Schematic drawings illustrate the sequence of amplified RT-
PCR products. Each RT-PCR product is marked by a number corresponding to the respective 
schematic drawing. Primer binding sites in exons 11 and 19 are indicated by horizontal gray 
bars. Numbers at the left represent DNA marker sizes and are given in base pairs. B RT-PCR 
of RPGR exon 11 to 19 of patient cell line 2550 and a control, either incubated with (+) or 
without (-) cycloheximide (CHX) to inhibit nonsense-mediated mRNA decay (NMD). The RT-
PCR reaction lacking a template is indicated as H2O. C Graphical illustration of mutation-
induced mechanisms in patient cell line 2550 leading to detectable levels of RPGR
skipEx12
 
transcripts. The asterisk labels a premature termination codon (PTC) in exon 12, which is 
generated in patient cell line 2550 because of the 4-bp deletion in exon 11. The PTC causes 
reduced expression levels of transcripts including exon 12, by NMD (upper). In contrast, 
transcripts lacking exon 12 in combination with the 4 bp deletion escape NMD because of 
preservation of the open reading frame (lower). 
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Figure 4 Relative abundance of alternative transcript isoforms of RPGR in human retina. 
Expression levels of alternative variants are displayed as percentages of the constitutive 
RPGR transcript in human retina. Numbers in bars represent mean values given in 
percentages. Error bars represent confidence intervals of 95% calculated from  3-4 
independently generated cDNA batches. 
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Figure 5 Multi-tissue expression analyses of novel and previously reported RPGR transcript 
isoforms. Quantitative RT-PCR to detect expression of A RPGR
+Ex11a
, B RPGR
skipEx12
, C 
RPGR
skipEx14
, D RPGR
skipEx15
, E RPGR
+Ex9a
, F RPGR
skipEx14/15
 from different donor tissues. For 
quantification of the novel RPGR transcript isoform we used expression of the constitutive 
RPGR transcript as endogenous control. Subsequently, relative expression levels of each 
isoform were compared with human retina (retinal levels were set to 1). Asterisks illustrate 
significance between measurements as described in the Results section. Error bars represent 
confidence intervals of 95% calculated from 3 to 4 independently generated cDNA batches. 
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Supplementary Table S1. Primer combinations used for RT-PCR assays to screen for splice defects in the RPGR transcript 
     
RT-PCR product 
Fw primer Rev primer 
Name Sequence (5'-3') Name Sequence (5’-3’) 
RPGR exon 1 to 5 Eco-RP3-5UTR1 ACCGAATTCCAAACCGTCCTCTACAGCC RP3-Ex4/5up ATATACATTGCCTCCTTCTG 
RPGR exon 2 to 5 RP3-ex2dn CGATTCGGGTGCTGTGTTTA RP3-Ex4/5up ATATACATTGCCTCCTTCTG 
RPGR exon 3 to 15 RP3-Ex3dn TGGGGTCAGTTAGGATTAGG RP3-Ex15up TTTGCTTCTACCTCTTGCTCCTCTATTCC 
RPGR exon 3 to 9 RP3-Ex3dn TGGGGTCAGTTAGGATTAGG RP3-Ex9up GGTAAAATTCTCCAGTCCAAGTC 
RPGR exon 11 to 15 RP3-Ex11dn GGGACTCTTGGCCTTTCTGCTTGTT RP3-Ex15up TTTGCTTCTACCTCTTGCTCCTCTATTCC 
RPGR exon 11 to 19 RP3-Ex11dn GGGACTCTTGGCCTTTCTGCTTGTT RP3-Ex19up ATTTGTTGGTGGGATATTCTGATGATT 
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3.1.9 Own contribution to the manuscript “Mutation- and tissue-specific  
 alterations of RPGR transcripts” 
 
Cell culture, cycloheximide treatment, sequencing analysis, RT-PCR analysis, 
contributions to interpretation of the data and manuscript writing 
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3.2.1. Abstract 
Bardet-Biedl syndrome (BBS) is a multi-system disorder caused by ciliary defects. To 
date, mutations in 15 genes have been associated with the disease and BBS1 is most 
frequently affected in BBS patients. 
We identified the splice donor site (SD) mutation c.479G>A in BBS1 exon 5 using 
homozygosity mapping in a large consanguineous family. Affected family members 
show retinitis pigmentosa (RP) and no other primary feature of BBS. In agreement 
with this exceptionally mild BBS phenotype, we did not detect obvious ciliary defects 
in patient derived cells. 
SDs are bound by the U1 small nuclear RNA (U1) which initiates exon recognition 
during splicing. The mutation described herein interferes with U1 binding and induces 
aberrant splicing of BBS1. To improve interaction of U1 to the mutated SD, we have 
increased complementarity of the U1 snRNA with the mutated SD. Lentivrial 
treatment of patient-derived fibroblasts with adapted U1 partially corrects aberrant 
splicing of endogenously expressed BBS1 transcripts. The therapeutic effect is dose-
dependent. These results suggest that the adaptation of U1 to rescue pathogenic 
effects of splice donor site mutations has a high potential for gene therapy. 
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3.2.2. Introduction 
Bardet-Biedl syndrome (BBS) constitutes a rare malformation syndrome which is 
primarily associated with retinal dystrophy, renal disease, polydactyly, obesity, 
hypogenitalism, and learning disabilities. In addition, secondary phenotypical features 
such as developmental delay, diabetes mellitus, dental and cardiovascular 
abnormalities, and hepatic involvement might occur in BBS patients. The diagnosis of 
BBS is usually established if the patient is affected by four primary features of the 
disease or by three primary plus two secondary features (Beales et al., 1999). The 
incidence of BBS has been estimated to be 1 individual in 120‟000 live births in North 
America and Europe, although population-dependent variations are reported (Blacque 
and Leroux, 2006). In general, the inheritance of the disease follows an autosomal 
recessive pattern, but triallelic inheritance patterns have also been described (Katsanis 
et al., 2001). To date, 15 genes have been associated with the disease and 
approximately 20% of the cases are likely to be caused by mutations in additional 
genes (Zaghloul and Katsanis, 2009; Kim et al., 2010; www.genetests.org). 
The Bardet-Biedl Syndrome 1 gene (BBS1) is most frequently affected in BBS 
patients. BBS1 localizes to chromosome 11q 13.1 and is composed of 17 exons which 
encode a protein of 593 amino acids (reference sequence NM_024649). The N-
terminal part of BBS1 shares homology with other BBS-associated gene products 
(BBS2 and 7) and predominantly localizes to the basal body / transitional zone of 
ciliated cells. BBS1 has been found in a heptameric complex with BBS2, BBS5, 
BBS7, BBS8 and BBS9 termed the BBSome and physically interacts with the GTP 
exchange factor Rabin8 (Nachury et al., 2007). These results suggested that Rabin8 
helps to recruit the BBSome from neighboring centriolar satellites to the centrosome 
and activates the Rab8 small GTPase which seems to facilitate the fusion and docking 
of vesicles to the ciliary membrane (Leroux, 2007). It has been demonstrated recently 
that the interaction of Arl6 (BBS3) with the BBSome constitutes a coat for membrane 
proteins to be directed towards the cilium (Jin et al., 2010). However, the precise 
molecular function of the BBSome remains to be elucidated. 
The mutational spectrum of BBS1 includes the missense mutation p.M390R (Mykytyn 
et al., 2002) which accounts for the majority of pathogenic sequence alterations found 
in this gene and causes BBS in about 20% to 30% of unrelated individuals (Mykytyn 
et al., 2003; Beales et al., 2003). Together with a frequent mutation in BBS10 
(p.C91fsX95) (Stoetzel et al., 2006), up to 40% of the cases can be explained. Among 
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other mutations, splice site mutations have been described to cause BBS. Most 
frequently splice site mutations interfere with exon recognition in pre-mRNA 
transcripts and lead to exon skipping or intron retention. Most of these mutations are 
not characterized in detail, but missplicing of corresponding transcripts can be 
assumed. In the majority of disease genes, more than 15% of point mutations affect 
classical splice sites (Faustino and Cooper, 2003). Furthermore, an unexpectedly high 
number (up to 60%) of the exonic and intronic mutations are reported to have their 
primary pathogenic effect on splicing rather than on the deduced protein composition 
(Wang and Cooper, 2007). Together, these findings emphasize the importance of 
splice site mutations. 
A mutation in a splice donor site (SD) often interferes with U1 snRNA (U1) binding 
to its pre-mRNA target which leads to aberrant splicing of the transcript. The 
recognition of the SD, is mediated by Watson-Crick base pairing of U1 and pre-
mRNA templates (Zhuang and Weiner, 1986). Together with seven Sm and other 
complex-specific proteins U1 constitutes the U1 small nuclear ribonucleoprotein. This 
splice factor is capable of recruiting other components of the spliceosome to the SD to 
further promote splicing of the pre-mRNA (Wahl et al., 2009). 
In order to overcome the pathogenic effect of SD mutations, we have developed a 
therapeutic approach for genes associated with eye diseases. Our approach uses the 
adaptation of U1 to increase recognition of the mutated SD. This therapeutic 
intervention corrected up to 90% of the misspliced transcripts that showed exon 
skipping (Tanner et al., 2009). In this report, we describe the identification and 
characterization of a SD mutation in BBS1 that leads to missplicing of the transcript. 
Interestingly, the affected family members show retinal degeneration but no additional 
primary features. Furthermore, we show that the U1-mediated intervention can correct 
the mutation-induced splice defect not only in the minigene assay, but also in 
endogenous BBS1 transcripts of patient-derived cell lines. In summary, the U1-
mediated intervention is a promising therapeutic approach to treat the pathogenic 
effect of SD mutations. 
 
Results 
72 
3.2.3. Materials and Methods 
Patients and clinical evaluation 
Prior to the examination, informed consent was obtained from patients and unaffected 
control individuals after explaining the nature, aims and consequences of the study. 
Peripheral blood samples of 10 family members were collected and used for DNA 
extraction. 
The index patient (IV:10), a 33 year old woman, was referred for genetic counselling 
of retinitis pigmentosa (RP) or related retinal diseases. Family history revealed 
multiple consanguineous marriages and a Turkish origin. The general medical history 
of the index patient and her affected sister was taken including prior surgeries, 
hospital admissions, education, past and present employments, learning difficulties, 
diabetes, blood pressure (mmHg), bodyweight (kg) and height (cm). 
Ophthalmological evaluation of the patients included funduscopy in mydriasis, slit 
lamp examination, Ganzfeld-electroretinography (ERG), testing of best corrected 
visual acuity, optical coherence tomography and Goldmann kinetic perimetry (kinetic 
perimetry module on the Octopus 101 visual field testing device, Haag-Streit, Köniz, 
Switzerland) (Neidhardt et al., 2007). 
To examine whether the RP phenotype in the affected family members was associated 
with additional features of BBS, a range of examinations were performed besides the 
ophthalmological examinations. In order to evaluate kidney and liver function and the 
hematologic system, both blood parameters (white and red blood cell count, 
creatinine, glucose, carbamide, uric acid, alkaline phosphatase) and urine parameters 
(urine status, creatinine, protein, glucose, sodium, potassium, phosphate, 24 hours 
urine collection, including protein and urine clearance) were examined. 
Gynaecological examinations of female patients included ultrasound of the 
reproductive system, hormonal status and medical history of pregnancies and life 
births. To exclude polydactyly and other limb anomalies, a careful examination of 
hands and feet was performed and photographs were taken. 
 
Linkage analysis 
To map the disease locus in the consanguineous family described herein, we 
genotyped 7 DNA samples using the Affymetrix GeneChip Human Mapping 250K 
Sty Array (Affymetrix, Santa Clara, CA). This array uses the Sty I restriction enzyme. 
Genotypes were called by the GeneChip DNA Analysis Software (GDAS v3.0, 
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Affymetrix). Genders of samples were verified by counting heterozygous SNPs on the 
X chromosome. Relationship errors were evaluated with the help of the program 
Graphical Relationship Representation (Abecasis et al., 2001). The program 
PedCheck was applied to detect Mendelian errors (O'Connell and Weeks, 1998) and 
data for SNPs with such errors were removed from the data set. Non-Mendelian errors 
were identified by using the program MERLIN (Abecasis et al., 2002) and unlikely 
genotypes for related samples were deleted. Nonparametric linkage analysis using all 
genotypes of a chromosome simultaneously was carried out with MERLIN. 
Parametric linkage analysis was performed by the program ALLEGRO (Gudbjartsson 
et al., 2000) assuming autosomal recessive inheritance with complete penetrance, a 
disease allele frequency of 0.0001. Haplotypes were reconstructed with ALLEGRO 
and presented graphically with HaploPainter (Thiele and Nurnberg, 2005). All data 
handling was performed using the graphical user interface ALOHOMORA 
(Ruschendorf and Nurnberg, 2005). 
 
Mutation screening and RT-PCR analysis 
We performed mutation screenings of both the rod outer membrane protein 1 (ROM1) 
and BBS1 in 10 family members of the consanguineous RP family 26223. Genomic 
DNA from blood samples and cell lines were extracted as described previously 
(Neidhardt et al., 2007). We amplified all coding exons and parts of the flanking 
intronic regions of ROM1 and BBS1 by PCR and directly sequenced the PCR 
products. Using SeqScape Software 2.0 (Applied Biosystems, Rotkreuz, Switzerland), 
ROM1 and BBS1 sequence profiles were compared to reference data base entries 
NM_000327 and NM_024649, respectively (NCBI data base; 
http://www.ncbi.nlm.nih.gov/). Sequence alterations are described as recommended 
(guidelines published by the Human Genome Variation Society 
http://www.hgvs.org/mutnomen). 
For RT-PCR analysis, we extracted total RNA from either cultured cells or blood 
samples using the RNeasy Mini Kit (Qiagene, Hombrechtikon, Switzerland) or 
PAXgene Kit (PreAnalytiX, Hombrechtikon, Switzerland). Total RNA was 
transcribed to cDNA by random priming according to the manufacturer‟s instructions 
(Superscript III reverse transcriptase; Invitrogen, Basel, Switzerland). RNA from 
cultured cells or blood derived from individuals IV:9, IV:10, and IV:11 of the 
consanguineous family (index patient 26223) was analyzed by RT-PCR using either 
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10, 100, or 300 ng of cDNA. For amplification of BBS1 transcripts, we used primers 
specific to exon 4 and 8 of BBS1 (BBS1-ex4dn: 5‟ GCCCCAATTGCCTCCAA 
ATCCT 3‟ and BBS1-ex8up: 5‟ GCATCCTCGTCAGCCAGGTTCTTC 3‟). The 
result of the experiment was verified by at least 3 different replicates. 
 
BBS1 minigenes and U1 snRNA expression constructs 
Minigenes were generated by PCR amplification of the BBS1 genomic region 
spanning intron 4 to 7 using ProofStart polymerase (Qiagen, Hombrechtikon, 
Switzerland). The PCR reaction was either performed with genomic DNA from 
affected or unaffected individuals using primers BBS1-ex5/6/7dn (5‟ 
ATGGCCATGAGACTGGATTCAGATA 3‟) and BBS1-ex5/6/7up (5‟ 
GGCTGGAAGGGATATAGCAAAGAGA 3‟). PCR products were subcloned into 
the pCRII TOPO vector (Invitrogen). XhoI and BamHI restriction sites in the pCRII 
TOPO vector were utilized to transfer the insert into the minigene vector pSPL3 
(Church et al., 1994).  
To express wild type U1 snRNA, we used the vector pG3U1 which includes the 
sequences coding for human U1 snRNA (Lund and Dahlberg, 1984; Pagani et al., 
2002). The U1 snRNA was adapted to the BBS1 splice donor site and/or mutation of 
exon 5 by site-directed mutagenesis as previously described (Tanner et al., 2009). 
PCR reactions were performed with specific primers for each construct (U1 mut: 
pGU1Mutfwd and pGU1Mutrev (Tanner et al., 2009), U1-BBS1_wt: 
F_U1_BBS1_adpt: 5‟CGAAGATCTCATTCTCACCGGGCAGGGGAGATACC 3‟ 
and R_U1_BBS1_adpt: 5‟GCCTGATCATGGTATCTCCCCTGCCCGGTGAGAA  
3‟; U1-BBS1_mut: F_U1_BBS1_Mut_adpt: 5‟ CGAAGATCTCATTCTCACTGGGC 
AGGGGAGATACC 3‟ and R_U1_BBS1_Mut_adpt: 5‟GCCTGATCATGGTATCTC 
CCCTGCCCAGTGAGAA 3‟). 
COS-7 cells were cultured in Dulbecco‟s modified Eagle‟s medium (DMEM) 
supplemented with 10% FBS, 1.3% L-glutamine and 1.1% penicillin/streptomycin 
(PAA) at 37°C, 5% CO2. 2*10
5
 cells/ml were cotransfected with either 2.4 g wt or 
mut minigene and 2.4 g U1 expression construct using branched polythyleneimine 
(PEI) (Sigma-Aldrich, Steinheim, Germany). cDNA was amplified by PCR using the 
forward primer SD6 (5‟TCTGAGTCACCTGGACAACC 3‟) which binds the splice 
donor exon of pSPL3 and the reverse primer BBS1-ex7up binding to BBS1 exon 7 
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(5‟TGCCGCTTGATGGAGTTGGACTT3‟). The RT-PCR reaction was performed 
with 300 ng cDNA at 66°C annealing temperature and 6 mM MgCl2 using Hotfire 
polymerase (Solis Biodyne, Tartu, Estonia). The experiment was replicated on at least 
3 independent transfections. 
 
Cell culture of patient-derived fibroblasts and immunocytochemistry 
Peripheral blood lymphocytes were isolated from whole blood samples by ficoll 
density gradient centrifugation and transformed with Epstein-Barr virus (EBV). EBV-
transformed lymphoblastoid cell lines from BBS1 mutation carriers IV:9, IV:10 and 
control IV:11 of family 26223 were cultured in RPMI 1640, 10% FBS, 1.1 % 
penicillin/ streptomycin, 1.3 % L-glutamine (PAA, Chemie Brunschwig AG, Basel, 
Switzerland) at 37°C, 5% CO2. 
Human dermal fibroblasts from individual IV:9, IV:10, and IV:11 were cultured as 
described (Villegas and McPhaul, 2005). Briefly, skin biopsies of about 5 mm
2
 were 
prepared under sterile conditions and transferred to fibroblast culture medium 
consisting of MEM with 20% FBS, 1.3% L-glutamine (PAA), 0.8% Antibiotic-
Antimycotic (Invitrogen). The biopsies were cut in smaller pieces of approximately 1 
mm
2
 and transferred to a sterile 25 cm
2
 culture flask to adhere for 15 min without 
medium, followed by 5 to 8 days of incubation with fibroblast culture medium at 
37°C and 5% CO2. After primary fibroblasts covered 75% of the culture flask, the 
cells were trypsinized and transferred to 75 cm
2
 flask for maintenance and 
experiments. 
To induce formation of monocilia in fibroblasts, we deprived cell cultures 
(approximately 90% confluent) from fetal calf serum for 24 hrs. 
Immunohistochemistry was performed with polyclonal rabbit antibodies against 
detyrosinated alpha tubulin (Chemicon International, Europe) and mouse monoclonal 
gamma tubulin (Abcam, Cambridge, UK) to stain cilia and basal bodies, respectively. 
Cells were fixed in 4% paraformaldehyde, blocked in 1x DPBS (PAA) containing 2% 
BSA, incubated with a 1:200 dilution of primary antibodies in 1x DPBS over night at 
4°C, followed by washing steps and incubation with Cy3 or Alexa-Fluor 488 
conjugated secondary antibody (1:200 diluted; Dianova, Hamburg, Germany; 
Molecular probes, Leiden, Netherlands). Respiratory epithelial cells were obtained by 
transnasal brush
 
biopsy, suspended
 
in RPMI 1640 medium without supplements and 
spread onto
 
glass slides. After air-drying, slides were stored at –80°C until use. 
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Samples were treated
 
with 4% paraformaldehyde, 0.2% Triton-X 100, and 5% skim 
milk
 
(all in PBS) before incubation with primary antibodies (mouse anti-acetylated-D-
tubulin (Sigma); rabbit-anti-BBS1, kindly provided by N. Katsanis, Baltimore) and
 
secondary antibodies (Alexa Fluor 488,
 
Alexa Fluor 546; Molecular Probes) at room 
temperature. Slides were
 
washed with PBS after each step and DNA
 
was stained with 
Hoechst 33342 (Sigma). Appropriate controls were performed
 
omitting the primary 
antibodies. Confocal images were
 
taken on a Zeiss laser scanning microscope 
(Axiovert 200 LSM510
 
META) using a 63 x 1.2 numerical aperture water immersion 
objective, and were processed with the Zeiss LSM software. 
 
Viral transduction of patient-derived fibroblasts 
The genomic sequence of the human U1 snRNA expression cassette (Lund and 
Dahlberg, 1984) was cloned into the lentiviral expression plasmid 
pRRLSIN.cPPT.SFFV/GFP.WPRE (Brenner and Malech, 2003; Werner et al., 2004) 
using HpaI restriction sites. The expression plasmid was co-transfected with 
packaging plasmids pSPAX2 and pMD2.G into HEK293T cells using branched PEI 
(Sigma-Aldrich) and culture medium containing the secreted viral shuttles was 
harvested twice within 3 days. Fibroblasts were directly added to fibroblast culture 
medium supplied with lentiviral particles and grown in 6-wells at 37°C, 5% CO2 for 3 
to 4 days. 
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3.2.4 Results 
Linkage  
We collected DNA samples from a family of Turkish origin with multiple 
consanguineous marriages. The family pedigree suggested an autosomal recessive 
inheritance pattern and showed three family members affected by RP (Figure 1). Two 
of the affected family members were siblings (IV:9 and IV:10) and the third was the 
daughter of their cousin (V:1). The parents of the two siblings IV:9 and IV:10 were 
cousins, whereas consanguinity was not documented for the parents of the patient 
V:1. 
To identify the chromosomal region that carries the causative mutation, we performed 
SNP homozygosity mapping including family members III:6, IV:3, IV:5, IV:7, IV:9, 
IV:10, and V:1. Significant linkage to a 5.6 Mb interval between SNP markers 
SNP_A-2212956 (rs10897271) and SNP_A-2224092 (rs7943216) on chromosome 
11q12.3-11q13.1 was identified and showed a multipoint parametric LOD score of 
3.08 for the RP phenotype (Figure 2). Within this region on chromosome 11, over 200 
genes were annotated. Among these, genes associated with RP included ROM1 and 
BBS1. Furthermore, refinement of the homozygosity mapping suggested a smaller 
region flanked by SNP markers SNP_A-2153886 (rs2226866) and SNP_A-2224092 
(rs7943216) (data not shown). This smaller region excluded the ROM1 locus from the 
interval on chromosome 11. In accordance with this finding, mutation screening did 
not identify sequence alterations in ROM1.  
 
Mutation analysis of BBS1  
The BBS1 gene consists of 17 exons, which contain an open reading frame of 1782 bp 
and codes for 593 amino acids. We performed mutation analysis of all exons and 
flanking intronic regions of BBS1 in the index patient IV:10 and identified the 
homozygous sequence alteration c.479G>A (NM_024649; Figure 3). The mutation 
affects the splice donor site (SD) of exon 5 and was confirmed to be homozygous in 
all RP affected family members (IV:9, IV:10, V:1). Six non-affected family members 
carried the mutation on one allele (II:3, III:1, III:6, IV:3, IV:5, IV:7). The unaffected 
husband of the index patient (IV:11) did not carry the mutation. Thus, the BBS1 
mutation c.479G>A cosegregates with the phenotype of RP (Figure 1). 
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The mutation affects the last base of exon 5 which strongly indicates an effect on pre-
mRNA splicing of BBS1 (Figure 3). Moreover, it is also predicted to substitute an 
arginine for a glutamine at position 160 (p.R160Q).  
 
Clinical characterization of the patients‟ phenotype 
BBS primarily includes features of retinal dystrophies, polydactyly, obesity, renal 
anomalies, learning disabilities, and genital abnormalities. The affected patients 
described herein were referred to ophthalmologic examination without any signs of 
additional features besides RP. 
All patients examined had normal intraocular pressure and normal anterior segment 
morphology. Patients IV:9 and IV:10 showed RP with nightblindness present since 
early childhood, extinguished ERG, concentrically constricted visual fields, reduced 
visual acuity, bone spicules and attenuated vessels (Table 1). Both patients had similar 
phenotypes, although patient IV:9 appeared to have a clincially more progressed stage 
of the disease. OCT examination of patients IV:9 and IV:10 revealed a reduction of 
retinal thickness that was more pronounced in the periphery compared to the fovea 
(data not shown). The patients completed their compulsory school without any 
problems and were employed after finishing school. Due to increasing visual 
problems both patients IV:9 and IV:10 could not continue working at the age of 23 
and 25 respectively. In patient IV:11 no signs of the disease were detected and all 
results of the clinical examinations were within normal ranges. Details are 
summarized in Table 1. 
In summary, we did not find clinical evidence for BBS in patients IV:9 and IV:10, 
which showed RP without signs of polydactyly, obvious kidney defects, obesity or 
genital abnormalities.  
 
Mutation-induced missplicing in BBS1 
To analyze possible consequences of the mutation c.479G>A for BBS1 splicing, we 
performed RT-PCR analysis on blood, EBV-transformed lymphocytes, and cultured 
skin fibroblasts of three family members (IV:9, affected, homozygous mutation 
carrier; IV:10, affected, homozygous mutation carrier; IV:11, unaffected, no carrier). 
RT-PCR analysis of IV:11 using primers to exon 4 and 8 resulted in a band at the 
expected size of about 300 base pairs (bp). In contrast, the two affected family 
members IV:9 and IV:10 showed three bands at approximately 400, 300, and 200 bp 
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(Figure 4). All three bands occurred in cDNA from blood, EBV-transformed 
lymphocytes, and fibroblasts. Sequencing of the RT-PCR products confirmed that the 
300 bp band contains exons 4 through 8 without any indication of missplicing. The 
400 bp band includes intron 5 in addition to constitutively spliced exons, whereas the 
200 bp band skips exon 5 from the normal transcript. These results show that the 
mutation c.479G>A leads to missplicing of BBS1. Unexpectedly, the correctly spliced 
transcript at 300 bp is also found in samples of homozygous mutation carriers, 
although clearly reduced (Figure 4). The inclusion of intron 5 leads to a premature 
stop at the first inserted codon and skipping of exon 5 results in a frameshift followed 
by 20 BBS1-unrelated amino acids and a stop codon in exon 7. Thus, both misspliced 
transcripts are predicted to lead to a truncated BBS1 protein. 
 
Analysis of cilia in patients with the homozygous BBS1 mutation 
The molecular pathomechanism underlying BBS is associated with ciliary defects. 
Depletion of BBS1 has been shown to prevent the formation of cilia in cultured cells 
(Nachury et al., 2007). 
Based on these observations, we analyzed monocilia of cultured fibroblasts from 
patients IV:9, IV:10, and IV:11. Fibroblasts were deprived from serum to induce 
generation of a monocilium on the surface of the cells. Immunocytochemical analysis 
of basal bodies and monocilia did not reveal an obvious ciliary defect in cell lines 
from affected patients (Figure 5A-D). We further analyzed cilia of patient-derived 
nasal epithelial cells (Figure 5E). The immunohistochemical staining for markers of 
the cilium and BBS1 in the transitional zone did not show obvious differences 
between affected and unaffected patient samples, thus confirming the results of the 
fibroblast culture. 
 
Correction of mutation-induced missplicing in a BBS1 minigene assay 
Recently, we have shown that adaptation of U1 snRNA to a mutated splice donor site 
can efficiently rescue mutation-induced missplicing (Tanner et al., 2009). In order to 
simulate the splice processes as observed in the patient, we generated minigene 
constructs that consist of the genomic region of BBS1 including intron 4 through 7. 
The minigenes either contained the wild-type (Mini-wt) or the mutated (Mini-mut) 
allele of IV:11 or IV:9, respectively (Figure 6A). The minigenes were transfected into 
COS-7 cells following RT-PCR amplification. We found that the splice patterns of 
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minigenes closely resemble the patterns identified in blood or cultured cells of either 
the control or patients (Figure 6C). PCR amplicons were analyzed by sequencing and 
confirmed splice products as detected in patient samples (intron 5 retention, normal 
splicing and exon 5 skipping). 
To correct missplicing from BBS1 minigenes, we adapted U1 with the aim to increase 
complementarity to the mutated SD sequence of BBS1 exon 5. To optimize the 
efficiency of the U1 intervention, four different U1 snRNA expression constructs 
were generated (Figure 6B): 1) wild-type U1 (U1-wt), 2) U1 only adapted to the BBS1 
mutation c.479G>A (U1-mut), 3) U1 matching all nucleotides of the reference SD of 
BBS1 exon 5 (U1-BBS1_wt), 4) U1 matching all nucleotides of the mutated SD (U1-
BBS1_mut). These expression constructs were cotransfected with one of the two 
minigenes and splicing of minigene-derived BBS1 transcripts was analyzed by RT-
PCR (Figure 6C). The splice pattern from the minigene Mini-wt was neither altered 
by overexpression of wild type U1, nor by any of the differently adapted U1 isoforms. 
In contrast, the aberrant splice pattern from minigene Mini-mut was corrected by 
different U1 isoforms. Especially, U1-BBS1_wt as well as U1-BBS1_mut rescued 
missplicing of BBS1 most efficiently and reverted the mutation-induced splice defect 
into a normal splice pattern (Figure 6C). Direct sequencing of correct BBS1 transcripts 
confirmed appropriate splicing of the mutated transcript. 
 
Correction of endogenously expressed BBS1 transcripts 
The minigene assay clearly showed that the splice defect can be corrected by the 
expression of a modified U1 with increased binding affinity to the mutated SD in 
BBS1 exon 5. In order to test whether this approach is able to correct missplicing of 
endogenously expressed BBS1 transcripts of patient-derived cell lines, we transduced 
fibroblasts using a lentiviral shuttle. The lentivirus contained the same U1 isoforms as 
used for the minigene assay. As evaluated by the co-expressed EGFP, the transduction 
efficiencies of the virus were within ranges between 90 to 100% (Figure 7A). 
Endogenously spliced BBS1 transcripts from lentivirus-treated fibroblasts were 
analyzed by RT-PCR. 
Upon treatment with fully adapted U1 (U1-BBS1_mut), a large increase in the amount 
of the correctly spliced BBS1 transcripts and a clear reduction of BBS1 lacking exon 5 
was detected (Figure 7B). A smaller increase in the amount of correctly spliced 
transcripts was observed by the expression of U1-BBS1_wt. In contrast, expression of 
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U1-wt as well as U1-mut had no detectable effect on BBS1 splicing. Importantly, 
treatment of control fibroblasts IV:11 with all of our adapted U1 isoforms did not alter 
splicing of BBS1. Sequence analysis confirmed that the corrected BBS1 transcript is 
accurately spliced. Taken together, these results demonstrate that treatment with the 
fully adapted U1 isoform efficiently abolishes exon 5 skipping and largely increases 
the amount of correctly spliced BBS1 transcripts in the patient-derived cell line. 
To test whether elevated levels of fully adapted U1 (U1-BBS1_mut) can improve 
therapeutic effects, we treated the fibroblasts with increasing amounts of the lentiviral 
shuttles. In fibroblasts derived from affected patients (IV:9 and IV:10), the efficiency 
of the treatment increased with higher concentrations of the lentivirus (Figure 7C). A 
similar treatment with U1-wt or mock showed no detectable effect on splicing of 
BBS1. The control cell line (IV:11) revealed unaltered BBS1 expression and splicing 
under all tested conditions and thus confirms that the treatment does not interfere with 
normal BBS1 splicing. Together, our data demonstrate that the adaptation of U1 to a 
mutated SD is a promising gene therapeutic approach to correct splice defects 
.
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3.2.5. Discussion 
BBS can be caused by mutations in at least 15 genes (Zaghloul and Katsanis, 2009; 
Kim et al., 2010). We identified the mutation c.479G>A in BBS1 in a large 
consanguineous family of Turkish origin. The same mutation has previously been 
described in a patient of Caucasian origin, who was compound heterozygous with the 
mutation p.M390R (Hichri et al., 2005) and diagnosed with a clear BBS phenotype. In 
contrast, patients of the family described herein, suffer from RP showing no 
additional symptoms that would clearly support the clinical diagnosis of BBS. 
Similarly, the occurrence of isolated RP has been recently described for mutations in 
BBS3 and BBS8 (Aldahmesh et al., 2009; Riazuddin et al., 2010). It has further been 
reported that patients with mutations in BBS1 may show milder BBS phenotypes with 
only one or two additional symptoms (Azari et al., 2006; Gerth et al., 2008). 
The mode of inheritance in BBS can be multiallelic and the expression or penetrance 
of the phenotype is variable depending on the total load and type of mutations (Fauser 
et al., 2003; Fan et al., 2004; Katsanis, 2004; Pawlik et al., 2010). A case has been 
published where three nonsense mutations in BBS2 and BBS6 genes are required to 
cause a phenotype, whereas two nonsense mutations in BBS2 alone did not lead to 
symptoms (Katsanis et al., 2001). These reports show that the mode of inheritance and 
the phenotypic expression in BBS can be highly variable. 
As found in RP patients described in this study, both alleles carry the BBS1 mutation 
c.479G>A. This results in aberrant splicing of the BBS1 pre-mRNA and reduces the 
amount of correctly spliced transcripts. A residual level of normally spliced BBS1 
transcripts is generated even in homozygous carriers of the mutation. Consequently, 
the c.479G>A mutation may be considered as a mild mutation, which only reduces 
BBS1 levels. The remaining amount of correctly spliced BBS1 transcripts seems to be 
enough to maintain BBS1 function in most tissues of the patient, but fails to ensure 
survival of photoreceptors. This hypothesis is supported by the disease phenotype 
which only shows rod photoreceptor degeneration as seen in RP. Furthermore, we did 
not find obvious defects in generating basal bodies or cilia in patient-derived 
fibroblasts or nasal epithelia cells. 
Photoreceptors are considered to have high demands for transport across the 
connecting cilium, a specialized nonmotile cilium which serves as a transition zone 
between inner and outer segments. The fact that about 2000 photopigment molecules 
have to be delivered to outer segments within a minute might explain the high 
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vulnerability of photoreceptors to defects in ciliary function (Badano et al., 2006). A 
mislocalization of rhodopsin has been detected in Bbs2 knock-out mice which 
precedes apoptosis of rod photoreceptors (Nishimura et al., 2004). Furthermore, it has 
recently been shown that the BBSome is involved in transport of membrane proteins 
to cilia (Jin et al., 2010). These findings suggest a functional link between the ciliary 
transport, the activity of the BBSome, and the survival of photoreceptors. 
 
The c.479G>A-induced splice defect of exon skipping and intron retention is likely 
caused by impaired interaction of the U1 with the mutated SD. We modified U1 in 
order to increase its binding affinity to the mutated transcript. In two different cell 
lines, our results revealed a significant increase of correctly spliced BBS1 transcripts 
and a simultaneous reduction of exon 5 skipping. From these results, we conclude that 
an increase in the binding affinity of U1 snRNA to its target sequence leads to an 
efficient correction of splice defects. This is the first time that the U1 approach has 
been successfully used to treat endogenously expressed transcripts in cell lines 
derived from eye disease patients. In conclusion, the presented technique is a 
promising gene therapeutic approach to treat splice defects caused by a SD site 
mutation. This is particularly true for autosomal recessive diseases that might only 
need 50% of the gene dose to avoid the expression or progression of the disease. 
The eye is an optimal target tissue for gene therapeutic treatments, because of its easy 
accessibility, transparency and immune privilege. Several different gene therapeutic 
strategies have been developed to treat inherited ocular diseases (Bainbridge, 2009; 
Stone, 2009) and important progress has been made using gene replacement therapy 
in human. Especially for Leber‟s congenital amourosis type 2 (LCA2), which involves 
retinal degeneration and severe vision loss in early childhood, three independent 
groups published the efficiency and safety of human gene therapy trials (Bainbridge et 
al., 2008; Cideciyan et al., 2008; Maguire et al., 2008). LCA can be caused by 
mutations in the RPE65 gene which is expressed in RPE cells and responsible for the 
regeneration of rod photoreceptor visual pigment. To improve vision, wild-type 
RPE65 was expressed by an AAV2-based vector and delivered to the eye of the 
patient by intraocular injections. In all three clinical trials, patients showed 
improvement in retinal functions. Furthermore, there was no significant systemic 
delivery of the vector or immunoreactive response detected upon exposure to the 
AAV vector, indicating high safety of the treatment. 
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In addition to gene replacement strategies, therapeutic approaches with the aim to 
restore pathogenic effects of mutation-induced aberrant splicing have been established 
using RNAi-based strategies or antisense oligonucleotides (Cooper et al., 2009). 
Nevertheless, the technique of U1 adaptation may have advantages compared to other 
gene therapeutic strategies: First, splice mutations are among the most frequent 
pathogenic sequence alterations. Around 15% of all point mutations are estimated to 
alter splice sites, an observation that is almost irrespective of the disease gene 
(Faustino and Cooper, 2003). Second, this method has the potential to be applied to 
different SD mutations requiring only simple modifications of the U1 binding 
sequence. Third, it simultaneously restores normal transcript levels and removes 
potentially pathogenic splice variants. 
Taken together, we show that the use of mutation-adapted U1 can efficiently correct 
aberrant splicing in cell lines of affected patients. To further clarify the potential of 
this approach for gene therapy, it will be instrumental to test animal models. 
 
Results 
85 
3.2.6. Acknowledgements 
We are grateful to Silke Feil for technical assistance and support of cell culture. We 
thank Gaby Tanner for assistance during cloning of BBS1 minigenes. Furthermore, we 
would like to thank Arun Pal and Marino Zerial for providing the lentiviral vector 
backbone. We thank Nicolas Katsanis for providing the antibody against BBS1. The 
study was financially supported by the Velux Foundation, the Forschungskredit of the 
University of Zurich, Schweizerischer Fonds zur Verhütung und Bekämpfung der 
Blindheit, Hartmann Müller Foundation (to J.N.). 
 
Results 
86 
3.2.7.  References 
 
 1.  Abecasis,G.R., Cherny,S.S., Cookson,W.O., and Cardon,L.R. (2001). GRR: 
graphical representation of relationship errors. Bioinformatics. 17, 742-743. 
 2.  Abecasis,G.R., Cherny,S.S., Cookson,W.O., and Cardon,L.R. (2002). Merlin--
rapid analysis of dense genetic maps using sparse gene flow trees. Nat. Genet. 
30, 97-101. 
 3.  Aldahmesh,M.A., Safieh,L.A., Alkuraya,H., Al-Rajhi,A., Shamseldin,H., 
Hashem,M., Alzahrani,F., Khan,A.O., Alqahtani,F., Rahbeeni,Z., Alowain,M., 
Khalak,H., Al-Hazzaa,S., Meyer,B.F., and Alkuraya,F.S. (2009). Molecular 
characterization of retinitis pigmentosa in Saudi Arabia. Mol. Vis. 15, 2464-
2469. 
 4.  Azari,A.A., Aleman,T.S., Cideciyan,A.V., Schwartz,S.B., Windsor,E.A., 
Sumaroka,A., Cheung,A.Y., Steinberg,J.D., Roman,A.J., Stone,E.M., 
Sheffield,V.C., and Jacobson,S.G. (2006). Retinal disease expression in Bardet-
Biedl syndrome-1 (BBS1) is a spectrum from maculopathy to retina-wide 
degeneration. Invest Ophthalmol. Vis. Sci. 47, 5004-5010. 
 5.  Badano,J.L., Mitsuma,N., Beales,P.L., and Katsanis,N. (2006). The ciliopathies: 
an emerging class of human genetic disorders. Annu. Rev. Genomics Hum. 
Genet. 7, 125-148. 
 6.  Bainbridge,J.W. (2009). Prospects for gene therapy of inherited retinal disease. 
Eye (Lond) 23, 1898-1903. 
 7.  Bainbridge,J.W., Smith,A.J., Barker,S.S., Robbie,S., Henderson,R., 
Balaggan,K., Viswanathan,A., Holder,G.E., Stockman,A., Tyler,N., Petersen-
Jones,S., Bhattacharya,S.S., Thrasher,A.J., Fitzke,F.W., Carter,B.J., Rubin,G.S., 
Moore,A.T., and Ali,R.R. (2008). Effect of gene therapy on visual function in 
Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239. 
 8.  Beales,P.L., Badano,J.L., Ross,A.J., Ansley,S.J., Hoskins,B.E., Kirsten,B., 
Mein,C.A., Froguel,P., Scambler,P.J., Lewis,R.A., Lupski,J.R., and Katsanis,N. 
(2003). Genetic interaction of BBS1 mutations with alleles at other BBS loci can 
result in non-Mendelian Bardet-Biedl syndrome. Am. J. Hum. Genet. 72, 1187-
1199. 
 9.  Beales,P.L., Elcioglu,N., Woolf,A.S., Parker,D., and Flinter,F.A. (1999). New 
criteria for improved diagnosis of Bardet-Biedl syndrome: results of a 
population survey. J. Med. Genet. 36, 437-446. 
 10.  Blacque,O.E. and Leroux,M.R. (2006). Bardet-Biedl syndrome: an emerging 
pathomechanism of intracellular transport. Cell Mol. Life Sci. 63, 2145-2161. 
 11.  Brenner,S. and Malech,H.L. (2003). Current developments in the design of 
onco-retrovirus and lentivirus vector systems for hematopoietic cell gene 
therapy. Biochim. Biophys. Acta 1640, 1-24. 
Results 
87 
 12.  Church,D.M., Stotler,C.J., Rutter,J.L., Murrell,J.R., Trofatter,J.A., and 
Buckler,A.J. (1994). Isolation of genes from complex sources of mammalian 
genomic DNA using exon amplification. Nat. Genet. 6, 98-105. 
 13.  Cideciyan,A.V., Aleman,T.S., Boye,S.L., Schwartz,S.B., Kaushal,S., 
Roman,A.J., Pang,J.J., Sumaroka,A., Windsor,E.A., Wilson,J.M., Flotte,T.R., 
Fishman,G.A., Heon,E., Stone,E.M., Byrne,B.J., Jacobson,S.G., and 
Hauswirth,W.W. (2008). Human gene therapy for RPE65 isomerase deficiency 
activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl. 
Acad. Sci. U. S. A 105, 15112-15117. 
 14.  Cooper,T.A., Wan,L., and Dreyfuss,G. (2009). RNA and disease. Cell 136, 777-
793. 
 15.  Fan,Y., Esmail,M.A., Ansley,S.J., Blacque,O.E., Boroevich,K., Ross,A.J., 
Moore,S.J., Badano,J.L., May-Simera,H., Compton,D.S., Green,J.S., 
Lewis,R.A., van Haelst,M.M., Parfrey,P.S., Baillie,D.L., Beales,P.L., 
Katsanis,N., Davidson,W.S., and Leroux,M.R. (2004). Mutations in a member 
of the Ras superfamily of small GTP-binding proteins causes Bardet-Biedl 
syndrome. Nat. Genet. 36, 989-993. 
 16.  Fauser,S., Munz,M., and Besch,D. (2003). Further support for digenic 
inheritance in Bardet-Biedl syndrome. J. Med. Genet. 40, e104. 
 17.  Faustino,N.A. and Cooper,T.A. (2003). Pre-mRNA splicing and human disease. 
Genes Dev. 17, 419-437. 
 18.  Gerth,C., Zawadzki,R.J., Werner,J.S., and Heon,E. (2008). Retinal morphology 
in patients with BBS1 and BBS10 related Bardet-Biedl Syndrome evaluated by 
Fourier-domain optical coherence tomography. Vision Res. 48, 392-399. 
 19.  Gudbjartsson,D.F., Jonasson,K., Frigge,M.L., and Kong,A. (2000). Allegro, a 
new computer program for multipoint linkage analysis. Nat. Genet. 25, 12-13. 
 20.  Hichri,H., Stoetzel,C., Laurier,V., Caron,S., Sigaudy,S., Sarda,P., Hamel,C., 
Martin-Coignard,D., Gilles,M., Leheup,B., Holder,M., Kaplan,J., Bitoun,P., 
Lacombe,D., Verloes,A., Bonneau,D., Perrin-Schmitt,F., Brandt,C., 
Besancon,A.F., Mandel,J.L., Cossee,M., and Dollfus,H. (2005). Testing for 
triallelism: analysis of six BBS genes in a Bardet-Biedl syndrome family cohort. 
Eur. J. Hum. Genet. 13, 607-616. 
 21.  Jin,H., White,S.R., Shida,T., Schulz,S., Aguiar,M., Gygi,S.P., Bazan,J.F., and 
Nachury,M.V. (2010). The conserved Bardet-Biedl syndrome proteins assemble 
a coat that traffics membrane proteins to cilia. Cell 141, 1208-1219. 
 22.  Katsanis,N. (2004). The oligogenic properties of Bardet-Biedl syndrome. Hum. 
Mol. Genet. 13 Spec No 1, R65-R71. 
 23.  Katsanis,N., Ansley,S.J., Badano,J.L., Eichers,E.R., Lewis,R.A., Hoskins,B.E., 
Scambler,P.J., Davidson,W.S., Beales,P.L., and Lupski,J.R. (2001). Triallelic 
inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science 
293, 2256-2259. 
Results 
88 
 24.  Kim,S.K., Shindo,A., Park,T.J., Oh,E.C., Ghosh,S., Gray,R.S., Lewis,R.A., 
Johnson,C.A., Attie-Bittach,T., Katsanis,N., and Wallingford,J.B. (2010). Planar 
cell polarity acts through septins to control collective cell movement and 
ciliogenesis. Science 329, 1337-1340. 
 25.  Leroux,M.R. (2007). Taking vesicular transport to the cilium. Cell 129, 1041-
1043. 
 26.  Lund,E. and Dahlberg,J.E. (1984). True genes for human U1 small nuclear 
RNA. Copy number, polymorphism, and methylation. J. Biol. Chem. 259, 2013-
2021. 
 27.  Maguire,A.M., Simonelli,F., Pierce,E.A., Pugh,E.N., Jr., Mingozzi,F., 
Bennicelli,J., Banfi,S., Marshall,K.A., Testa,F., Surace,E.M., Rossi,S., 
Lyubarsky,A., Arruda,V.R., Konkle,B., Stone,E., Sun,J., Jacobs,J., Dell'Osso,L., 
Hertle,R., Ma,J.X., Redmond,T.M., Zhu,X., Hauck,B., Zelenaia,O., 
Shindler,K.S., Maguire,M.G., Wright,J.F., Volpe,N.J., McDonnell,J.W., 
Auricchio,A., High,K.A., and Bennett,J. (2008). Safety and efficacy of gene 
transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. 
 28.  Mykytyn,K., Nishimura,D.Y., Searby,C.C., Beck,G., Bugge,K., Haines,H.L., 
Cornier,A.S., Cox,G.F., Fulton,A.B., Carmi,R., Iannaccone,A., Jacobson,S.G., 
Weleber,R.G., Wright,A.F., Riise,R., Hennekam,R.C., Luleci,G., Berker-
Karauzum,S., Biesecker,L.G., Stone,E.M., and Sheffield,V.C. (2003). 
Evaluation of complex inheritance involving the most common Bardet-Biedl 
syndrome locus (BBS1). Am. J. Hum. Genet. 72, 429-437. 
 29.  Mykytyn,K., Nishimura,D.Y., Searby,C.C., Shastri,M., Yen,H.J., Beck,J.S., 
Braun,T., Streb,L.M., Cornier,A.S., Cox,G.F., Fulton,A.B., Carmi,R., Luleci,G., 
Chandrasekharappa,S.C., Collins,F.S., Jacobson,S.G., Heckenlively,J.R., 
Weleber,R.G., Stone,E.M., and Sheffield,V.C. (2002). Identification of the gene 
(BBS1) most commonly involved in Bardet-Biedl syndrome, a complex human 
obesity syndrome. Nat. Genet. 31, 435-438. 
 30.  Nachury,M.V., Loktev,A.V., Zhang,Q., Westlake,C.J., Peranen,J., Merdes,A., 
Slusarski,D.C., Scheller,R.H., Bazan,J.F., Sheffield,V.C., and Jackson,P.K. 
(2007). A core complex of BBS proteins cooperates with the GTPase Rab8 to 
promote ciliary membrane biogenesis. Cell 129, 1201-1213. 
 31.  Neidhardt,J., Glaus,E., Barthelmes,D., Zeitz,C., Fleischhauer,J., and Berger,W. 
(2007). Identification and characterization of a novel RPGR isoform in human 
retina. Hum. Mutat. 28, 797-807. 
 32.  Nishimura,D.Y., Fath,M., Mullins,R.F., Searby,C., Andrews,M., Davis,R., 
Andorf,J.L., Mykytyn,K., Swiderski,R.E., Yang,B., Carmi,R., Stone,E.M., and 
Sheffield,V.C. (2004). Bbs2-null mice have neurosensory deficits, a defect in 
social dominance, and retinopathy associated with mislocalization of rhodopsin. 
Proc. Natl. Acad. Sci. U. S. A 101, 16588-16593. 
Results 
89 
 33.  O'Connell,J.R. and Weeks,D.E. (1998). PedCheck: a program for identification 
of genotype incompatibilities in linkage analysis. Am. J. Hum. Genet. 63, 259-
266. 
 34.  Pagani,F., Buratti,E., Stuani,C., Bendix,R., Dork,T., and Baralle,F.E. (2002). A 
new type of mutation causes a splicing defect in ATM. Nat. Genet. 30, 426-429. 
 35.  Pawlik,B., Mir,A., Iqbal,H., Li,Y., Nurnberg,G., Becker,C., Qamar,R., 
Nurnberg,P., and Wollnik,B. (2010). A Novel Familial BBS12 Mutation 
Associated with a Mild Phenotype: Implications for Clinical and Molecular 
Diagnostic Strategies. Mol. Syndromol. 1, 27-34. 
 36.  Riazuddin,S.A., Iqbal,M., Wang,Y., Masuda,T., Chen,Y., Bowne,S., 
Sullivan,L.S., Waseem,N.H., Bhattacharya,S., Daiger,S.P., Zhang,K., 
Khan,S.N., Riazuddin,S., Hejtmancik,J.F., Sieving,P.A., Zack,D.J., and 
Katsanis,N. (2010). A splice-site mutation in a retina-specific exon of BBS8 
causes nonsyndromic retinitis pigmentosa. Am. J. Hum. Genet. 86, 805-812. 
 37.  Ruschendorf,F. and Nurnberg,P. (2005). ALOHOMORA: a tool for linkage 
analysis using 10K SNP array data. Bioinformatics. 21, 2123-2125. 
 38.  Stoetzel,C., Laurier,V., Davis,E.E., Muller,J., Rix,S., Badano,J.L., Leitch,C.C., 
Salem,N., Chouery,E., Corbani,S., Jalk,N., Vicaire,S., Sarda,P., Hamel,C., 
Lacombe,D., Holder,M., Odent,S., Holder,S., Brooks,A.S., Elcioglu,N.H., 
Silva,E.D., Rossillion,B., Sigaudy,S., de Ravel,T.J., Lewis,R.A., Leheup,B., 
Verloes,A., Amati-Bonneau,P., Megarbane,A., Poch,O., Bonneau,D., 
Beales,P.L., Mandel,J.L., Katsanis,N., and Dollfus,H. (2006). BBS10 encodes a 
vertebrate-specific chaperonin-like protein and is a major BBS locus. Nat. 
Genet. 38, 521-524. 
 39.  Stone,E.M. (2009). Progress toward effective treatments for human 
photoreceptor degenerations. Curr. Opin. Genet. Dev. 19, 283-289. 
 40.  Tanner,G., Glaus,E., Barthelmes,D., Ader,M., Fleischhauer,J., Pagani,F., 
Berger,W., and Neidhardt,J. (2009). Therapeutic strategy to rescue mutation-
induced exon skipping in rhodopsin by adaptation of U1 snRNA. Hum. Mutat. 
30, 255-263. 
 41.  Thiele,H. and Nurnberg,P. (2005). HaploPainter: a tool for drawing pedigrees 
with complex haplotypes. Bioinformatics. 21, 1730-1732. 
 42.  Villegas,J. and McPhaul,M. (2005). Establishment and culture of human skin 
fibroblasts. Curr. Protoc. Mol. Biol. Chapter 28, Unit. 
 43.  Wahl,M.C., Will,C.L., and Luhrmann,R. (2009). The spliceosome: design 
principles of a dynamic RNP machine. Cell 136, 701-718. 
 44.  Wang,G.S. and Cooper,T.A. (2007). Splicing in disease: disruption of the 
splicing code and the decoding machinery. Nat. Rev. Genet. 8, 749-761. 
 45.  Werner,M., Kraunus,J., Baum,C., and Brocker,T. (2004). B-cell-specific 
transgene expression using a self-inactivating retroviral vector with human 
Results 
90 
CD19 promoter and viral post-transcriptional regulatory element. Gene Ther. 11, 
992-1000. 
 46.  Zaghloul,N.A. and Katsanis,N. (2009). Mechanistic insights into Bardet-Biedl 
syndrome, a model ciliopathy. J. Clin. Invest 119, 428-437. 
 47.  Zhuang,Y. and Weiner,A.M. (1986). A compensatory base change in U1 snRNA 
suppresses a 5' splice site mutation. Cell 46, 827-835. 
 
 
Results 
91 
3.2.8. Figures and Tables 
 
Table 1 Clinical examinations of family members IV:9, IV:10, and IV:11 
   Patient  
    IV:9 IV:10 IV:11 
Demographic Year of birth 1981 1974 1964 
 gender female female male 
 height in cm 168 167 172 
 BMI in kg/m
2
 28.7 28.6 27.0 
      
Diabetes 
mellitus 
 none gestational diabetes in 
the second pregnancy 
none 
Limbs  No polydactyly, no 
other anomalies 
No polydactyly, no 
other anomalies 
No polydactyly, no 
other anomalies 
      
Eye night blindness present since childhood present since childhood none 
 VA (OD - OS) 20/800 - 20/400 20/400 - 20/200 20/20 - 20/20 
 IOP (OD - OS) 12 - 12 12 - 14 14 - 14 
 anterior 
segment 
normal morphology normal morphology normal morphology 
 fundus bone spicules, 
attenuated vessels, 
epiretinal gliosis, 
atrophic retina, pale 
discs 
bone spicules, 
narrowed vessels, 
atrophic retina, pale 
discs 
normal 
 ERG extinguished extinguished normal rod- and cone-
driven signals 
 Visual field severely concentrically 
constricted 
severely constricted 
with only a small central 
island left 
normal 
      
Kidney lab tests within normal ranges within normal ranges within normal ranges 
Liver lab tests within normal ranges within normal ranges within normal ranges 
Hematologic 
system 
lab tests within normal ranges within normal ranges within normal ranges 
      
Reproductive 
system 
 Ultrasound, 
hormonal status 
irregular menstrual 
cycle, otherwise normal  
normal, 2 healthy 
children with IV:11 
normal, 2 healthy 
children with IV:10 
 
BMI: Body Mass Index (weight in kg / (height in m)
2
); VA: Visual acuity; IOP: Intraocular 
pressure in mmHg; ERG: Ganzfeld Electroretinography 
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Figure 1 Pedigree of the consanguineous family 26223 segregating RP. Filled symbols 
represent affected family members whereas symbols with dots represent unaffected mutation 
carriers. Double lines indicate consanguinity. Analyzed patients are marked by horizontal bars 
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Figure 2 LOD scores across the genome for the RP phenotype in family 26223. Genetic map 
position (cM) and chromosome numbers are displayed horizontally. LOD scores are indicated 
on the vertical axis. 
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Figure 3 Electropherograms of parts of the exon/intron boundary containing the mutation 
c.479G>A found in BBS1 exon 5 of affected family members. Three different 
electropherograms are shown representing homozygous (IV:10) and heterozygous (IV:7) 
mutations carriers as well as an unaffected family member (IV:11). The position of the 
mutation is marked by an arrow head. The exon/intron boundary at the BBS1 exon 5 splice 
donor site is depicted as splice junction. 
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Figure 4 Amplification of BBS1 transcripts in affected family members. RNA from blood, 
ARPE9, EBV-transformed lymphoblast (EBV) or fibroblast (fibro) cells from different family 
members was analyzed by RT-PCR using primers in exon 4 and exon 8. RT-PCR reaction 
lacking a template is indicated by H2O. DNA marker sizes are given in base pairs (bp). 
Detected splice isoforms are illustrated by schematic drawings. 
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Figure 5 Immunostaining of patient-derived fibroblasts to detect cilia. Fluorescence images of 
serum-starved cells stained with A DAPI, B anti gamma tubulin, C anti D-tubulin are merged 
in D. E Patient-derived epithelial cells extracted from nose by brushing were stained with 
antibodies against acetylated -tubulin or BBS1. Scale bars represent sizes of 10 m. 
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Figure 6 Amplification of minigene-derived BBS1 transcripts by RT-PCR. A Graphical 
illustration of the minigene construct in pSPL3 containing the human genomic sequence of 
BBS1 spanning intron 4 to 7. SDv: vector-derived splice donor; SAv: vector-derived splice 
acceptor. B Molecular interaction of wild-type U1 (U1-wt) with the splice donor site (SD) of 
BBS1 exon 5. Watson and Crick base pairing is indicated by vertical lines. The position of the 
mutation c.479G>A in the mutated minigene (Mini-mut) is highlighted in gray. In addition to 
the construct expressing the U1-wt, we generated different modifications of U1 effecting its 
SD binding sequence: U1-mut (U1 adapted to the mutation c.479G>A only), U1-BBS1_wt (U1 
adapted to the reference SD of BBS1 exon 5) and U1-BBS1_mut (U1 fully adapted to the 
mutated SD). Adaptations of the SD are illustrated in bold letters. C Rescue of minigene-
derived BBS1 missplicing by co-transfection of wild type (Mini-wt) or mutated minigenes (Mini-
mut) with adapted U1 isoforms or empty vector (mock) in COS-7 cells. RT-PCR reaction 
lacking a template is indicated by H2O. DNA marker sizes are given in base pairs (bp). 
Detected splice isoforms are illustrated by schematic drawings. 
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Figure 7 Correction of endogenously expressed BBS1 transcripts in patient-derived 
fibroblasts. Cells were transduced with lentiviral vectors expressing adapted U1. A 
Fluorescence microscopy image of fibroblast cells transduced with lentiviral vectors 
expressing modified U1 and EGFP. Scale bars represents sizes of 100 m. B RT-PCR 
amplification of exons 4 to 8 of endogenous BBS1 transcripts in transduced fibroblasts from 
patient IV:10. Fibroblasts transduced with lentiviral particles containing no U1 are designated 
as mock. DNA marker sizes are given in base pairs (bp). C Stepwise increase of the amount 
of lentiviral shuttles containing fully adapted U1 to achieve higher correction efficiencies. 
Fibroblasts from patients IV:9 and IV:10 and the unaffected control IV:11 were transfected 
with either 1 ml, 3 ml, 6 ml or 9 ml culture medium containing lentiviral shuttles. Either wild-
type U1 (U1-wt), fully adapted U1 (U1-BBS1_mut) or no U1 (mock) was encoded by the 
lentivirus. DNA marker sizes are given in bp. Detected splice isoforms are illustrated by 
schematic drawings. 
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3.2.9. Own contribution to the manuscript “U1 snRNA-mediated gene  
 therapeutic correction of splice defects caused by an exceptionally  
 mild BBS mutation” 
 
Cell culture, adapting U1 snRNA, lentivirus production, transfection and transduction, 
evaluation of transduction efficiency, RT-PCR analysis of minigene-derived and 
endogenous BBS1 splicing, contributions to data interpretation and manuscript writing 
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3.3. Search for downstream target genes of BBS1 
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3.3.1. Abstract 
We have identified a splice donor site mutation in the Bardet-Biedl-Syndrome 1 gene 
(BBS1) and characterized its effect on splicing of BBS1. The mutation was 
homozygous in three members of a consanguineous family affected by retinitis 
pigmentosa. By overexpression of a modified isoform of the U1 snRNA (U1), which 
features full complementary to the mutated splice donor site, we could significantly 
increase the amount of normal BBS1 transcripts in patient derived fibroblasts. The 
correction of the splice defect might also result in altered expression of downstream 
targets or BBS1 interaction partners. In addition, the expression of the modified U1 
might not only restore correct BBS1 splicing, but may also interfere with normal 
splicing of other genes. Thus, we aimed to understand possible consequences of the 
treatment and focused on effects at the transcript level. To assess pre-mRNA splicing 
in treated fibroblasts from the patient, we used the Human Exon 1.0 ST array chip 
comparing the fully adapted U1 with the wild-type U1 treatment. The outcome of the 
study revealed only mild effects on splicing of non-target mRNAs upon treatment 
with fully adapted U1, especially for retinopathy-associated genes. Nevertheless, 
possible consequences of this therapeutic approach need to be further investigated 
with particular focus on retinal cells. Furthermore, we identified CKAP5 as a potential 
downstream target gene the expression of which might be controlled by the function 
of BBS1. 
 
Results 
102 
3.3.2. Introduction 
Bardet-Biedl syndrome (BBS) is a pleiotropic disorder affecting functions of cilia in 
different tissues. So far, all mutations found in BBS1 cause BBS (Zaghloul and 
Katsanis, 2009). BBS1 has been found in a complex together with six other BBS 
proteins, called the BBSome (Nachury et al., 2007). One of its assumed cellular 
functions is the transport of membrane proteins to cilia (Jin et al., 2010). Cilia are 
present on many human cell types where they accomplish different functions. 
Mutation-induced dysfunctions of the cilium may cause the different disease 
symptoms associated with BBS. 
We have previously identified a splice defect in patients with RP having a 
homozygous splice donor site (SD) mutation in BBS1 (c.479G>A, p.Arg160Gln). The 
mutation leads to reduced levels of correctly spliced transcripts and skipping of exon 
5. Moreover, we have developed a gene therapeutic approach using an adapted form 
of the U1 snRNA (U1) to correct the splice defect (see Results 3.2.4., page 77). 
U1 interacts with splice donor sites in a pre-mRNA transcript through RNA base 
pairing and recruits other component of the spliceosome to initiate splicing (Wahl et 
al., 2009). In addition, it has been found that binding of U1 to the splice donor can be 
impaired by mutations (Zhuang and Weiner, 1986). In order to increase binding 
affinity and subsequent recognition of the exon, we modified U1 to have perfect 
complementarity to the mutated SD of BBS1 exon 5 in the patients. Treatment with 
this fully adapted U1 (U1-BBS1_mut) significantly increased the amount of correctly 
spliced transcripts and abolished exon 5 skipping (see Results 3.2.4., page 80). 
Because the expression of an adapted form of U1 might affect splicing of other genes, 
we performed global analysis of splicing in patient derived fibroblast treated with 
either wild-type U1 (U1-wt) or U1-BBS1_mut using the Human Exon 1.0 ST array 
chip (Affymetrix). This gene expression array contains 1.4 million probe sets that 
cover exonic as well as intronic pre-mRNA sequences enable the detection of splice 
defects in almost all human gene transcripts. First results derived from this analysis 
revealed effects on splicing of only a few genes after a treatment with U1-BBS1_mut 
compared with U1-wt (Boettinger, 2009, Master Thesis). 
Many studies reported that the primary cilium can influence the activity of serveral 
signaling pathways (Singla and Reiter, 2006; Lancaster and Gleeson, 2009; Goetz and 
Anderson, 2010). Based on these findings, we assumed that reduced levels of BBS1 as 
found in the patients, might also affect transcription of target genes regulated by these 
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pathways in our patients. The exon array data served as the primary source to search 
for genes the expression of which might be regulated through the ciliary function of 
BBS1. Since increased levels of normal BBS1 transcripts were obtain by the U1-
BBS1_mut treatment, but not with U1-wt, a comparison of these two treatments could 
identify potential candidates regulated by the amount of BBS1 protein. The analysis 
of the expression of selected candidate genes using RT-PCR detected genes that have 
the potential to genetically and functionally interact with BBS1. 
 
Results 
104 
3.3.3. Methods and Results 
Selection of potential candidate genes 
In samples analyzed by the Human Exon 1.0 ST array, the correction efficiency of the 
splice defect mediated by U1 was confirmed by RT-PCR analysis. We detected higher 
frequencies of exon 5 inclusion after the U1-BBS1_mut treatment compared to U1-wt 
within a range between fold changes of - 0.9 and + 0.9 (Figure 1A). This result 
suggested a high reliability for the array data on exon level within this range. 
In contrast, to find differences on the level of gene expression, the data from the 
Human Exon 1.0 ST array was processed at the Functional Genomics Center Zurich 
(FGCZ) by averaging all corresponding exonic probe sets of a gene. Thereby, a list of 
all genes showing their differences in expression between U1-wt (calibrator sample) 
and U1-BBS1_mut in patient IV:9 with corresponding p-values calculated from 3 
replicates was created. We restricted our analysis to entries showing either fold 
changes lower than - 0.9 or higher than + 0.9 (Supplementary Table 1). Among that 
list, many genes were not consistently annotated comparing ENSEMBL and Entrez 
Gene (NCBI) databases. Therefore, we primarily selected genes that were validated as 
protein coding and correctly annotated in both databases. These selection criteria 
reduced the amount of candidates to 11 genes (Table 1, upper part). 
Because fold changes on the level of gene expression might not be representative due 
to a loss of data during processing, we additionally sorted the raw list for p-values 
smaller than 0.05 and excluded genes with fold changes lower than 0.5. This created 
another list containing 286 genes (Supplementary Table 2) from which 10 potential 
candidates were selected (Table 1, middle part). 
Since it is known that the primary cilium can influence activity of several signaling 
pathways, we extended our data analysis to select for genes clustered in the same 
signaling cascade. In order to find these, we used the GeneGo MetaCore 
(http://www.genego.com; open access through FGCZ) software focusing on pathways 
controlling cytoskeletal remodeling and cell cycle progression. We were also 
interested in genes of the canonical Wnt pathway, because it has been reported that 
the amount of functional BBS1 protein can influence Wnt signaling activity (Gerdes 
et al., 2007). Altogether, another 7 potential candidate genes have been selected 
(Table 1, lower part) which extended our list up to 28 potential candidate genes which 
we further analyzed by RT-PCR (Table 1). 
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Expression analysis of selected genes upon different U1 treatments 
To verify changes in expression levels of candidate genes selected from the exon 
array data, we have established several RT-PCR assays. RT-PCR conditions and 
primer sequences are given in Supplementary Table 3. Reactions were performed on 
RNA from fibroblasts of patient IV:9 and IV:10 affected by the splice donor site 
mutation (c.479G>A) in BBS1 and a unaffected control (IV:11) from the same family. 
The control was used to eliminate genes showing unspecific effects not due to 
increased BBS1 transcript levels. Fibroblast cell lines were transduced with increasing 
amounts (1 ml, 3 ml, 6 ml, 9 ml) of lentiviral shuttles expressing either no U1 (mock), 
U1-wt or U1-BBS1_mut (see Results 3.2.4., page 80). The high increase of normal 
BBS1 transcript levels found in both patient cell lines upon the U1-BBS1_mut 
treatment (Figure 1B) provides the basis to look for genetic interaction partners. 
Expression analysis of selected candidate genes in transduced fibroblasts from patient 
IV:9 and a control detected several effects on transcript expression. We found that 
many genes showed differences in expression levels between control and patient. 
Furthermore, we could also identify adverse effects in patient and control, which were 
not specific to the U1-BBS1_mut treatment and caused a decrease of transcript levels 
in most of the cases (Table 2; Supplementary Figures 1-6). Interstingly, for two genes, 
CCDC162 (coiled-coil domain containing 162 pseudogene) and GRAP (GBR2-related 
adaptor protein), we found higher expression levels (Supplementary Figure 1) which 
were specific for the U1-BBS1_mut treatment. 
In contrast to the effects described above, AP1S2 (adaptor-related protein complex 1, 
sigma subunit 2), CKAP5 (cytoskeleton associated protein 5), TCF4 (transcription 
factor 4) and IDE (insulin degrading enzyme) appeared to be reduced only in the 
patient upon the treatment with U1-BBS1_mut. In addition, expression levels of these 
genes were different between patient and control, thus making them good candidates 
to be regulated by BBS1 (Table 2; Supplementary Figures 2-4). 
 
Confirmation of results in different fibroblast cell lines 
To verify the significance of our findings we treated fibroblasts from the other patient 
(IV:10) and another control (Control II) accordingly. For AP1S2, TCF4 and IDE we 
now detected changes in the expression level upon treatment with U1-BBS1_mut 
and/or mock in both cell lines indicating possible adverse effects (Figure 2). 
Interestingly, we again found changes in CKAP5 expression upon treatment with U1-
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BBS1_mut but only minor effects using mock in the patient. In contrast, the control 
showed no obvious effect among all treatments (Figure 2). In summary, these results 
still suggest that CKAP5 expression might be specifically regulated through the 
amount of BBS1. 
 
Quantification of lentiviral copy numbers in treated fibroblasts 
The results from the expression analysis also indicated that lentiviral shuttles themself 
could affect the expression of certain genes. In order to compare treatments with 
similar lentivirus copy numbers, we quantified the amount of integrated proviral DNA 
into the host genome in transduced fibroblasts. To do so, we used a quantitative real-
time PCR method which has been previously described (Lizee et al., 2003). For every 
cell line, we were able to find conditions with copy numbers of integrated proviral 
DNA at comparable levels among the different treatments (Figure 3). Under these 
conditions, we identified slight differences in AP1S2 and TCF4 transcript expression 
between U1-wt and U1-BBS1_mut treatments (asterisks in Figure 2 and 
Supplementary Figures 2 and 3), whereas for IDE we observed again a decrease upon 
treatment with U1-BBS1_mut in both cell lines (asterisks in Figure 2 and 
Supplementary Figure 4). Interestingly, expression levels of CKAP5 transcripts were 
significantly reduced in both patients upon treatment with U1-BBS1_mut, but not or 
only slightly in the two controls (asterisks in Figure 2 and Supplementary Figure 4), 
still making CKAP5 a good candidate gene to be regulated by BBS1. 
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3.3.4. Discussion 
Most of the data from the exon array was in accordance with our results gained by the 
RT-PCR assays. However, for a few cases we were not able to confirm the data. 
Although olfactory receptor genes revealed high differences between expression 
levels among U1-wt and U1-BBS1_mut in the exon array, we could not detect any 
amplification product by RT-PCR. This result is not very surprising, because these 
receptors are specifically expressed in olfactory receptor neurons of the dorsal nasal 
cavity in human (Su et al., 2009) and thus, not found in fibroblasts of the skin. It still 
remains an open question why these genes seemed to be expressed according to the 
exon array data. 
Many of the tested genes revealed only slight alterations in transcript expression due 
to U1-BBS1_mut and/or mock treatment. However, the impact of these adverse 
effects especially on the viability of retinal cells has to be further evaluated. For genes 
which reacted upon both U1-BBS1_mut and mock treatment, we conclude that 
integration of lentiviral shuttles alone must have a significant effect on their 
expression level. In particular, we assume that high amounts of integrated proviral 
DNA might influence cell cycle progression and thus also the expression of genes 
involved in this process. 
Expression level changes detected only upon U1-BBS1_mut treatment in controls and 
patient-derived fibroblasts indicate that the fully adapted U1 snRNA might interfere 
with correct pre-mRNA splicing of non-target genes. These adverse effects showed 
either an increase or decrease in mRNA expression. We speculate that alterations in 
splicing induced by the U1-BBS1_mut treatment might lead to premature termination 
codon (PTC) containing gene transcripts which are subject to degradation by 
nonsense-mediated mRNA decay (NMD). The involvement of NMD in this process 
might be a reasonable explanation for the observed reduction of whole transcript 
levels upon U1-BBS1_mut treatment. In contrast, we have found an increase of 
transcript levels for GRAP and CCDC162. This finding can be explained through 
NMD too. In this case, U1-BBS1_mut might interfere with pre-mRNA splicing of 
genes that represent negative transcriptional regulators of CCDC162 and GRAP 
leading finally to their degradation by NMD. For the latter, it is reasonable to suppose 
that the gene targeted by the fully adapted U1 snRNA is somehow involved in TGF-
signaling, because it is mentioned that this pathway regulates expression of GRAP 
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in cultured renal tubule cells (Cummins et al., 2010). However our exon array analysis 
did not identify a U1-BBS1_mut mediated reduction in the expression of genes 
involved in TGF- signaling which would further support this idea. The identification 
of genes controlling expression of GRAP or CCDC162 will help to further elucidate 
their cellular functions. We can not exclude that other NMD-independent mechanisms 
also cause the observed side effects. 
 
The only gene that seemed to be significantly downregulated by higher amounts of 
BBS1 was CKAP5. Since it has been demonstrated in different vertebrate cell types 
that BBS1 is important for correct functioning of the primary cilium (Kulaga et al., 
2004; Gerdes et al., 2007; Shah et al., 2008; Tayeh et al., 2008), it is possible that 
CKAP5 might be regulated by the activity of this organelle, rather than by the 
function of BBS1 itself. This might also hold true for other genes which could be 
regulated by BBS1. CKAP5 was primarily identified as overexpressed in human 
hepatomas and colonic tumors (Charrasse et al., 1995) and appeared to be a crucial 
player in spindle pole assembly and centrosome integrity (Gergely et al., 2003; 
Cassimeris and Morabito, 2004). Furthermore, the protein is annotated in the ciliary 
proteome database (http://www.ciliaproteome.org; Gherman et al., 2006) suggesting a 
functional link between CKAP5 and the cilium. Nevertheless, to verify the 
significance of these findings expression levels of CKAP5 upon treatment of U1-wt, 
U1-BBS1_mut and mock have to be evaluated by quantitative real-time RT-PCR. 
Moreover, we have also detected slight effects on CKAP5 expression, which were 
exclusively due to the lentiviral vector. To further clarify the correlation between 
BBS1 and CKAP5, it will be crucial to check whether CKAP5 becomes upregulated 
upon RNAi-mediated BBS1 knockdown in fibroblasts of healthy, unaffected 
individuals. The outcome of that experiment will finally help to clarify whether 
CKAP5 is really regulated through the activity of BBS1 and will gain more insight 
into the function of CKAP5 and its connection with the primary cilium. 
A comparison of data gained by a whole expression analysis in BBS1 depleted cells 
with the data from the exon array will simplify our search for other candidate genes. 
The identification of these genes might extend our knowledge about the functions of 
the primary cilium and BBS1, and could also increase the number of genes associated 
with ciliopathies. 
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3.3.7. Figures and Tables 
Table 1 Selection of genes from exon array data to further evaluate their expression 
upon treatment with either U1-BBS1_mut or U1 wt. 
 
Gene Symbol Fold change P-value Probe Sets Selection 
OR8G1* 1.000929433 0.160168194 1 fold change: <-0.9 or > 0.9 
SERHL * 0.996271677 0.1033489 1 fold change: <-0.9 or > 0.9 
OR10G2 * 0.967081652 0.141329187 1 fold change: <-0.9 or > 0.9 
PLGLA1 -0.901545367 0.130864559 1 fold change: <-0.9 or > 0.9 
CCDC144B -0.920253259 0.097830558 1 fold change: <-0.9 or > 0.9 
PCOLCE2 -1.036802132 0.000207559 1 fold change: <-0.9 or > 0.9 
C2orf27A -1.2537138 0.115494124 1 fold change: <-0.9 or > 0.9 
CCDC162 0.910767977 0.015352589 5 fold change: <-0.9 or > 0.9; probe set: >1 
SEC24A -0.939305783 0.033251092 20 fold change: <-0.9 or > 0.9; probe set: >1 
ORC6L -1.008795795 0.010408435 6 fold change: <-0.9 or > 0.9; probe set: >1 
ANAPC5 -1.012129768 0.000879074 11 fold change: <-0.9 or > 0.9; probe set: >1 
GRAP 0.767820089 0.037558602 ? p-value <0.05; FC +/- 0.5 
OR6B3 * 0.647933659 0.026703847 ? p-value <0.05; FC +/- 0.5 
OR10H4 * 0.501354595 0.016606359 ? p-value <0.05; FC +/- 0.5 
AP1S2 -0.556877562 0.007877637 ? p-value <0.05; FC +/- 0.5 
PRDX3 -0.705029442 0.003791025 ? p-value <0.05; FC +/- 0.5 
KIF20B -0.712239297 0.036897943 ? p-value <0.05; FC +/- 0.5 
CKAP5 -0.722091211 0.019759787 ? p-value <0.05; FC +/- 0.5 
FAM111B -0.747902385 0.032349634 ? p-value <0.05; FC +/- 0.5 
IDE -0.826560618 0.016511654 ? p-value <0.05; FC +/- 0.5 
NDC80/KNTC2 -0.812153617 0.037874319 ? p-value <0.05; FC +/- 0.5 ( also found in GeneGo) 
EFNB3 0.296063081 0.047072584 ? GeneGo: Ephrin signaling in cytoskeletal remodeling 
EPHB2 0.125229211 0.035425694 ? GeneGo: Ephrin signaling in cytoskeletal remodeling 
TUBB4 0.177578585 0.033655026 ? GeneGo: Nek pathway in regulation of cell cycle 
IRS1 0.150166445 0.00594226 ? GeneGo: Nek pathway in regulation of cell cycle 
TUBA1A -0.161051111 0.028263008 ? GeneGo: Nek pathway in regulation of cell cycle 
H3F3B -0.427254946 0.041089699 ? GeneGo: Nek pathway in regulation of cell cycle 
TCF4 -0.161174107 0.222067531 ? GeneGo: Wnt signaling 
     
Gene Symbol: gene symbol annotated by the Gene Chip
®
 Human Exon 1.0 ST Array (Affimetrix) 
Fold Change: difference between U1-BBS1_mut vs. U1-wt treatment of means derived from exonic 
probe sets of the gene and displayed on logarithmic scale 
P-Value: p-value of the t-test on the means of exonic probe sets of the gene between U1-BBS1_mut 
vs. U1-wt treatment 
Probe sets: number of exonic probe sets found for that gene which are higher or lower than a fold 
change of 0.9 or -0.9, respectively 
Selection: desicion critera for RT-PCR analysis  
* no amplification product    
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Table 2 Summary of results from RT-PCR expression analysis of selected candidate 
genes acquired by 3 independent transductions. 
 
Gene Symbol Difference Rescue Side effect 
CCDC162 
2
 + - ++ 
GRAP + - ++ 
EFNB3 + - (+/v) 
TUBB4 ? ? ? 
IRS1 + - ? 
EPHB2 + - +/v 
TUBA1A
 2
 - - - 
TCF4 + + (+/v) 
H3F3B - - - 
AP1S2 ++ + (+/v) 
PRDX3
 1
 - - + 
KIF20B + - +/v 
CKAP5 + + - 
FAM111B ++ - +/v 
NDC80/KNTC2 + - +/v 
IDE + + - 
PLGLA1 - - - 
CCDC144B - - - 
SEC24A
 2
 - - + 
ORC6L
 2
 - - + 
ANAPC5
 2
 - - + 
PCOLCE2 ? ? ? 
C2orf27A - - - 
++: high  +: low  ?: inconsistent  -: no effect  +/v: additional virus effect 
1 
replicated only one time   
2
 weak rescue; different virus production  
    
Gene Symbol: gene symbol annotated by the Gene Chip
®
 Human Exon 1.0 ST Array 
(Affimetrix) 
Difference: difference in expression levels between control and patient fibroblast 
Rescue: expression level of the patient becomes similar to the control by the U1-
BBS1_mut treatment 
Side effect: side effect because of U1-BBS1_mut treatment 
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Figure 1 RT-PCR analysis of patient and control fibroblasts. A Efficiency of splice defect 
correction in fibroblasts from patient IV:9 used in exon array analysis. Cells were treated with 
either wild type U1 (U1-wt), U1 adapted to the splice donor site (U1-BBS1_wt) or fully 
adapted U1 (U1-BBS1_mut). Replicates of three independent transductions (I-III) have been 
analyzed. The increased amount of exon 5 inclusion into the BBS1 transcript, detected by the 
exon array upon the U1-BBS1_mut treatment, is given in fold changes (FC) below. B Patient-
derived fibroblasts IV:9 and IV:10 treated with increasing amounts (1 ml, 3 ml, 6 ml and 9 ml) 
of either U1-wt, U1-BBS1_mut or no (mock) U1 containing virus. A similar treatment in 
fibroblasts from the unaffected family member IV:11 was used as a control. The composition 
of the different BBS1 spliced products is illustrated graphically at most right. Product sizes are 
given in base pairs. This figure has been previously shown (see Results 3.2.4., page 75).
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Figure 2 RT-PCR expression analysis of AP1S2, TCF4, IDE and CKAP5 in U1-treated 
fibroblasts. Representative gel images from 3 replicates are shown. Fibroblasts from patient 
(IV:10) or the second control (Control II) were treated with increasing amounts of lentiviral 
shuttles expressing either wild type (U1-wt), fully adapted (U1-BBS1_mut) or no (mock) U1. 
Numbers below each lane define the amount (ml) of virus used in this sample. M labels the 
DNA ladder. Sizes of RT-PCR amplification products are given in base pairs (bp). Conditions 
with similar amounts of proviral DNA are labeled by asterisks and are only comparable within 
the same cell line. 
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Figure 3 Relative amount of integrated proviral DNA into the host genome of transduced 
fibroblasts. Amounts of virus used for transduction is given in ml. The relative amount was 
determined by quantitative real-time PCR using the woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) as target sequence and normalized to the 
expression level of human albumin. Numbers on the top of each data bar indicate comparable 
amounts of integrated provirus for each cell line. 
 
Results 
117 
3.3.8. Supplementary Material 
 
Supplementary Figure 1 
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Supplementary Figure 2 
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Supplementary Figure 3 
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Supplementary Figure 4 
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Supplementary Figure 5 
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Supplementary Figure 6 
 
 
Supplementary Figures 1-6 RT-PCR expression analysis of selected candidate genes in 
transduced fibroblasts. Representative gel images from 3 replicates are shown. Fibroblasts 
from patient (IV:9) or the unaffected control (Control) were treated with increasing amounts of 
lentiviral shuttles expressing either wild type (U1-wt), fully adapted (U1-BBS1_mut) or no 
(mock) U1. Numbers below each lane define the volume (ml) of virus used in this sample. M 
labels the DNA ladder. Sizes of RT-PCR amplification products are given in base pairs (bp). 
Conditions with similar amounts of proviral DNA are labeled by asterisks and only comparable 
within the same cell line. CCDC162, TUBA1A, SEC24A, ORC6L and ANAPC5 lack asterisks 
because the amount of proviral DNA was not determined. 
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Supplementary Table 1 List of genes differentially expressed between U1-BBS1_wt and U1-wt treatment with fold changes in the 
range of < -0.9 and > 0.9. 
 
Gene Symbol Fold Change P-Value ENSEMBL ID Probe Sets ENSEMBL Gene Annotations from Entrez Gene (NCBI) 
AL359711.18 3.889451976 0.001966179 ENSG00000208901 1 not found CD164, CCDC162, RPL7P28, PPIL6, C6orf184 
AC026740.6 1.88736613 0.0118438 ENSG00000215247 2 AC026740.1 TPPP, CEP72, LOC100132605, ZDHHC11 
AL450023.21 1.678130162 9.81E-05 ENSG00000211022 1 not found SSX2, SSX2B, SSXP5 etc. 
AC011744.8 1.458691732 0.169987172 ENSG00000198787 1 AC011744.1 ZBTB49, OTOP1, OR4D12P, OR7E103P, OR7E99P, 
      LYAR, TMEM128, UNC93B4 
AL162376.15 1.382811293 0.029820921 ENSG00000206697 1 Y_RNA not found 
AC012435.13 1.354108139 0.061764049 ENSG00000212279 1 SNORD77 UBL7,LOC440288,SEMA7A 
AC006357.5 1.171581475 0.008226601 ENSG00000213992 1 AC006357.1 LOC645249, MNX1, NOM1 
IGLV11-55 1.160350228 0.15058778 ENSG00000211641 1 IGLV11-55 IGLV11-55 
AL358780.22 1.159951483 0.015221737 ENSG00000207347 1 U6 MLLT10,C10orf114,C10orf140,MIR1915 
AC108867.3 1.155289102 0.15691948 ENSG00000207188 1 U6 LOC100418792 
AC015804.14 1.113945054 0.009179416 ENSG00000207107 1 not found TNRC6B, FLJ45079 
AC015980.4 1.105844832 0.076878667 ENSG00000201671 1 5S_rRNA CAPN14,GALNT14 
AL136163.15 1.086419311 0.025313397 ENSG00000208711 1 Not found NCOA7 
AL161450.14 1.075780518 0.06648095 ENSG00000210198 1 not found INSL6, TRNAQ9, LOC100129107, JAK2, IGHEP2 
hsa-mir-184 1.063481098 0.133515286 ENSG00000207695 1 hsa-mir-184 not found 
AL450023.21 1.059426936 0.009858163 ENSG00000157965 1 SSX8 
SSX2, SSX8, SSX7, SSXP5, SSXP4, SSXP1, 
LOC100420089, 
      
LOC791099, LOC791098, LOC791098, LOC791097, 
SSX2B, 
      LOC100128981, LOC100288328, LOC100128321 
AC097526.3 1.059301147 0.022776002 ENSG00000208748 1 not found TRNAQ54P, TRNAl31 
AC006120.1 1.051445058 0.172146009 ENSG00000211172 1 not found CCDC46, PSMD7L, APOH 
AC131055.10 1.040945532 0.065449957 ENSG00000209968 1 not found TRNAS30P,LOC100289154,LOC100289127, 
      LOC100289062,LOC100289032,LOC100288998 
TMEM78 1.031015536 0.067085917 ENSG00000177800 1 TMEM78 TMEM78 
AL158196.24 1.021895292 0.076878465 ENSG00000214488 1 not found MED4, NUDT15, RP11-90M2.3 
TRAV8-4 1.010188708 0.158268776 ENSG00000211790 1 AE000659.13 TRAV8-4 
OR8G1 1.000929433 0.160168194 ENSG00000197849 1 OR8G1 OR8G1 
AP003732.4 1.000295616 0.1136081 ENSG00000212416 1 5S_rRNA CPT1A,MTL5 
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Gene Symbol Fold Change P-Value ENSEMBL ID Probe Sets ENSEMBL Gene Annotations from Entrez Gene (NCBI) 
SERHL 0.996271677 0.1033489 ENSG00000172250 1 SERHL SERHL 
RP11-290P14.2 0.993920466 0.045809483 ENSG00000216496 1 not found not found 
AC140847.4 0.985484801 0.101164685 ENSG00000209785 1 not found LOC260338, LOC100132086, LOC100131369 
AL392105.13 0.974395802 0.117260695 ENSG00000208590 1 not found GPR107, LOC100129785 
AL159153.17 0.973986984 0.150115456 ENSG00000210514 1 not found COL4A2, LOC100129836 
AL391122.9 0.972967497 0.073749459 ENSG00000210366 1 not found RPS6P23, RP11-122A8.1, LOC100129122, DOCK9 
OR10G2 0.967081652 0.141329187 ENSG00000169202 1 OR10G2 OR10G2 
TRGV1 0.965330375 0.109133179 ENSG00000211701 1 AC007245.3 TRGV1 
RP5-931E15.4 0.96496641 0.058415107 ENSG00000213737 2 not found not found 
AL513168.4 0.961471015 0.166051694 ENSG00000202495 1 Y_RNA not found 
AL359712.12 0.956321451 0.002394581 ENSG00000177460 6 RP11-352J4.1 C6orf183, FJ37396 
RP11-425D10.1 0.954266748 0.388475589 ENSG00000220527 1 not found not found 
AC096543.2 0.939412646 0.008419546 ENSG00000210790 1 not found LOC199899 
AL357150.7 0.93712017 0.014062357 ENSG00000211383 1 not found PTBP2, RPL7P9, RPL7 3 75 
AC004147.2 0.936932797 0.184062355 ENSG00000210348 1 not found LOC100131744, ACCN1 
AC117476.6 0.93453064 0.194568967 ENSG00000208537 1 not found RNY5P3 
GS1-466O4.5 0.929458224 0.123089442 ENSG00000217931 1 not found not found 
AC007283.3 0.925416138 0.039889153 ENSG00000208149 1 not found LOC100130026,LOC729172,CASP10, 
      CASP8,CFLAR,RNU7-45P 
hsa-mir-181c 0.924109812 0.165612578 ENSG00000207613 1 hsa-mir-181c not found 
AC110777.3 0.923321908 0.080416816 ENSG00000209239 1 not found NDST4 
AC136896.6 0.922636885 0.048259244 ENSG00000200326 1 5S_rRNA GABRG3, LOC653227 
AC126389.7 0.919932324 0.04392405 ENSG00000201586 1 U6 PIK3C2A, RPL34P24 
AP001924.5 0.918822853 0.016597138 ENSG00000211358 1 not found LOC399959, MIR125B, BLID 
AC094106.3 0.91102318 0.013371912 ENSG00000176183 1 AC233964.1 LOC402221, LOC100289160, LOC100289133, 
      MRPS35P2 
C6orf184 0.910767977 0.015352589 ENSG00000203799 5 C6orf184 CCDC162 or C6orf184 
AC090465.15 0.903787009 0.213540653 ENSG00000207154 1 U1 not found 
CYP2G1P 0.902874989 0.036528192 ENSG00000198461 1 AC008962.1 CYP2G1P 
RP5-967N21.7 0.902112443 0.24580477 ENSG00000219953 1 not found not found 
AL591398.2 0.9020043 0.302762005 ENSG00000208538 1 not found LOC100289259 
PLGLA1 -0.901545367 0.130864559 ENSG00000169659 1 PLGLA PLGLA1 
AC004381.1 -0.906452457 0.167388486 ENSG00000209026 1 not found THUMPD1, LOC730079, ACSM3, ERI2, LOC81691,  
      LOC646810 
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AP001318.6 -0.906632149 0.246165888 ENSG00000209258 1 not found TIRAP,FLJ39051,FOXRED1,LOC100289010, 
      FAM118B,SRPR,DCPS,RPL35AP26,ST3GAL4 
AC121344.5 -0.909095002 0.106485185 ENSG00000210617 1 not found IL1RAPL1 
AL390237.9 -0.915922975 0.019134966 ENSG00000214561 1 RP11-278J20.1 LOC727842, LOC100288628 
AL731569.18 -0.917592779 0.070325642 ENSG00000212332 1 U6 LOC100289138, WAPAL 
AC119041.6 -0.919963473 0.101323129 ENSG00000210218 1 not found LOC100287892 
AL109806.22 -0.920194795 0.321197247 ENSG00000210826 1 not found C20orf107,LOC100130156, C20orf106,C20orf43, 
      GCNT7 
CCDC144B -0.920253259 0.097830558 ENSG00000154874 1 CCDC144B CCDC144B 
AC124312.5 -0.925279867 0.122998901 ENSG00000206621 1 SNORD116 SNORDs and others 
AP001273.4 -0.926384308 0.098565662 ENSG00000210825 1 SNORA40 SNORDs and others 
AC068896.9 -0.929776527 0.06346643 ENSG00000207494 1 Y_RNA LOC100287472, FAM53B, FAM175B 
AP000240.1 -0.930857464 0.046255892 ENSG00000209835 1 not found C21orf41, BACH1 
AP000361.2 -0.932918193 0.08368405 ENSG00000220686 1 not found not found 
RP11-503K16.2 -0.933322582 0.081943938 ENSG00000217817 1 not found not found 
SEC24A -0.939305783 0.033251092 ENSG00000113615 20 SEC24A SEC24A 
AL442663.3 -0.951746978 0.055331601 ENSG00000209100 1 not found LOC100287446, TRNAC24, RBM25, RPS12P1,  
      DCAF4, ZFYVE1 
AF129075.3 -0.952042091 0.071420604 ENSG00000201984 1 Y_RNA CCT8, USP16,RPL12P9,RWDD2B,C21orf7,  
      RPL23P2,RNF160 
AC108477.5 -0.952326163 0.157711254 ENSG00000201433 1 U6 C4orf41, RWDD4A 
AP001160.4 -0.952689543 0.357605781 ENSG00000206653 1 SNORD29 SNORDs and others 
AC068056.7 -0.955983274 0.302330713 ENSG00000208171 1 not found MYO1B 
AL391728.19 -0.961892033 0.030061379 ENSG00000210993 1 not found LRC7, PIN1L 
AC008635.6 -0.96311748 0.048732443 ENSG00000210192 1 not found STRN4, PRKD2 
AC011747.5 -0.965584758 0.232356308 ENSG00000182367 1 not found not found 
RP11-11N7.2 -0.979310805 0.163617309 ENSG00000188206 1 C1orf199 NCRNA00201 
AC099337.2 -0.980956923 0.001558388 ENSG00000201493 1 U1 RRP15 
AC009884.8 -0.982763079 0.090000943 ENSG00000201157 1 SNORA62 PSD3 
RP4-566D2.1 -0.98800418 0.168112795 ENSG00000205179 1 not found not found 
AL132989.5 -1.00034451 0.040970153 ENSG00000209824 1 not found HMGB1L14,ACTR10,TRNAK13,FLJ31306, 
      ARID4A,PSMA3 
AL136305.14 -1.006727472 0.114783319 ENSG00000209103 1 not found RBM24 
Results 
126 
Gene Symbol Fold Change P-Value ENSEMBL ID Probe Sets ENSEMBL Gene Annotations from Entrez Gene (NCBI) 
AL451165.19 -1.007873917 0.091409653 ENSG00000210647 1 not found C6orf106, LOC100131607 
ORC6L -1.008795795 0.010408435 ENSG00000091651 6 ORC6L ORC6L 
ANAPC5 -1.012129768 0.000879074 ENSG00000089053 11 ANAPC5 ANAPC5 
AL049542.10 -1.016193066 0.010906895 ENSG00000201034 1 Y_RNA RAB11FIP3 
AC023389.13 -1.022713709 0.107565341 ENSG00000200961 1 not found SSH2 
AC104653.5 -1.027414746 0.029883558 ENSG00000208621 1 not found not found 
RP11-697G4.3 -1.02744096 0.148381901 ENSG00000217466 1 not found not found 
AL359540.19 -1.029461862 0.216752337 ENSG00000210479 1 not found MUTYH,TESK2,TOE,LOC100288481,HPDL, 
      hCG 1820661 
AC122179.6 -1.033203074 0.055741884 ENSG00000209444 1 not found WEE1 
PCOLCE2 -1.036802132 0.000207559 ENSG00000163710 1 PCOLCE2 PCOLCE2 
hsa-mir-32 -1.038626557 0.1007958 ENSG00000207698 1 hsa-mir-32 MIR32 
AL161450.14 -1.041676617 0.049580201 ENSG00000210157 1 not found INSL6, TRNAQ9, LOC100129107, JAK2, IGHEP2 
AC064799.6 -1.042178938 0.004699737 ENSG00000175333 1 not found THSD4, RPL17P39 
AL355608.11 -1.048207268 0.04766562 ENSG00000207268 1 SNORA70 SNORA70C, ASTN2, RPL10P3 
AL451005.9 -1.088393151 0.240406689 ENSG00000208765 1 not found CUL4B 
AC073575.30 -1.095881176 0.042243036 ENSG00000200688 1 Y_RNA ERP29,TRAFD1,C12orf30, C12orf51, LOC728543, 
      LOC100287839,TMEM116 
AC090510.4 -1.098824275 0.228918193 ENSG00000210523 1 not found LOC100289126, STARD9,CDAN1,TTBK2 
AC021654.25 -1.11504749 0.175734028 ENSG00000208651 1 not found SCHIP1 
AL121809.6 -1.13078268 0.027531616 ENSG00000214919 1 AL121809.3 FKBP3,SNORD127,C14orf106,PRPF39,FANCM, 
      FAM179B 
AC092868.2 -1.132295402 0.040175367 ENSG00000199512 1 U6 MYO1E,LOC100132644 
AL049712.12 -1.142341904 0.015872884 ENSG00000207262 1 SNORD57 SNORD56,57,88,110 etc 
AL445648.18 -1.143706916 0.216724119 ENSG00000212350 1 not found SRRM1,CLIC4 
AP001160.4 -1.151870699 0.079744505 ENSG00000207437 1 SNORD28 SNORD22 +25-31, and others 
AL449963.2 -1.153615665 0.142490702 ENSG00000210401 1 not found ADAMTSL1 
AL591807.1 -1.185913859 0.022237101 ENSG00000201376 1 SNORA70 TMX1 
AC124312.5 -1.186376975 0.04912134 ENSG00000209418 1 SNORD64 div SNORDs and others 
AC087650.12 -1.187113008 0.100497145 ENSG00000210609 1 not found 
LOC100130581,RNU2-
4P,DHX8,RPL29P31,MIR2117, 
      ARL4D 
AC093602.5 -1.204175229 0.151055081 ENSG00000208967 1 not found ELF2,CCRN4L 
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AC003043.1 -1.205655359 0.015727766 ENSG00000210683 1 not found not found 
C2orf27 -1.2537138 0.115494124 ENSG00000197927 1 C2orf27A C2orf27A 
AC007016.5 -1.264953481 0.077124883 ENSG00000214165 1  CC2D2A,LOC100288116,C1QTNF7 
EIF1AX -1.265205141 0.085168458 ENSG00000173674 1 EIF1AX EIF1AX, IPO13, EIF5, EIF2S1, EIF5B, EIF3C 
AL732366.7 -1.265205141 0.085168458 ENSG00000201882 1 snoU2-30 MAP7D2,EIF1AX,SCARNA9L,LOC729609,RPS6KA3 
AL109897.30 -1.266087527 0.107674918 ENSG00000211267 1 not found MYO6,SENP6 
AC069483.6 -1.333991077 0.122955078 ENSG00000206676 1 Y_RNA MEIS2 
AL360091.28 -1.336648887 0.007571362 ENSG00000201544 1 SNORA16 PPP2R5A,TMEM206,SNORA16B,RPL23AP18 
AC019209.3 -1.337538973 0.05639091 ENSG00000205706 1 not found LOC645233 
AL136170.14 -1.366582839 0.128413781 ENSG00000208317 1 SNORD78 div. SNORDs  and others 
AC005104.1 -1.389958657 0.072518332 ENSG00000208039 1 not found SEPT2,FARP2 
AL139021.6 -1.403286842 0.064646933 ENSG00000209829 1 not found TOMM20L,HSBP1P1,TIMM9,KIAA0586,ARID4A 
RP11-444I9.2 -1.408900617 0.006261549 ENSG00000219530 1 not found not found 
AL136162.18 -1.417658561 0.137158587 ENSG00000201367 1 U6 JARID2 
RPL39P -1.420316171 0.123536336 ENSG00000216467 1 not found RPL39P 
AL592166.16 -1.433050238 0.143336603 ENSG00000207421 1 SNORD38 div. SNORDs, KIF2C,RPS8,TCTEX1D4,PLK3, 
      BTBD19,RPS15AP11,BEST4,PTCH2 
RP11-220I1.4 -1.441177157 0.050584163 ENSG00000217860 1 not found not found 
AC073195.5 -1.452884236 0.136903814 ENSG00000207086 1 Y_RNA LOC100127913,YWHAQ,ADAM17 
AL513497.21 -1.481301716 0.123623914 ENSG00000201808 1 SNORA73 SNORDs and others 
AL589675.5 -1.54464195 0.014316349 ENSG00000187770 1 not found KIAA0020,CARM1L, LOC138234,LOC392281 
AP001065.1 -1.568805669 0.047596025 ENSG00000210065 1 not found TRPM2,PIRC105,C21orf30,LBRC3 
AL732366.7 -1.71746527 0.019786683 ENSG00000206663 1 Y_RNA MAP7D2,EIF1AX,SCARNA9L,LOC729609,RPS6KA3 
AC087292.14 -2.14096641 0.013508814 ENSG00000207390 1 Y_RNA CYB5D2,ANKFY1,ZZEF1 
 
Gene Symbol: gene symbol or GeneBank accession number annotated by the Gene Chip
®
 Human Exon 1.0 ST Array (Affimetrix) 
Fold Change: difference between U1-BBS1_mut vs. U1-wt treatment of means derived from exonic probe sets of the gene and dsiplayed on logarithmic 
scale 
P-Value: p-value of the t-test on the means of exonic probe sets of the gene between U1-BBS1_mut vs. U1-wt treatment 
Probe sets: number of exonic probe sets found for that gene which are higher or lower than a fold change of 0.9 or -0.9, respectively 
ENSEMBL Gene: gene symbol annotated by ENSEMBL    
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Supplementary Table 2 List of genes differently expressed between U1-BBS1_mut 
and U1-wt treatment showing p-values lower than 0.05 and fold changes larger than 
0.5. 
 
Gene Symbol ENSEMBL ID Fold Change P-value 
AL450023.21 ENSG00000211022 1.678130162 9.81E-05 
PCOLCE2 ENSG00000163710 -1.036802132 0.000208 
AL445663.10 ENSG00000184353 -0.562778942 0.000531 
ANAPC5 ENSG00000089053 -1.012129768 0.000879 
AL365260.11 ENSG00000208881 -0.66237004 0.000962 
AL391382.10 ENSG00000206787 0.641892817 0.00111 
AC015550.19 ENSG00000198751 -0.681534812 0.001233 
AC048348.25 ENSG00000209178 -0.803167174 0.00124 
AL133387.8 ENSG00000210922 -0.696550324 0.001256 
AL137226.3 ENSG00000188831 0.77435412 0.001498 
GINS1 ENSG00000101003 -0.544718551 0.001527 
AC099337.2 ENSG00000201493 -0.980956923 0.001558 
AL359711.18 ENSG00000208901 3.889451976 0.001966 
PYY3 ENSG00000204474 0.833171179 0.002123 
RP11-318G11.2 ENSG00000219290 -0.513575233 0.002371 
AL359712.12 ENSG00000177460 0.956321451 0.002395 
AL359878.13 ENSG00000205740 0.692406079 0.003583 
PRDX3 ENSG00000165672 -0.705029442 0.003791 
AC032011.15 ENSG00000182015 0.771048419 0.003792 
AC064799.6 ENSG00000175333 -1.042178938 0.0047 
RP11-176F3.9 ENSG00000219724 -0.580993978 0.004784 
AL357374.11 ENSG00000210251 0.804439742 0.00494 
AC098817.3 ENSG00000208842 -0.557425933 0.00499 
AL008721.1 ENSG00000206062 0.69842191 0.005322 
AC105050.2 ENSG00000208615 0.656636603 0.005393 
AC010761.10 ENSG00000206735 -0.637481934 0.005447 
AP001273.4 ENSG00000207145 -0.773167975 0.005808 
RP11-444I9.2 ENSG00000219530 -1.408900617 0.006262 
RP11-481A12.2 ENSG00000220508 0.566748961 0.006693 
RP3-391O22.3 ENSG00000196114 0.510048292 0.006891 
AC018720.5 ENSG00000170092 -0.868953104 0.007173 
AC012183.9 ENSG00000210394 0.596764102 0.007413 
AL160270.19 ENSG00000210712 0.579439039 0.007552 
AL360091.28 ENSG00000201544 -1.336648887 0.007571 
AL135998.6 ENSG00000199716 0.633140154 0.007757 
AC016876.10 ENSG00000207152 -0.628983588 0.007849 
AP1S2 ENSG00000182287 -0.556877562 0.007878 
AC006357.5 ENSG00000213992 1.171581475 0.008227 
AC117395.5 ENSG00000208760 0.863103858 0.008313 
AC096543.2 ENSG00000210790 0.939412646 0.00842 
AC092964.8 ENSG00000208521 -0.651084024 0.008795 
AL358790.22 ENSG00000203886 0.660903474 0.009132 
AC015804.14 ENSG00000207107 1.113945054 0.009179 
AF347015.1 ENSG00000211459 -0.555399384 0.009488 
TRAJ15 ENSG00000211874 0.593821413 0.009519 
AC093106.3 ENSG00000172400 0.641682857 0.009617 
AC012314.8 ENSG00000210694 -0.53850507 0.00971 
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AL132989.5 ENSG00000180189 -0.702257354 0.009799 
AL450023.21 ENSG00000157965 1.059426936 0.009858 
AC025731.12 ENSG00000210355 0.543061714 0.009936 
AL391557.11 ENSG00000209185 0.726136225 0.010164 
AL158155.24 ENSG00000206784 -0.780370413 0.010186 
AL357037.13 ENSG00000213525 0.544175528 0.010306 
AC008942.6 ENSG00000201223 -0.724953713 0.010405 
ORC6L ENSG00000091651 -1.008795795 0.010408 
AC078953.20 ENSG00000208522 0.791273058 0.010701 
AL355305.9 ENSG00000203800 0.798289373 0.010737 
AL590708.18 ENSG00000208605 0.820515191 0.010749 
AL049542.10 ENSG00000201034 -1.016193066 0.010907 
AC093844.3 ENSG00000219943 0.628270489 0.011576 
RP11-468L18.1 ENSG00000217870 0.57144147 0.011642 
AC026740.6 ENSG00000215247 1.88736613 0.011844 
AC068228.8 ENSG00000208604 -0.898204404 0.01239 
AF111169.2 ENSG00000213379 -0.664054691 0.012894 
AP001629.1 ENSG00000196847 0.608994411 0.012995 
DEFB112 ENSG00000180872 -0.607080633 0.013242 
AC094106.3 ENSG00000176183 0.91102318 0.013372 
AC087292.14 ENSG00000207390 -2.14096641 0.013509 
AC006271.2 ENSG00000188314 0.582617153 0.013713 
hsa-mir-296 ENSG00000207950 0.576270751 0.013778 
AC107071.3 ENSG00000206601 -0.638567124 0.01379 
CDKN3 ENSG00000100526 -0.627590769 0.013883 
AL357150.7 ENSG00000137970 0.93712017 0.014062 
AL357150.7 ENSG00000211383 0.93712017 0.014062 
C11orf81 ENSG00000205872 0.607386877 0.014165 
AL589675.5 ENSG00000187770 -1.54464195 0.014316 
AC009309.4 ENSG00000200241 0.513730703 0.014403 
RP11-70K10.2 ENSG00000217321 0.514017316 0.015076 
AL358780.22 ENSG00000207347 1.159951483 0.015222 
RP1-20I3.3 ENSG00000220016 -0.575022174 0.015228 
C6orf184 ENSG00000203799 0.910767977 0.015353 
AP000080.1 ENSG00000206871 0.69331703 0.015449 
hsa-mir-133a-2 ENSG00000207764 0.715562551 0.015647 
AC003043.1 ENSG00000221496 -1.205655359 0.015728 
AC003043.1 ENSG00000210683 -1.205655359 0.015728 
RP11-294H11.4 ENSG00000216977 -0.848758322 0.015792 
AL137849.13 ENSG00000211334 0.549692959 0.015843 
AL049712.12 ENSG00000207262 -1.142341904 0.015873 
RP11-570F6.1 ENSG00000217615 -0.522390396 0.016065 
AC020629.6 ENSG00000209911 -0.719217838 0.016295 
IDE ENSG00000119912 -0.826560618 0.016512 
AL590396.13 ENSG00000208077 -0.870167661 0.016512 
AC004932.4 ENSG00000208274 -0.517530547 0.016596 
AP001924.5 ENSG00000211358 0.918822853 0.016597 
OR10H4 ENSG00000176231 0.501354595 0.016606 
AL731546.4 ENSG00000209535 0.723895785 0.016683 
AL671966.1 ENSG00000208802 -0.588029241 0.016685 
AC025429.6 ENSG00000210449 0.644506349 0.016747 
AL139404.9 ENSG00000206605 -0.706499137 0.01676 
AC139070.3 ENSG00000199728 0.604178586 0.01691 
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PSIP1 ENSG00000164985 -0.52573609 0.017164 
AC004522.3 ENSG00000199711 0.742106734 0.018269 
AC006070.12 ENSG00000218712 -0.645853416 0.018321 
AC005067.2 ENSG00000201643 0.850567538 0.01891 
OR2C1 ENSG00000168158 -0.535261844 0.019002 
AC114810.4 ENSG00000210538 -0.557849619 0.019063 
AL390237.9 ENSG00000214561 -0.915922975 0.019135 
AL390196.17 ENSG00000209037 -0.623829132 0.01941 
RP11-235D19.2 ENSG00000218727 -0.717320745 0.019557 
CKAP5 ENSG00000175216 -0.722091211 0.01976 
AL732366.7 ENSG00000206663 -1.71746527 0.019787 
AL122013.5 ENSG00000213482 -0.610721759 0.019983 
USP3 ENSG00000140455 -0.500231685 0.020154 
USP3 ENSG00000140455 -0.500231685 0.020154 
AL137009.8 ENSG00000208773 0.660116538 0.020369 
AC020907.6 ENSG00000203404 0.562557535 0.020398 
AL513526.19 ENSG00000175658 0.595253082 0.020562 
AC139143.1 ENSG00000216482 0.506718601 0.020856 
AL355336.15 ENSG00000201483 0.84416656 0.021313 
IGLC4 ENSG00000214522 0.72359719 0.02135 
ZBTB40 ENSG00000184677 0.629924418 0.021682 
RP11-271B5.1 ENSG00000218366 -0.705410647 0.021918 
AC007535.3 ENSG00000200475 0.664932866 0.021919 
PPY2 ENSG00000126657 0.719038248 0.022179 
AL591807.1 ENSG00000201376 -1.185913859 0.022237 
AC079789.7 ENSG00000213370 -0.525792681 0.022368 
RP11-244N20.7 ENSG00000218423 -0.658708986 0.022724 
AC097526.3 ENSG00000208748 1.059301147 0.022776 
ARHGAP11B ENSG00000187951 -0.591719589 0.022837 
AC119618.4 ENSG00000200852 0.895077394 0.023044 
AL049780.4 ENSG00000206924 -0.649837988 0.023143 
MBOAT4 ENSG00000177669 0.5566696 0.023303 
TRAV12-3 ENSG00000211794 0.532708016 0.023346 
AC007880.2 ENSG00000199964 0.626889944 0.023725 
RP13-465B17.2 ENSG00000216546 0.636483476 0.023735 
RP11-185C18.4 ENSG00000218696 -0.814500004 0.02396 
OR52E1P ENSG00000216987 0.510529099 0.024179 
AC010287.9 ENSG00000206952 -0.715363419 0.024816 
AC080112.15 ENSG00000131747 -0.582868832 0.024869 
C6orf185 ENSG00000203798 0.816996034 0.025028 
RP11-134A8.1 ENSG00000218425 0.531449412 0.025148 
AC098477.2 ENSG00000201962 0.59350445 0.025305 
AL136163.15 ENSG00000208711 1.086419311 0.025313 
HS6ST1 ENSG00000136720 0.607115489 0.025317 
AC016585.8 ENSG00000210667 0.526603272 0.025406 
AC018892.8 ENSG00000144188 0.512404393 0.025412 
GLYATL2 ENSG00000156689 -0.766470533 0.025596 
RP4-666O22.1 ENSG00000218392 -0.562425659 0.025648 
AC006132.1 ENSG00000210152 0.685018715 0.026064 
AL139240.9 ENSG00000210069 0.678835257 0.026603 
OR6B3 ENSG00000178586 0.647933659 0.026704 
RP1-106C24.1 ENSG00000220366 -0.553247092 0.02702 
AL121809.6 ENSG00000214919 -1.13078268 0.027532 
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AC010260.7 ENSG00000211056 -0.68201634 0.028056 
AL662914.8 ENSG00000201447 0.725860813 0.028107 
ACSL4 ENSG00000068366 -0.531582519 0.028164 
DGKI ENSG00000157680 0.69509023 0.028517 
AC003013.1 ENSG00000179418 0.678775283 0.028616 
AC112166.3 ENSG00000209898 0.797852137 0.028642 
BX322799.22 ENSG00000214358 0.51357186 0.028872 
RP11-50K12.1 ENSG00000218777 0.518995935 0.028922 
AC103590.2 ENSG00000208180 -0.762446382 0.029212 
AC018628.13 ENSG00000200842 -0.880541997 0.029288 
RP1-321E8.2 ENSG00000217987 -0.524266513 0.029638 
AC079148.9 ENSG00000207170 -0.793755846 0.029666 
C14orf70 ENSG00000196273 0.613187073 0.029707 
AL662871.9 ENSG00000212240 -0.624359738 0.029722 
AL449214.6 ENSG00000212344 -0.573099445 0.029814 
AL162376.15 ENSG00000206697 1.382811293 0.029821 
AC104653.5 ENSG00000208621 -1.027414746 0.029884 
AP001324.4 ENSG00000171579 -0.547989621 0.029979 
CCNE2 ENSG00000175305 -0.676237668 0.030033 
AL391728.19 ENSG00000210993 -0.961892033 0.030061 
RP11-569O4.4 ENSG00000220289 0.549215327 0.030861 
AC002457.2 ENSG00000209318 0.772732659 0.031023 
AF070718.1 ENSG00000199354 0.869899651 0.031272 
RP11-156G14.6 ENSG00000218082 -0.691765171 0.031478 
NUSAP1 ENSG00000137804 -0.647275496 0.031583 
RPL18A ENSG00000105640 0.781637385 0.031595 
AC005796.1 ENSG00000207166 0.781637385 0.031595 
AC104170.2 ENSG00000210578 -0.601163181 0.031613 
RGS4 ENSG00000117152 -0.659466495 0.032323 
FAM111B ENSG00000189057 -0.747902385 0.03235 
CCL19 ENSG00000172724 0.533551978 0.032609 
AC002064.1 ENSG00000207488 -0.51600327 0.032612 
RP11-254N18.1 ENSG00000217496 -0.673034548 0.032649 
AC104967.4 ENSG00000214954 0.516604997 0.032941 
APPL2 ENSG00000136044 -0.55233265 0.033038 
SEC24A ENSG00000113615 -0.939305783 0.033251 
AC079804.5 ENSG00000155070 0.655559992 0.033827 
AL353660.11 ENSG00000206617 -0.768418022 0.033883 
RPL12P3 ENSG00000217037 -0.57533243 0.034021 
hsa-mir-24-2 ENSG00000209707 0.50158958 0.034043 
OR52L2P ENSG00000180923 0.545012613 0.034076 
AC017100.4 ENSG00000209937 -0.660208879 0.034339 
C13orf3 ENSG00000165480 -0.697289229 0.034347 
ANKRD26 ENSG00000107890 -0.53547385 0.034434 
AC131009.7 ENSG00000200516 0.526493424 0.034454 
SHCBP1 ENSG00000171241 -0.519861728 0.034482 
AC023933.9 ENSG00000208905 -0.610114264 0.034503 
RP1-144F13.4 ENSG00000212671 -0.628703982 0.034566 
RP13-60P5.2 ENSG00000218677 0.579239949 0.034725 
AC087632.10 ENSG00000219244 -0.50664587 0.035079 
Z82185.1 ENSG00000183822 0.841979254 0.035489 
STAG3L4 ENSG00000106610 0.576280835 0.03577 
DIAPH1 ENSG00000131504 -0.621646194 0.035886 
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CASC5 ENSG00000137812 -0.517446529 0.035907 
AC093900.3 ENSG00000206820 -0.794995568 0.036451 
CYP2G1P ENSG00000198461 0.902874989 0.036528 
EFTUD2 ENSG00000108883 -0.513148337 0.036563 
MPHOSPH1 ENSG00000138182 -0.712239297 0.036898 
RP11-543N17.2 ENSG00000220795 0.615545977 0.036931 
AC004668.1 ENSG00000214221 0.507182849 0.036936 
AL356115.9 ENSG00000178429 -0.558325527 0.036989 
AL445431.16 ENSG00000201364 0.76624801 0.037019 
GRAP ENSG00000154016 0.767820089 0.037559 
AL392104.19 ENSG00000199535 -0.729597136 0.037726 
KNTC2 ENSG00000080986 -0.812153617 0.037874 
AC021451.8 ENSG00000210898 -0.878090609 0.0379 
AC022394.7 ENSG00000200789 0.620641884 0.038088 
AC009464.8 ENSG00000209242 -0.623060248 0.038241 
AL135842.15 ENSG00000183586 -0.723940545 0.0383 
AC134509.2 ENSG00000199465 0.669112324 0.038377 
AL109823.23 ENSG00000199507 -0.752874669 0.038581 
AL137792.11 ENSG00000214812 -0.8914577 0.039057 
U52112.2 ENSG00000211524 0.894856789 0.039263 
C9orf71 ENSG00000181778 0.54510016 0.039313 
WDR76 ENSG00000092470 -0.587284949 0.03981 
AC007283.3 ENSG00000208149 0.925416138 0.039889 
AL358117.11 ENSG00000210379 0.796879735 0.039957 
RP11-117O7.2 ENSG00000218149 0.827586838 0.040015 
AC092868.2 ENSG00000199512 -1.132295402 0.040175 
AC121344.5 ENSG00000201356 0.783519987 0.040211 
AC008732.9 ENSG00000212382 0.520177677 0.040422 
AC011447.7 ENSG00000187928 0.569879528 0.040505 
OR6S1 ENSG00000181803 0.671792533 0.040594 
AL022149.2 ENSG00000202410 0.513279222 0.04069 
RP11-38M15.4 ENSG00000219849 0.666442396 0.040843 
AL132989.5 ENSG00000209824 -1.00034451 0.04097 
AL353092.6 ENSG00000212571 0.566366109 0.041154 
AL645940.4 ENSG00000202441 -0.760766885 0.041202 
TRIM55 ENSG00000147573 -0.565026446 0.041389 
GTF2E2 ENSG00000197265 -0.550804181 0.041619 
CENPI ENSG00000102384 -0.673194359 0.041815 
hsa-mir-223 ENSG00000207939 0.84585314 0.041924 
AC073575.30 ENSG00000200688 -1.095881176 0.042243 
AL158205.12 ENSG00000204446 0.557184014 0.04232 
AC006023.2 ENSG00000199273 0.509275132 0.042584 
AC105224.8 ENSG00000210248 -0.805199976 0.043051 
AC091057.6 ENSG00000210161 -0.888035143 0.043542 
IGHV3-35 ENSG00000211957 0.680687694 0.043631 
AC126389.7 ENSG00000201586 0.919932324 0.043924 
RP11-35N6.4 ENSG00000220198 0.871230507 0.044102 
GAS2L3 ENSG00000139354 -0.532301905 0.044834 
AL589947.3 ENSG00000209206 0.89014805 0.044851 
AL589947.3 ENSG00000221455 0.89014805 0.044851 
AC096587.1 ENSG00000202216 0.741869484 0.044987 
AL137247.14 ENSG00000212293 -0.588736741 0.045137 
HELLS ENSG00000119969 -0.72964393 0.045574 
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AC073995.6 ENSG00000135976 -0.655681679 0.04567 
RP11-290P14.2 ENSG00000216496 0.993920466 0.045809 
AP000240.1 ENSG00000209835 -0.930857464 0.046256 
RP11-163N15.1 ENSG00000217002 0.787588111 0.046369 
AC098591.4 ENSG00000200455 -0.691386241 0.046623 
AL049576.19 ENSG00000209629 0.609039096 0.046776 
hsa-mir-21 ENSG00000199004 -0.532589084 0.046945 
AC004073.1 ENSG00000211376 -0.722250067 0.047389 
AC100852.2 ENSG00000210020 -0.877957658 0.047575 
AP001065.1 ENSG00000210065 -1.568805669 0.047596 
AL355608.11 ENSG00000207268 -1.048207268 0.047666 
AC091167.19 ENSG00000208939 0.544409037 0.047788 
AC087672.7 ENSG00000212348 0.51209892 0.047882 
AC136896.6 ENSG00000200326 0.922636885 0.048259 
OR51B4 ENSG00000183251 0.571861332 0.04837 
AL358253.16 ENSG00000209591 -0.849563993 0.048416 
AL138919.12 ENSG00000211435 -0.584688743 0.048468 
AC008635.6 ENSG00000210192 -0.96311748 0.048732 
RPS6KA3 ENSG00000177189 -0.540531222 0.048802 
PARP14 ENSG00000173193 -0.537432059 0.048992 
AC124312.5 ENSG00000209418 -1.186376975 0.049121 
AL161450.14 ENSG00000210157 -1.041676617 0.04958 
RP1-313I6.8 ENSG00000217751 0.767445006 0.04988 
ARHGDIB ENSG00000111348 -0.676303212 0.049943 
AL121890.34 ENSG00000212536 0.540164615 0.049974 
    
Gene Symbol: gene symbol or GeneBank accession number annotated by the Gene Chip
®
 
Human Exon 1.0 ST Array (Affimetrix) 
Fold Change: difference between U1-BBS1_mut vs. U1-wt treatment of means derived from 
exonic probe sets of the gene and displayed on logarithmic scale 
P-Value: p-value of the t-test on the means of exonic probe sets of the gene between U1-
BBS1_mut vs. U1-wt treatment 
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Supplementary Table 3 List of primers used for RT-PCR analysis of candidate 
genes. 
 
Gene Primer Name Sequence Tm [°C] Product size [bp] 
OR8G1 
OR8G1_E1F 5‟ ctctcagaacagccagagctccag 60.8 
690 
OR8G1_E1R 5‟ caacatgtgggagctacaagtgctg 60.2 
SERHL 
SERHL_E1F 5‟ ggcctggaactgcaggatacactc 59.6 
550 
SERHL_E7R 5‟ tgctctatggctctccgcttgtag 59.9 
OR10G2 
OR10G2_E1F 5‟ ctggatgccgtggtgacagatttc 60.1 
550 
ORG10G2_E1R 5‟ ctcaatactgcgcggatgtcacag 59.9 
CCDC162 
CCDC162_E1F 5‟ cgatgtttgctgtcagcggatgg 60.7 
500 
CCDC162_E4R 5‟ ggtatctgggctgttactcataactggg 60.1 
GRAP 
GRAP_E4F 5‟ agctggtcgacttctaccgcac 60.6 
510 
GRAP_E5R 5‟ acagctggcagccaatggaaag 60.5 
OR6B3 
OR6B3_E1F 5‟ gtacctgctcttcctcctcttcctg 60.1 
520 
OR6B3_E1R 5‟ accagctctgcagtggagaagtc 60.5 
OR10H4 
OR10H4_E1F 5‟ caaccttctcatcatggccacaatctg 59.9 
520 
OR10H4_E1R 5‟ gaataaacagcctatcagggctgtgac 59.3 
EFNB3 
EFNB3_E1F 5‟ cctggagcctgtctactggaactc 60.4 
400 
EFNB3_E4R 5‟ ccttcatgcctctggttaggcac 59.9 
TUBB4 
TUBB4_E2F 5‟ aggttatcagtgacgaacatggcatcg 60.3 
540 
TUBB4_E4R 5‟ gatgcagtaggtctcatccgtattctcc 59.7 
IRS1 
IRS1_E1F 5‟ cctatgccagcatcagtttccagaag 59.6 
500 
IRS1_E2R 5‟ atactctctccacccaacgtgaacag 59.7 
EPHB2 
EPHB2_E5F 5‟ cctcgtctacaacatcatctgcaagagc 60.7 
560 
EPHB2_E8R 5‟ gtggcaacttctcctggatgcttg 60.4 
TUBA1A 
TUBA1A_E1F 5‟ cttacatcgaccgcctaagagtcgc 60.7 
530 
TUBA1A_E4R 5‟ agaaccagttcccccaccaaag 59.3 
TCF4 
TCF4_E2F 5‟ gccttagggacggacaaagagc 59.9 
560 
TCF4_E9R 5‟ agtcggcagtgcttgctgatg 60 
H3F3B 
H3F3B_E1F 5‟ ggagaagtggcctaaaacttcggc 60.2 
400 
H3F3B_E3R 5‟ catgatggtgactctcttagcgtggatg 60.4 
AP1S2 
AP1S2_E2F 5‟ agtcgtcagggaaagcttcgactgc 60.4 
520 
AP1S2_E5R 5‟ catggacatgaagggagtgaccatc 59.3 
PRDX3 
PRDX3_E4F 5' ttgcttttagtgacaaagctaacg 60 
490 
PRDX3_E7R 5‟ tttcaactgtggttcttctctcag 60 
KIF20B 
KIF20B_E23F 5‟ aacagtatgagagagcatgcaaag 60 
430 
KIF20B_E26R 5‟ tccatttcattctgttgcttaaaa 60 
CKAP5 
CKAP5_E6F 5‟ tgctcctagacctactcgatttct 59.9 
450 
CKAP5_E10R 5‟ ctctttgaatttctccaagatggt 60 
FAM111B 
FAM111B_E1F 5‟ ataaaagagcagtctttccagcac 60.3 
790 
FAM11B_E4R 5‟ tagcaacaacatgaaaaagaatgc 60.5 
NDC80 
NDC80_E5F 5‟ tgtgcccctcatacgaacttcctg 60.5 
550 
NDC80_E10R 5‟ gagactccaaattgctcatgtatgcctg 59.6 
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IDE 
IDE_E2F 5‟ gacaagcgagaatatcgagggctagag 59.9 
520 
IDE_E5R 5‟ ccttcttggtttggtctagtctccagag 59.9 
PLGLA1 
PLGLA_E1F 5‟ gcaggaagcagagaagaatgtgcag 60.2 
600 
PLGLA_E3R 5‟ gggttccacatccacaaattcaaccaac 60.7 
CCDC144B 
CCDC144B_E5F 5‟ gcaaggaacccagaagtggttacg 60.1 
640 
CCDC144B_E9R 5‟ gtgtcttggattcttggtaggctagcag 60.5 
SEC24A 
Sec24A_E3F 5‟ ctcacgcccctgacatcatcatatagag 59.8 
620 
Sec24A_E8R 5‟ caattgtactggaggtaaccacaggc  59.1 
ORC6L 
ORC6L_E2F 5‟ agtgcagtcatgtgcctggaccttg 60.7 
460 
ORC6L_E6R 5‟ ccgtggtggagtagctacatctcc  60.3 
ANAPC5 
ANAPC5_E3F 5‟ ctggaactgaaccagaggttcacaaaac 59.8 
500 
ANAPC5_E7R 5‟ cggctccggtaagaatcagacgatc  60.7 
PCOLCE2 
PCOLCE2_E3F 5‟ catagacctcgagagtgacaacctgtg 60 
450 
PCOLCE2_E5R 5‟ ttctagcatcgttgacttccccgc  60.7 
C2orf27A 
C2orf27A_E1F 5‟ aatgtacagactagcacagaagctggac 59.7 
550 
C2orf27A_E4R 5‟ ggctctacaggaggtgccatgaag 59.4 
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3.3.9. Own contributions to the manuscript “Search for downstream target  
 genes of BBS1” 
 
Cell culture, lentivirus production, candidate gene selection, RT-PCR analysis, qPCR 
analysis of integrated proviral DNA, contributions to data interpretation and 
manuscript writing 
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4. General Discussion 
 
4.1. Ciliopathies 
We have identified and characterized splice defects in two ciliary genes, designated 
BBS1 and RPGR, which cause RP. We speculate that photoreceptor degeneration is 
caused by mislocalization of RHO or other proteins transported through the CC. 
Ectopic localization of RHO has been associated with RPGR mutations in both RP 
mouse models (Hong et al., 2000; Brunner et al., 2010) and human patients (Adamian 
et al., 2006). It was also found in different BBS mouse models (Nishimura et al., 
2004; Mykytyn et al., 2004; Fath et al., 2005). The mislocalization of RHO is 
generally assumed to occur because of impaired transport along the connecting 
cilium. 
The connecting cilium is a specialized structure which derives from a primary cilium 
(see General Introduction 1.1.4., page 11). Almost all human cell types carry this 
single, non-motile cilium which can act as a sensor for e.g. odor or mechanical 
stimuli. A complete list of tissues with a primary cilium can be found at 
http://www.bowserlab.org/primarycilia/cilia3.htm. Cilia are evolutionary conserved 
microtubule-based cell organelles which represent protrusions of the plasma 
membrane on the surface of the cell. These organelles are involved in many processes 
in the human body including for instance movement of extracellular fluid in epithelial 
cells, establishment of the left-right asymmetry and processing of external signals 
(Fliegauf et al., 2007). The ciliary membrane contains different receptors or ion 
channels that bind proteins like growth factors or sonic hedgehog and link the 
presence of these ligands to intracellular transduction cascades (Satir and Christensen, 
2007). Consequently, mutations in genes disrupting the morphology or functions of 
cilia can result in a broad range of human disorders which are summarized by the term 
ciliopathies (Badano et al., 2006a). Dysfunctions in cilia can lead to defects in kidney, 
retina, developing limbs, pancreas, liver, spleen, bone, and several parts of the central 
nervous system. Interestingly, in all cilia-associated disorders, only a fraction of 
ciliated tissues are affected. These findings point towards the fact that mutated genes 
accomplish distinct ciliary tasks in different tissues. The mutations identified in BBS1 
and RPGR may only disrupt their properties necessary for correct functioning of 
photoreceptors which is for instance the proper localization of RHO to OS. This may 
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finally lead to the tissue-specific, ocular phenotype. A further explanation for the 
variable disease symptoms in ciliopathies could be that ciliary proteins may have 
other functions which are not limited to the cilium and only important in certain 
tissues. This might be in part due to variable protein redundancies and/or buffering 
capacities of individual tissues and cell types (Badano et al., 2006a). Although many 
studies have elucidated the pathogenic mechanisms in ciliopathies, the question how 
defects in this almost ubiquitous cell organelle can lead to variable and diverse 
phenotypes is not fully understood. 
 
4.1.1. Ciliary genes BBS1 and RPGR 
Most mutations in BBS1 lead to different symptoms associated with BBS. In contrast, 
RPGR mutations generally cause a non-pleiotropic disorder showing only retinal 
degeneration. Consequently, it is assumed that BBS1 has a more general ciliary 
function, whereas the function of RPGR is restricted to the retina. 
BBS1 interacts in a complex with other BBS proteins, called the BBSome (Nachury et 
al., 2007). This complex is involved in active transport of membrane protein-
containing vesicles to the cilium (Jin et al., 2010). Thus mutations in BBS1 may 
impair transport of proteins to cilia. Several lines of evidence demonstrated that the 
BBSome accomplishes transport of important signaling receptors into the ciliary 
membrane. Mislocalization of somatostatin receptor type 3 (Sstr3) was found in 
neurons of mice lacking BBS genes (Berbari et al., 2008). Since aberrant levels of 
somatostatin are linked to cognitive impairment in humans, this aberrant localization 
of the receptor might explain the learning disabilities usually observed in BBS 
patients. Furthermore, the obesity phenotype in BBS could be due to impaired 
signaling by the leptin receptor (LepR) or the melanin-concentrating hormone 
receptor 1 (Mchr1). These receptors are both involved in the regulation of food intake 
in the CNS and do not localize to cilia in BBS knock out mice (Berbari et al., 2008; 
Seo et al., 2009). Likewise, another ciliary disease, termed polycystic kidney disease 
(PKD), might also occur because of defective trafficking of signaling pathway 
proteins to cilia. Cyst formation in the kidney is presumed to result from defects in the 
planar cell polarity pathway (PCP) (Fischer et al., 2006). PCP regulates mitotic 
spindle orientation to promote oriented cell division which is necessary for correct 
development of the kidney morphology (Fischer and Pontoglio, 2009). Because 
disruption of some BBS proteins leads to defects in planar cell polarity in mice (Ross 
General Discussion 
139 
et al., 2005) there might be a link between PCP signaling, the cilium and PKD in BBS 
patients. Together, these findings may explain why mutations in BBS1 can lead to a 
pleiotropic disorder. 
In contrast to BBS1 mutations, sequence alterations in RPGR mainly affect retinal 
function. RPGR proteins localize to the basal body and photoreceptor connecting 
cilium (Shu et al., 2005; Khanna et al., 2005) and directly interact with the RPGR 
interacting protein 1 (RPGRIP1) at centrioles and basal bodies (Roepman et al., 2000; 
Shu et al., 2005). RPGRIP1 was found to be mutated in LCA patients suggesting that 
both proteins play an important role in the retina (Dryja et al., 2001). Many other 
interaction partners of RPGR have been identified. All these findings support a model 
in which RPGR is in a complex with many other ciliary proteins at the basal body of 
the photoreceptor connecting cilium. There, RPGR might have different functions 
necessary for survival of photoreceptors. To date, these functions remain very 
speculative. Of note, mislocalization of RHO was found in RPGR mutant mice (Hong 
et al., 2000; Brunner et al., 2010). These findings together with its interaction with 
microtubule-associated proteins, IFT motors, RAB8A and its localization to the 
connecting cilium (Khanna et al., 2005; Murga-Zamalloa et al., 2010), suggest a role 
for RPGR in IFT transport. It seems that RPGR may act as a scaffold protein which 
clusters essential components of the IFT machinery at the connecting cilium. The 
clustering of these IFT components might be essential to accomplish the high 
intersegmental protein transport, needed in photoreceptors. Consequently, lower 
trafficking efficiencies induced by mutations in RPGR might lead to RP. Other 
disease phenotypes occasionally observed in patients with RPGR mutations could also 
be explained by this model. Although RPGR is expressed in many cell types, it might 
not be essential for correct functioning of cilia in other tissues than retina. This may 
be due to protein redundancies or lower rates of ciliary protein transport in these cell 
types. Nevertheless, it cannot be excluded that RPGR mutations could have a 
dominant negative effect by retaining essential ciliary components at the basal body. 
As a consequence, these components cannot perform their specific functions which 
may also result in defects of motile cilia, which are the flagella of sperms or multi-
cilia on lung epithelial cells. This could explain infertility and lung infections present 
in PCD patients with RPGR mutations (Moore et al., 2006). Supportively, male 
infertility was also found in RPGR overexpressing mice (Brunner et al., 2008). 
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4.1.2. Genotype-phenotype correlations in BBS1- and RPGR-associated  
 ciliopathies 
Our studies in patients affected by mutations in ciliary genes BBS1 and RPGR, 
revealed variations in disease expression which are usually not associated with 
mutations in either of these two genes. To give an example, the two patients with the 
splice site mutation in BBS1 showed only RP, although BBS1 mutations are usually 
associated with multiple phenotypes (Mykytyn et al., 2002). The observed phenotypic 
differences in expressivity of the disease suggest the presence of disease modifying 
factors. 
The position of the mutation and its effect on protein function is one aspect which 
should be considered in order to make phenotype-genotype correlations. A major hot 
spot for RPGR mutations is in the alternative exon ORF15 whereas a minor fraction 
has been found in consitutive exons 1 to 14 and none in exons 16 to 19 (Vervoort et 
al., 2000; Vervoort and Wright, 2002; Pelletier et al., 2007; Neidhardt et al., 2008). 
Interestingly, mutations in exon ORF15 were reported to cause less severe forms of 
RP (Sharon et al., 2003). This might be reasonable because many of the mutations 
ranging from exons 1 to 14 lay in the conserved RCC1-like domain, through which 
important interactions with many other proteins may be performed. Supportively, a 
deletion spanning the entire RCC1-like domain was identified in patients with very 
severe RP symptoms (Jin et al., 2005). 
In BBS, one of the most frequent mutation is p.M390R in BBS1 (Mykytyn et al., 
2002). It accounts for more than 70% of the total BBS1 mutational load in Caucasian 
families and is considered to be a founder mutation (Mykytyn et al., 2003; Beales et 
al., 2003; Muller et al., 2010). Many other BBS1 mutations have been identified to a 
minor fraction in the other exons, but none was initially found at extreme N and C 
termini. Recently, a mutation affecting the first nucleotide of the gene (c.1A>G, 
p.M1?) has been identified in a BBS patient showing more severe, abnormal 
morphologies of inner retinal layers compared to patients with mutations laying more 
distal at the N terminus (Gerth et al., 2008). Nevertheless, a clear phenotype-genotype 
correlation couldn‟t be established in this study. 
The expression of the disease phenotype can also be modified by other genes. At least 
seven BBS proteins genes reside in the BBSome complex (Nachury et al., 2007). 
Mutations that disrupt BBSome assembly are very likely to cause BBS. Triallelic 
inheritance and the variable phenotypic expression in BBS might be thus explained by 
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the accumulation of defects in interactions of BBS proteins gained through additional 
mutations in other BBS loci. Likewise, mutations in other genes, not directly 
associated with BBS, might also disturb interactions at the BBSome. For instance, a 
heterozygous splice site mutation in the gene CCDC28B increases disease severity in 
BBS patients, whereas the homozygous mutations in CCDC28B alone did not cause 
BBS. CCDC28B interacts biochemically with all tested BBS proteins and localizes to 
the basal body (Badano et al., 2006b). In summary, these findings suggest that 
CCDC28B might be a modifier of the disease phenotype in patients with BBS. 
Recently, several groups have reported the existence of modifier genes responsible for 
the additional ocular manifestation found in several ciliopathies. A common allele in 
RPGRIP1L has been associated with syndromic phenotypes that always include RP as 
a disease component (Khanna et al., 2009). More recently, it has been published that 
certain alleles in the genes PDZD7 or AHI1 can also contribute to the retinal 
phenotype in ciliary disorders (Ebermann et al., 2010; Louie et al., 2010). Together, 
these findings further indicate the high complexity of pathogenic mechanisms leading 
to the different forms of ciliopathies, which makes it very difficult to predict 
phenotypes from genotypes. 
Genetic modifiers could also exist in RP patients described in our studies. In these 
cases, sequence alterations in modifier genes may have either a protective (for the 
patients with mutations in BBS1) or a deteriorating effect on the disease pathogenesis 
(for the patients with mutations in RPGR). It would be of further interest to screen our 
patients for sequence alterations in genetic modifiers as mentioned above which are 
associated with retinal degeneration. The outcome might probably help to explain the 
observed phenotypes in our patients. 
 
4.1.3. Splicing as a modifier in RPGR- associated ciliopathies 
The manifestation of the disease could also be modified by aberrant pre-mRNA 
splicing. Many reports have demonstrated that defects in splicing can modulate the 
severity of the disease (Nissim-Rafinia and Kerem, 2002; Garcia-Blanco et al., 2004; 
Nissim-Rafinia and Kerem, 2005). In two RP patients, we have found mutations in 
RPGR that changed the expression level of a specific, alternative transcript isoform. 
In addition, we observed variability in the expression of the disease (see Results 
Discussion 3.1.5, page 50). These findings suggest that misregulation of alternative 
RPGR splicing acts as a modifier. Mutation-induced differences in expression of 
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alternative RPGR isoforms may influence expression of the disease through different 
pathogenic mechanisms. 
We have identified four novel RPGR transcript isoforms which were differently 
expressed among tissues examined (see Results 3.1.4., page 48). These results 
confirm previous findings demonstrating tissue-specific RPGR splicing (Kirschner et 
al., 1999; Vervoort et al., 2000; Neidhardt et al., 2007). From our expression analysis, 
we assume that RPGR transcript isoforms have specific functions, especially in tissues 
where expression levels are high. Of note, very high expression was detected for the 
isoform skipping exon 12 (RPGR
skipEx12
) in lung and kidney, whereas simultaneous 
skipping of exons 14 and 15 (RPGR
skipEx14/15
) was very frequently observed in brain. 
These findings suggest that RPGR
skipEx12
 and RPGR
skipEx14/15
 perform specific 
functions in lung and kidney or in brain, respectively. Distinct complexes of RPGR 
and tissue-specifc interactions partners might be essential for ciliary properties in 
these tissues. As a consequence, misregulation of alternative splicing may reduce the 
amount of protein isoforms needed to build up these RPGR complexes. Lack of these 
protein variants could thereby cause the additional phenotypic manifestations 
observed in a few patients. On one hand, downregulation of RPGR
skipEx12 
could 
explain why patients sometimes exhibit additional defects in the respiratory system. 
On the other hand, we are not aware of cases showing dysfunctions of the kidney or 
the central nervous system. Therefore, the physiological function of these isoforms 
remains to be elucidated. Furthermore, it is unclear to what extend a reduction in their 
expression could contribute to the pathogenesis of the disease. 
Mutation-induced overexpression of an alternative transcript isoform can also cause a 
disease phenotype. This idea is supported by the finding that overexpression of a 
cone-specific RPGR isoform causes retinal degeneration (Neidhardt et al., 2007). 
Given that RPGR protein isoforms bind tissue-specific interaction partners, the 
increased presence of a protein variant in a tissue, where it is normally expressed at 
lower levels, might induce the disease through a dominant negative effect. Thereby, it 
might prevent precise assembly of the tissue-specific RPGR complex and will 
subsequently lead to dysfunctions of the cilium. Interestingly, we found affected 
female carriers in the family of the patient who showed increased levels of exon 11a 
containing RPGR transcripts (RPGR
+Ex11a
). The elevated level is most probably due to 
a sequence alteration in the alternative exon creating a novel ESE binding site. The 
RPGR exon 11a contains a stop codon and is assumed to generate a truncated protein 
General Discussion 
143 
when introduced into the transcript. Competing with constitutive and alternative 
ORF15 protein isoforms for interaction partners, a higher amount of RPGR
+Ex11a
 
derived proteins may impair correct formation of the complex at the connecting 
cilium. This mechanism could explain the unusual dominant mode of inheritance in 
this XlRP family. To further confirm the hypothesis it would be crucial to find 
overexpression of RPGR
+Ex11a
 also in affected female carriers. Unfortunately, material 
from other family members that would allow expression analysis of RPGR
+Ex11a
 
transcripts is not available. 
It has not been proven so far whether the four alternative RPGR transcript isoforms 
identified, give rise to a functional protein as previously shown for the RPGR
+Ex9a
 
isoform (Neidhardt et al., 2007). RPGR
+Ex11a
, RPGR
skipEx12
, RPGR
skipEx14
 and 
RPGR
skipEx15
 all contain a PTC making them more susceptible for degradation 
mediated by NMD. Alternative splicing events that result in PTC containing 
transcripts and their subsequent degradation by NMD can also be used by the cell to 
regulate gene expression. The cellular mechanism which couples alternative splicing 
(AS) with NMD is referred to as AS-NMD and used for instance as an autoregulatory 
process to control the expression of certain splicing factors (McGlincy and Smith, 
2008). We assume that AS-NMD could also participate in the maintenance of a 
certain level of functional RPGR proteins. Since overexpression of RPGR can cause 
ciliary defects (Brunner et al., 2008), a precise control of its expression might be 
crucial for correct functioning of cilia in several tissues. Consequently, an abnormal 
change in the amount of an AS-NMD-generated RPGR isoform used to control RPGR 
expression, might alter the level of functionally relevant RPGR leading to a 
pathogenic effects in different tissues. Interestingly, preliminary data indicate (data 
not shown) that at least RPGR
+Ex11a
 might be partially degraded by NMD in human 
blood lymphoblasts. However, we did not find any indication that normal RPGR 
transcript levels were affected by increased levels of RPGR
+Ex11a
 in the patient, which 
would point towards a pathogenic mechanism mediated by AS-NMD. To date, this 
mechanism has never been found to cause pathogenesis of the disease. It could be of 
interest to know whether AS-NMD is used to control the amount of RPGR proteins in 
certain tissues. 
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4.2. Therapy of splice defects by adaptation of the U1 snRNA 
We have found that defects in mRNA splicing can cause a reduction of the transcript, 
the presence of aberrant splice products, or the ectopic expression of tissue-specific 
alternative isoforms, which could all be toxic for the cell. This further implicates that 
the restoration of normal splicing patterns may lead to a successful treatment of the 
splice defect. Thus, the therapeutic intervention must act on the level of pre-mRNA 
splicing. We have demonstrated that the expression of a modified form of the U1 
snRNA significantly improved correct splicing of the mRNA in fibroblast from RP 
patients with a splice defects in BBS1. The U1 snRNA was fully adapted to the 
mutated splice donor site in exon 5 of BBS1 with the aim to restore normal binding 
affinities of the U1snRNP to this site. The treatment abolished mutation-induced exon 
5 skipping and increased the amount of normal BBS1 transcripts (see Results 3.2.4., 
page 79 and 80). 
 
4.2.1. Functional assays 
A recent publication demonstrated that the U1 approach can increase the amount of 
functional protein in fibroblasts from Fanconi anemia patients (Hartmann et al., 
2010). Likewise, we performed several functional assays to verify whether the 
correction of the splice defect in BBS1 can restore the amount of functional BBS1 
protein. Moreover, we presumed that an increase in BBS1 protein will subsequently 
improve functional properties of the primary cilium. Depletion of BBS1 has been 
shown to increase activity of the Wnt signaling pathway (Gerdes et al., 2007). Since 
the amount of normal BBS1 transcripts is reduced in our patients and could be 
significantly restored by the U1-mediated approach, we expected increased BBS1 
protein levels in fully adapted U1-treated fibroblasts, which should decrease Wnt 
activity. However, we did not detect conclusive differences in Wnt signaling 
comparing these fibroblasts with wild type U1 and untreated cells (data not shown). 
Technical difficulties complicated the conclusions from these experiments. 
Nevertheless, there are alternative pathways reflecting the performance of the primary 
cilium in fibroblasts. There is accumulating evidence that hedgehog-mediated signal 
transduction is highly dependent on correct functioning of the cilium. In addition, 
signaling accomplished by the platelet-derived growth factor receptor- might be the 
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most promising pathway, because it depends on the primary cilium of fibroblasts 
(Goetz and Anderson, 2010). 
Furthermore, we evaluated the expression of different genes which might be regulated 
through the cilium. We could identify CKAP5 as a potential candidate gene whose 
expression might be regulated through the ciliary function of BBS1 (see Results 
3.3.3., page 105). However, further experiments need to be done to confirm these 
findings. Finally, we counted the amount of primary cilia in patient and control 
fibroblasts treated with or without the adapted U1 snRNA, because the lack of BBS1 
has already been linked to lower amounts of primary cilia in cultured cells (Nachury 
et al., 2007). Counting of cilia revealed no clear differences between treated and 
untreated control and patient fibroblasts. 
Together, these results led to the assumption that the number of primary cilia as well 
as the ciliary function in fibroblasts is not dramatically affected by the lower amount 
of BBS1 found in the patient. These findings might indicate that the reduced BBS1 
level causes the disease through a photoreceptor-specific effect. We cannot exlude 
that we have overlooked mild alterations of the ciliary properties. The amino acid 
change in BBS1 (p.Arg160Gln) could also be relevant to modify the ciliary 
phenotype. 
 
4.2.2. Side effects and improvements of the U1-based approach 
The modification of the ubiquitously used U1 snRNA might bear the risk to interfere 
with splicing of other genes. The process of pre-mRNA splicing is highly dynamic. 
During splicing, many spliceosome components enter and exit the complex. Thus 
changes in binding properties of certain splicing factors could cause aberrant splicing. 
Alterations in binding affinities of the U1 snRNA might lead to a reduction or an 
increase in the usage of a classical splice site. Furthermore, it may also activate 
utilization of cryptic splice sites. 
We tested for splice defects after the treatment with a modified U1 snRNA with 
particular interest on genes associated with retinal degenerations (Boettinger, 2009, 
Master Thesis). We identified 80 to 90% sequence complementarity of the fully 
adapted U1 snRNA to splice donor sites in genes SEMA4A, PRPF31, PRPF8 and 
RPGR that primarily cause RP. To check whether these genes showed splice defects 
after the U1 treatment, we analyzed the expression of affected exons by RT-PCR 
using flanking primers. Our studies revealed normal splicing for all tested genes 
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(Boettinger, 2009, Master Thesis). In order to get a more general overview about 
possible adverse effects on splicing, we performed mRNA expression analyses in U1 
treated fibroblasts with the Human Exon 1.0 ST array. Comparing fibroblasts treated 
either with wt or fully adapted U1 snRNA we found changes in splicing of 5 
retinopathy-associated genes (Boettinger, 2009, Master Thesis). Nevertheless, a 
further analysis by RT-PCR is necessary to clarify whether these genes show aberrant 
splicing due to the U1 treatment. Expression analysis of other gene transcripts 
selected from the array demonstrated only mild effects upon treatment with fully 
adapted U1 (see Results 3.3.3., page 101). Finally, the study of animal models will be 
needed to evaluate the balance between benefits and side effects caused by the U1 
treatment on the physiologic level. 
The specificity of the U1 approach might be increased by nucleotide extensions at the 
5‟ end of the U1 snRNA. A U1 snRNA extended by nucleotides (nt) complementary 
to the intronic sequence downstream of the splice donor site might have higher 
affinities to the target site and should reduce its interaction with non-target splice 
sites. We expanded the 5‟ splice site of the adapted U1 snRNA by 15 nts which were 
fully complementary to the intronic sequence following the splice donor site of exon 5 
in BBS1. The efficiency of the extended U1 snRNA was then evaluated by co-
transfection with minigenes comprising genomic sequence of BBS1 spanning from 
intron 4 to intron 7, as previously described (see Results 3.2.4., page 79). For both, wt 
and mutant minigenes, co-expression of the extended U1 snRNA had no effect on the 
splice pattern suggesting that the generated U1 snRNP is not functional (data not 
shown). Probably, there might be a size limitation in the U1 snRNA which is crucial 
for correct maturation of the U1 snRNP. The threshold might be exceeded by the 
addition of 15 nts making the snRNP non-functional. However, successful treatment 
of a mouse model for Duchenne muscular dystrophy using 54 nts antisense 
oligonucleotides linked to the U1 snRNA has been reported (Denti et al., 2006). These 
findings show that the generated U1 snRNP is functional and contradicts our 
hypothesis. Probably, dimerization of sequences at the 5‟ end of the U1 snRNA might 
better explain why our extended U1 snRNA appeared to be not functional. Since this 
mechanism may block binding of U1 to its target sequence, 5‟ extensions shorter than 
15 nucleotides could be more favorable. In order to achieve high specificity of the 
treatment and most efficient correction of the splice defect, the ideal extension length 
at 5‟ end of the U1 snRNA has to be determined in further experiments. 
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4.3. Concluding remarks 
Taken together, we have detected splice defects in RPGR and BBS1 in patients whose 
disease phenotypes were different from those which are normally associated with 
mutations in these genes. The findings indicated that defects in mRNA splicing might 
modify the phenotype and will further help to clarify disease pathogenesis in the 
patients. 
To prevent deleterious effects of aberrant splicing, we have developed a therapeutic 
approach that significantly corrected splicing in patient-derived fibroblasts. Following 
successful treatment in animal models, these promising results might lead to the 
development of a gene therapy in patients with eye diseases caused by splice defects. 
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